- 1 Statin skeletal muscle-related phenotypes: insights from uses and
- epidemiological and Mendelian randomization analyses 2
- 3 **Running title: Statin Uses and Skeletal Muscle-related Phenotypes**
- Fan Tang^{1†}, Zhanchao Chen^{2,3†}, Hongbing Qiu¹, Yige Liu^{2,3}, Yanjiao Shen^{4,5}, 4
- Yiying Zhang1*, Shanjie Wang^{2,3*}, Bo Yu^{2,3} 5
- 6 ¹Department of Epidemiology and Biostatistics, School of Public Health, Jiamusi
- 7 University, Jiamusi, China.
- ² Department of Cardiology, Second Affiliated Hospital of Harbin Medical 8
- University; 9
- ³ The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education; 10
- National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin, China; 11
- ⁴ Innovation Institute for Integration of Medicine and Engineering, Chinese 12
- Evidence-Based Medicine Center, West China Hospital, Sichuan University, 13
- Chengdu, Sichuan, 610041, P.R. China; 14
- ⁵ Department of Health Research Methods, Evidence, and Impact, McMaster 15
- University, Hamilton, Ontario, Canada. 16
- † Contributed equally to this article. 17
- * Corresponding authors: Yiving Zhang, 258 Xuefu Road, Xiangyang District, 18
- 19 154007 Jiamusi, China. Tel: 15245488123, Email: zhangyiying@jmsu.edu.cn; Shanjie
- 20 Wang, 246 Xuefu Road, Nangang District, 150086 Harbin, China. Tel: +86 451 8660
- 5180, Fax: +86 451 8660 5180, Email: shanjie wang@hrbmu.edu.cn; ORCID: 21
- 22 https://orcid.org/0000-0002-1148-1570
- Fan Tang, Hongbing Qiu, Yiying Zhang District: 154007 Jiamusi, China 23
- Zhanchao Chen, Yige Liu, Shanjie Wang, Bo Yu District, 150086 Harbin, China. 24
- The category of the manuscript: Original Articles 25
- Word counts:3890 26
- Number of tables: 4 plus 11 supplementary tables 27
- 28 Number of figures: 1

Abstract:

Background:

The association between statin use and skeletal muscle-related side effects is always controversial. This study aimed to comprehensively investigate the associations between statin use and muscle-related phenotypes including sarcopenia, sarcopenic obesity, serum lactate dehydrogenase (LDH), and musculoskeletal pain symptoms among adults with indications for statin use for secondary prevention (cardiovascular disease, diabetes, or hyperlipidemia).

Methods:

This cross-sectional study included 22,549 patients aged ≥20 years with cardiovascular disease, diabetes, or hyperlipidemia. Weighted generalized linear regression analysis and propensity score matching methods were used to estimate the associations between the use of statins or other lipid-lowering agents and skeletal muscle-related phenotypes. Mendelian randomization (MR) analysis was additionally used to verify the causal relationship between statin use and skeletal muscle-related phenotypes.

Results:

The weighted mean age was 59 years, 50.3% were male, and 37.6% (n=8,481) received statin treatment. In the unadjusted model, compared with adults without any lipid-lowering drugs, statin use was associated with a higher likelihood of sarcopenia (appendicular skeletal muscle mass [ASM]/Body mass index [BMI] OR 1.35 (95%CI 1.12 to 1.62, p < 0.001), ASM/weight [Wt] OR 1.86 (95%CI 1.62 to 2.13, p < 0.001), max HGS β -3.01 (95% CI -3.97 to -2.06, p < 0.001), relative HGS β -0.23

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

(95% CI - 0.30 to -0.17, p < 0.001) and combined HGS β -5.90 (95% CI -7.86 to -3.93, p < 0.001)), sarcopenic obesity (ASM/height squared [Ht²] and body fat percentage definition [OR 1.36 (95% CI 1.13 to 1.63, p < 0.001]). After multivariable adjustment or propensity score match, the independent associations of statin use with sarcopenia, sarcopenic obesity, HGS, LDH, and musculoskeletal pain became nonsignificant. Stepwise regression suggested that age was the predominant confounding factor for the associations. MR analysis also revealed no significant causality between statin use and skeletal muscle-related phenotypes. **Conclusions:** Our epidemiological and MR analyses did not support the causality between statin use and skeletal muscle-related phenotypes. A higher likelihood of skeletal muscle-related adverse phenotypes in statin users may be attributed to age. Future studies should further explore the biological factors that may affect statin-related muscle phenotypes to provide evidence for the safety of statins. **Keywords:** Statins, sarcopenia, sarcopenic obesity, handgrip strength, lactate dehydrogenase, musculoskeletal pain

1. Introduction

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

Statins are the first-line prescribed drugs that lower lipid levels by inhibiting 3hydroxy-3-methylglutaryl-CoA reductase[1]. Numerous studies demonstrated the cornerstone status of statins in preventing the risk of atherosclerotic cardiovascular disease (ASCVD) and relevant mortality[2, 3]. Thus, current clinical guidelines underline the importance of statin use in cardiovascular disease, diabetes, and hyperlipidemia[2, 4, 5]. Despite the significant benefits of statins, the controversy surrounding Statinassociated muscle symptoms (SAMS) persists. The potential adverse effects of statin use remain a significant subject of discussion, prompting concerns among patients and physicians [6, 7]. SAMS, encompassing muscle-related symptoms such as myalgia, tenderness, stiffness, cramps, and weakness, with or without elevated creatine kinase levels, are frequently reported as the predominant side effects. These symptoms can lead to causes medication nonadherence, potentially leading to suboptimal cardiovascular management [8, 9]. Statin discontinuation related to SAMS has been shown to cause a nearly 3-fold increased risk of cardiovascular events[10]. Most randomized controlled trials indicate that the risk of SAMS is minimal or insignificant compared with a placebo[11]. A study showed[2]that older adults receiving statins for primary and secondary prevention do not have an increased risk of myopathy. A recent systematic review showed[12]that statin use was not significantly related to the

risk of SAMS and relevant mortality among older statin users. A cross-sectional study

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

showed no correlation between statin use and musculoskeletal pain in arthritis patients[13]. However, it is important to note that previous trials and meta-analyses may have several limitations. For example, study points by self-reported symptoms may be subjective; severe myopathy and rhabdomyolysis, both are rare in humans as statin-related musculoskeletal disorders; and the study population may lack representativeness due to small sample sizes and potential selection bias[12].

Sarcopenia is an age-related syndrome characterized by loss of muscle mass, strength, and function[14]. Dual-energy X-ray absorptiometry (DXA) is employed for assessing total body lean tissue mass or appendicular skeletal muscle mass[15]. However, the relationship between statins and muscle mass or sarcopenia has not been reported. Handgrip strength (HGS) serves as another indicator for assessing skeletal muscle function[16]. Only two studies reported inconsistent results on the association between statins and muscle function (e.g., grip strength, and gait speed) in older adults[17, 18]. Overall, there's a lack of large-scale studies comprehensively examining the association between statin use and instrument-based muscle characteristics. Mendelian randomization (MR) analysis is acknowledged as a complementary method to imitate randomized controlled trials, which is increasingly recognized as an emerging epidemiological approach that utilizes genetic factors to evaluate the causal impact of exposure on a particular outcome[19]. Therefore, this study combined a large-scale observational study in the National Nutrition Health and Nutrition Examination Survey (1999-2020) 1999-2020, and a two-sample MR

analysis was conducted to evaluate the relationships between statin use and musclerelated phenotypes including sarcopenia, sarcopenic obesity, serum lactate dehydrogenase (LDH), and musculoskeletal pain among adults with the indications for statin use for secondary prevention (cardiovascular disease, diabetes, or hyperlipidemia).

112

113

114

115

116

All rights reserved. No reuse allowed without permission

2. Methods

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

2.1 Study Population

As we have previously reported[20], the National Nutrition Health and Nutrition Examination Survey employs a stratified, multistage probability sampling method to represent the noninstitutionalized population of the United States. In this study, datasets from 11 two-year cycles of the National Nutrition Health and Nutrition Examination Survey (from 1999-2000 to 2017-2020). The data from the 11 cycles were standardized and combined, using interview weights consistent with the recommendations from the National Center for Health Statistics. A total of 116,876 participants were involved in the survey over two cycles. We excluded individuals aged < 20 years (n = 52,563), those without assessment for cardiovascular disease (CVD), diabetes, or hyperlipidemia (n = 37,051), and those lacking data on muscle-related phenotypes (n = 4,713). In total, 22,549 subjects were analyzed, including 13,474 non-statin users, 8,481 statin users, and 594 users of lipidlowering drugs other than statins (Figure 1). The study was approved by the research ethics review board of the Centers for Disease Control and Prevention, and all participants provided informed consent. CVD was defined as a self-reported history of coronary heart disease, heart failure, or stroke. Diabetes was defined as a physician-reported diagnosis, plasma HbA1c \geq 6.5%, or fasting blood glucose \geq 7.0 mmol/L[21]. Hyperlipidemia was defined as a physician-reported diagnosis in the primary analysis. In sensitivity analyses, hyperlipidemia is defined as total cholesterol 200 mg/dL, triglycerides 150

mg/dL, HDL 40 mg/dL in men, 50 mg/dL in women, or hypolipidemia—high-density lipoprotein cholesterol 130 mg/dL[22]. Additionally, individuals reporting the use of cholesterol-lowering medications were also categorized as having hyperlipidemia.

Two-sample MR was performed to evaluate the causal effects between s statin use and muscle-related phenotypes (Figure 1). The current MR research is based on three main assumptions[23]. First, the selected SNPs were associated with statins; second, the SNPs were not associated with other confounding factors; third, the SNPs only affected sarcopenia-related indicators and the risk of LDH through statins, without affecting other pathways. Detailed information about the data downloading and screening processes is displayed in Table S1 and Table S2.

2.2 The use of statins and lipid-lowering agents

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

At baseline, during a personal interview, participants were asked about the prescription medications they had taken in the past 30 days. The prescription drug names are recorded on the drug container label. Each drug is associated with a standardized generic prescription drug name[20]. Table S3 contains a list of statins and lipid-lowering drugs.

2.3 Definition of skeletal muscle-related phenotypes

2.3.1 Sarcopenia and sarcopenic obesity

The survey provides an accurate set of muscle mass data, assessed by dualenergy X-ray absorptiometry (DEXA). Appendicular skeletal muscle mass (ASM (kg)) was defined as the sum of the muscle mass of the four limbs. The skeletal 160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

muscle index was calculated as the appendicular skeletal muscle mass divided by the body mass index (BMI) or weight (Wt). In this study, the cutoff value for sarcopenia was defined by BMI-adjusted ASM according to the Foundation for National Institutes of Health (FNIH) criteria[24], male < 0.789, female < 0.512. The cutoff for sarcopenia was defined by a weight-adjusted ASM of 29.76% for males and 22.31% for females[25]. The appendicular skeletal mass index (ASMI) was defined as the ASM divided by the square of the height(ht²). According to the European Working Group on Sarcopenia in Older Population(EWGSOP2)[26], sarcopenia was defined as an ASMI <7 kg/m² in men or <5.5 kg/m² in women[27]. Subjects were classified as obese using standard BMI categories (≥30 kg/m²) or a body fat percentage ≥25% for men and ≥35% for women. If the subject met the criteria for both sarcopenia and obesity using these definitions, a diagnosis of sarcopenic obesity was considered. The muscle strength/grip strength was assessed by isometric HGS using a handgrip dynamometer[28]. Grip strength testing is typically conducted with participants in a standing position unless they have physical constraints. Muscle strength was measured in three indicators: maximum HGS, combined HGS, and relative HGS. Participants underwent three HGS tests for both their left and right hands. The study selected the highest value from the three tests for maximum HGS; combined HGS was calculated as the sum of the highest readings from each hand. Relative grip strength was defined as the sum of the highest readings from each hand, divided by BMI.

2.3.2 Lactate dehydrogenase

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

The survey measures serum LDH levels at baseline in all adult participants using an enzymatic rate method; more information on LDH analysis techniques can be found in the Laboratory Procedure Manual [29]

2.3.3 Musculoskeletal pain in different anatomical regions

Participants were asked, 'In the past month, have you had problems with pain that lasted for more than 24 hours?' Those who answered 'yes' were asked to specify the location of the pain. We assessed reports of pain in the neck or upper back, upper extremities, lower back, and lower extremities. Musculoskeletal pain was defined as pain in one of these areas.

2.4 Other variables

The covariates included age, sex, race/ethnicity, education level, income-topoverty ratio, marital status, alcohol use status, smoking status, physical activity, BMI, hypertension, cardiovascular disease, diabetes, hyperlipidemia, chronic kidney disease, chronic obstructive pulmonary disease, and cancer. The poverty income ratio was categorized into three categories: 1.5, 1.5-3.5, and >3.5[30]. BMI categories of <25 kg/m², 25 to 30 kg/m², and >30 kg/m² were established. Hypertension, cardiovascular disease, diabetes, hyperlipidemia, chronic obstructive pulmonary disease, and cancer were defined based on self-reported prior diagnoses.

2.5 Propensity score matching

Propensity score matching was used to balance baseline differences in cardiovascular disease, diabetes, and hyperlipidemia between the statin and non-statin groups. Propensity scores were calculated for individuals using logistic regression, including all covariates. Paired patients were selected using the nearest neighbor matching algorithm without replacement, with a caliper size of 0.2 standard deviations of the propensity score logit[20]. In addition, standardized differences were used after matching to assess the balance of covariates between the two groups; covariates with standardized differences less than 0.01 were considered well-balanced.

2.6 Statistical analysis

Statistical analyses were performed according to the analysis guidelines for the dataset. Because the amount of missing data in the covariates was small (<5%), we used multivariate interpolation with chained equations to handle the missing data[31]. The baseline characteristics of the participants were summarized via descriptive analysis according to their statin use status. Chi-square tests and t-tests were used to compare categorical and continuous data[30]. Weighted generalized linear regression analyses were used to estimate the associations between statin or lipid-lowering drug use and sarcopenic, sarcopenic obesity, HGS, LDH, and musculoskeletal pain. Multivariate models were adjusted for covariates included in propensity score matching. We further redefined the population with hyperlipidemia to examine the association between statin or lipid-lowering drug use and low muscle mass, grip strength, or musculoskeletal pain. Other analyses were limited to patients aged 65 years or older with cardiovascular disease, diabetes, or hyperlipidemia.

224

225

226

227

228

229

230

231

232

233

We performed two-sample MR analyses to assess the causal relationships between statin use and appendicular lean mass, hand grip strength (left and right), low hand grip strength, walking pace, and LDH. Handling missing values using multiple imputations. In the main analyses, we used a random-effects inverse variance weighted (IVW) approach to estimate causal effects. In addition, sensitivity analyses using weighted median, MR-Egger, and MR-pleiotropic residuals and outliers (MR-PRESSO) methods were performed to assess the robustness of the IVW results. We considered two-sided p-values less than 0.05 as statistically significant. Stata (version 15.0) and R (version 4.1.2) were used for all analyses.

3. Results

3.1 Participant characteristics

This cross-sectional study included 22,549 individuals diagnosed with cardiovascular disease, diabetes, or hyperlipidemia at baseline between 1999 - 2020. Overall, 37.6% of patients (n=8481) were taking statins at baseline. The mean age of all subjects was 59 ± 15 years, and 50.3% were male. Those taking statins were more likely to be older, have a greater body mass index, and were less likely to smoke (P< 0.05) (Table 1). Adults without any lipid-lowering drugs had a higher proportion of chronic diseases such as hypertension, chronic kidney disease, or cancer (P< 0.05) (**Table 1**). We also matched statin and non-statin users separately (**Table S4**).

3.2 Relationship between statin use and muscle-related phenotypes.

Table 2 shows the relationships between statin use and muscle-related phenotypes including sarcopenia, sarcopenic obesity, and LDH. Compared with adults without any lipid-lowering drugs, statin user was associated with a higher likelihood of muscle-related phenotypes, ASM/BMI (OR=1.35, 95% CI: 1.12 to 1.62), ASM/Wt (OR=1.86, 95% CI: 1.62 to 2.13), maximum HGS (β=-3.01, 95% CI: -3.97 to -2.06), relative HGS (β=-0.23 95% CI: -0.30 to -0.17), and combined HGS (β=-5.90 95% CI: -7.86 to -3.93), ASM/Ht² and body fat percentage defined as sarcopenic obesity (OR=1.36, 95% CI: 1.13 to 1.63) in the unadjusted model.

Multivariate linear regression analysis revealed that compared with adults without any lipid-lowering drugs, statin user was not associated with a higher likelihood of muscle-related phenotypes including ASM/BMI (OR=1.31, 95% CI:

perpetuity.
All rights reserved. No reuse allowed without permission.

0.99 to 1.74), ASM/Wt (OR=1.23, 95% CI: 0.99 to 1.54), ASM/Ht² (OR=1.11, 95% 256 CI: 0.77 to 1.60), maximum HGS (β =-3.01, 95% CI: -3.97 to -2.06), relative HGS (β 257 =-0.23 95% CI: -0.30 to -0.17), and combined HGS (β =-5.90 95% CI: -7.86 to -3.93), 258 ASM/Ht² and body fat percentage defined as sarcopenic obesity (OR= 1.32, 95% CI: 259 260 1.00 to 1.75), ASM and BMI defined as sarcopenic obesity (OR=0.92, 95% CI: 0.51 261 to 1.66). We further performed propensity score-matched analyses (Table 2) to account 262 for possible confounding factors that may have contributed to the protective 263 264 associations between statin use and muscle-related phenotypes. Statin user was not associated with a higher likelihood of muscle-related phenotypes including ASM/BMI 265 (OR=1.25, 95% CI: 1.00 to 1.55), ASM/Wt (OR=1.14, 95% CI: 0.97 to 1.34), 266 ASM/Ht² (OR=0.87, 95% CI: 0.64 to 1.18), maximum HGS (β =-0.13 95% CI: -0.66 267 to 0.40), relative HGS (β = -0.01 95% CI: -0.04 to 0.03), combined HGS (β =-0.32 268 95% CI: -1.32 to 0.67), or LDH (β =-0.57, 95% CI: -1.72 to 0.58), ASM/Ht² and body 269 fat percentage defined as sarcopenic obesity (OR= 1.26, 95% CI: 1.00 to 1.56), ASM 270 and BMI defined as sarcopenic obesity (OR=0.74, 95% CI: 0.23 to 2.44). 271 272 **Table 3** shows the adjusted and unadjusted odds ratios for musculoskeletal pain and statin use. Multivariate linear regression analysis revealed that compared with 273 without any lipid-lowering drugs, statin user was not associated with a higher 274 likelihood of musculoskeletal pain including any regional pain (OR=1.15, 95% CI: 275 0.88 to 1.50), neck/upper back pain (OR= 0.96, 95% CI: 0.64 to 1.44), upper 276 277 extremities pain (OR=1.11, 95% CI: 0.81 to 1.51), lower back pain (OR=1.05, 95%

CI: 0.77 to 1.45) or lower extremities pain (OR=1.12, 95% CI: 0.83 to 1.51). We further performed propensity score-matched analyses (**Table 3**) to account for possible confounding factors that may have contributed to the protective association between statin use and musculoskeletal pain. Compared without any lipid-lowering drugs, statin user was not associated with any regional pain (OR=1.09, 95% CI: 0.91 to 1.31), neck/upper back pain (OR=0.94, 95% CI: 0.67 to 1.32), upper extremities pain (OR=1.13, 95% CI: 0.93 to 1.39), lower back pain (OR=1.05, 95% CI: 0.79 to 1.39) or lower extremities pain (OR=1.08, 95% CI: 0.84 to 1.41).

We conducted a stepwise regression analysis to observe the association between

statin use and muscle-related phenotypes and found that the associations were substantially attenuated after adjustment for age (**Table S5**).

3.3 MR analysis

There was moderate heterogeneity in the estimated effects of statins on the sarcopenia-related indicators appendicular lean mass, hand grip strength, and LDH (P of Cochran's Q < 0.05) but no pleiotropy (intercept > P of 0.05) (**Table S6**). Overall IVW MR analysis (**Table 4**) revealed that compared without a statin, statin user was not associated with a higher likelihood of muscle-related phenotypes including appendicular lean mass (β =-0.060, 95% CI: -0.153 to 0.033), right-hand grip strength (β =-0.014, 95% CI: -0.039 to 0.012), left-hand grip strength (β =-0.216, 95% CI: -0.044 to 0.001), low hand grip strength (OR=1.042, 95% CI: 0.889 to 1.221), walking pace (β =0.001, 95% CI: -0.010 to 0.011), and LDH (β =-0.080, 95% CI: -0.230 to 0.053).

3.4 Sensitivity analysis

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

to 1.30).

Sensitivity analysis revealed that among the population aged 65 and over (**Table** S7), population with cardiovascular disease (Table S8), population with diabetes (Table S9), and population with hyperlipidemia (Table S10), statin user was not associated with a higher likelihood of muscle-related phenotypes. Table S11 shows the relationships between statin use and muscle-related phenotypes in the redefined hyperlipidemic population. Propensity score matching revealed that statin user was not associated with a higher likelihood of muscle-related phenotypes including ASM/BMI (OR=1.25, 95% CI: 0.99 to 1.59), ASM/Ht² (OR=0.94, 95% CI: 0.66 to 1.33), maximum HGS ($\beta=-0.45, 95\% CI: -1.04 \text{ to } 0.14$), relative HGS(β =-0.03, 95% CI: -0.07 to 0.01), combined HGS (β =-2.33, 95% CI: -5.47 to 0.81), ASM/Ht² and body fat percentage defined as sarcopenic obesity (OR=1.23, 95% CI: 0.96 to 1.57), ASM and BMI defined as sarcopenic obesity (OR=0.85, 95% CI: 0.53 to 1.34), LDH ($\beta=-0.62, 95\% CI: -4.69 \text{ to } 3.46)$, any region pain (OR=1.10, 95% CI: 0.89 to 1.35), neck/upper back pain (OR=0.89, 95% CI: 0.61

4. Discussion

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

In this nationally representative cross-sectional study with 22,549 patients with a history of cardiovascular disease, diabetes, or hyperlipidemia, 8,481 (37.6%) participants used statin. We found that in the unadjusted model, compared with adults not using any lipid-lowering drugs, statin use was associated with a higher likelihood of sarcopenia, sarcopenic obesity, lower HGS, and combined HGS. However, after multivariable adjustment or propensity score match, the independent associations of statin use with sarcopenia, sarcopenic obesity, HGS, LDH, and musculoskeletal pain became nonsignificant. Stepwise regression suggested that age was the predominant confounding factor for these associations. MR analysis also showed no significant causality between statin use and skeletal muscle-related phenotypes including appendicular lean mass, hand grip strength (left and right), low hand grip strength, walking pace, or LDH. Our results are inconsistent with previous studies, in which we found no association between statin use and skeletal muscle-related phenotypes. Chronic heart failure resulting from various cardiovascular diseases may contribute to secondary sarcopenia related to disease in patients with cardiovascular disease[32]. Notably, sarcopenia is associated with worse quality of life and increased mortality in patients with CVD[32]. A meta-analysis found significant differences in myopathic symptoms and muscle pain between patients on low- and high-intensity statin therapy. However, only 57% of myopathy symptoms and 16% of muscle pain were dose-related[33]. In a large observational study of 46,249 participants, statin users exhibited higher rates of 338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

arthropathy, musculoskeletal injuries, and pain compared to controls matched for age, sex, and comorbidities[34]. While this study found no association between statin use and increased likelihood of musculoskeletal pain among individuals with cardiovascular disease, diabetes, or hyperlipidemia, another observational study reported a significantly higher incidence of musculoskeletal pain in various regions, including the lower back and lower extremities, among statin users without arthritis[13]. The study revealed that statin user was not associated with a higher likelihood of maximum HGS, relative HGS, or combined HGS, and other observational results conflicted. For instance, findings from the Hertfordshire cohort study indicated that calcium channel blockers and fibrates were linked to reduced grip strength in women, whereas statins showed no such association[17]. There is no evidence of an increased likelihood of muscle-related phenotypes in the population receiving statins. Data from RCTs on the efficacy of statins in patients aged 65 years and older showed that [35] although older adults are at a higher risk for cardiovascular disease and are most likely to benefit from lipid-lowering therapy, they are the group least likely to receive statins[36]. This suggests that statins are still underutilized, with patients >65 years less likely to receive a statin prescription than younger patients[37]. This phenomenon primarily stems from concerns among older adults regarding myopathy as an adverse reaction linked to statin therapy. However, this cross-sectional study revealed statin user was not associated with a higher likelihood of muscle-related phenotypes including sarcopenia, HGS, or LDH in the population over 65 years of age, indicating that in terms of adverse muscle effects,

statins may play a role in cardiovascular disease, diabetes, or relative safety in patients with hyperlipidemia.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

Our results found that the association between statin use and muscle-related phenotypes was significantly attenuated after adjustment for age. Muscle complaints are commonly reported by older adults and can stem from various causes, including sarcopenia, increased physical activity, diseases that predispose to or exacerbate and medications known for their myotoxic effects. muscle issues, misinterpretation could lead to a significant number of older adults avoiding statin therapy, thereby missing out on potential cardiovascular benefits and experiencing more unintended events. One randomized controlled trial revealed that 90% of the symptoms experienced while taking statins also occurred while taking a placebo[38]. Furthermore, a recent systematic review revealed that between 38% and 78% of individuals reported statin-related muscle symptoms[39]. A recent meta-analysis proposed a "nocebo effect", which occurs when subjective adverse effects, such as aches and pains, result from patients' anticipation of harm from statin therapy due to their awareness of and concern about potential side effects. A meta-analysis of randomized clinical trials on statins indicated comparable rates of adverse events between participants assigned to statins or placebo, suggesting no notable increase in adverse event rates associated with statin use[39]. However, many researchers argue that because trial populations are often healthier than real-world clinical populations, observational studies can more accurately estimate the frequency of adverse events in clinical practice.

The findings of our study demonstrate the long-term safety of statin use, which can enhance patient compliance and address the concerns of both users and healthcare providers. Concurrently, the aging of the population will undoubtedly increase the incidence of musculoskeletal disorders closely associated with aging, including sarcopenia, osteoporosis, and osteopenia[40], therefore muscle-related symptoms should be examined through the lens of the aging process. Our study provides a convincing supplement to the current small sample RCTs, which are insufficient in terms of generalizability and outreach.

4.1 Limitations and Strengths

The strengths of the present study include its large and representative sample, facilitating adjustment for numerous confounding factors and thereby enhancing the reliability of the results. Furthermore, propensity score matching was employed to balance confounding factors related to key medications, thereby reducing potential drug interactions. The main strength of this study lies in combining observational data from the National Nutrition Health and Nutrition Examination Survey 1999–2020 with the MR approach.

Our study has several limitations. First, the cross-sectional design prevents us from establishing causality or accounting for individuals who may have initiated or ceased statin use due to skeletal muscle adverse events, which were assessed using MR analysis to explore causal relationships. Second, we assessed statin use only for the month before the interview, so we could not determine the duration of statin use or whether non-users had recently stopped taking statins. Additionally, our study faced

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

limitations in obtaining enough statin users to evaluate the effects of various types of statins on outcomes. We also lacked dosage information to investigate potential associations with high statin doses, which contribute to statin-induced muscle-related side effects[13]. Future studies should gather comprehensive medication use histories, including dosage details from prescription labels, frequency, duration of use, and discontinuation patterns. This would enhance the robustness of the study findings. Third, due to the absence of creatine kinase level data, we were unable to investigate the association between statin or other lipid-lowering drug use and creatine kinase levels. These data, combined with longitudinal follow-up, could provide further insights into the musculoskeletal side effects of statins, despite this study utilizing LDH as a muscle damage marker. Moreover, our study sample was representative of the U.S. population, primarily comprising self-reported non-Hispanic White participants. However, data on individuals of Asian descent were not captured. This detail is crucial as research suggests that individuals of Asian descent may exhibit higher susceptibility to statin-induced musculoskeletal side effects compared to other demographic groups. Fourth, this study only focused on skeletal muscle-related phenotypes. Other side effects such as diabetes, cognition, and liver damage require special research. Furthermore, data exclude hospitalized patients, who typically exhibit poorer health statuses, multiple comorbidities, and potentially heightened susceptibility to adverse drug reactions. Last, in this observational study, despite efforts to control for numerous critical confounding factors, residual and unmeasured confounders may have constrained the findings.

4.2 Conclusions

426

427

428

429

430

431

432

433

Our epidemiological and MR analyses did not support the causality between statin use and skeletal muscle-related phenotypes. A higher likelihood of skeletal muscle-related adverse phenotypes in statin users may be attributed to age. Future studies should further explore the biological factors that may affect the statin-related muscle phenotype. These findings will provide evidence for the drug safety of statin therapy for the secondary prevention of cardiovascular disease, diabetes, or hyperlipidemia.

Ethical Standards Disclosure: This study was conducted according to the guidelines

laid down in the Declaration of Helsinki and all procedures involving research study

participants were approved by the [NCHS]. Written informed consent was obtained

from all subjects.

Consent for publication: Not applicable.

Availability of data and materials: The datasets supporting the conclusions of this

article are available in the National Health and Nutrition Examination Survey

unique persistent identifier and hyperlink repository. to the dataset

https://wwwn.cdc.gov/nchs/nhanes/default.aspx.

Competing interests: The authors declare that they have no competing interests.

Sources of Funding: SW was funded by the National Natural Science Foundation of

China (82200396), Natural Science Foundation of Heilongjiang Province of China

(YQ2022H006), New era Longjiang outstanding doctoral key project (LJYXL2022-

013), Cultivation Project of Second Affiliated Hospital of Harbin Medical University

(PYMS2023-3); YZ was funded by the Gout Etiology and Functional Food Research

Innovation Team, the North Medicine and Functional Food Characteristic Subject

Project in Heilongjiang Province (HLJTSXK-2022-03), Postdoctoral Science

Foundation of Heilongjiang Province of China (LBH-Q21047), National Fund

Cultivation Program of Jiamusi University (JMSUGPZR2022-022), Scientific and

Technological Innovation Team of Jiamusi University (cxtd202101).

Authors contributions: FT, ZC, and SW conceived and designed the study. FT, HQ,

YL, ZH, and BY organized all data. FT, ZC, and SW analyzed and visualized the

23

results. FT, YS, and SW contributed to the manuscript. Reviewed and edited the manuscript, YZ and SF take responsibility for the integrity and accuracy of this analysis. All authors reviewed and edited the manuscript.

Acknowledgments: The authors thank all the participants and staff in the National Health and Nutrition Examination Survey for their substantial contributions. perpetuity.
All rights reserved. No reuse allowed without permission.

References:

- [1] Bose S, Steussy CN, Lopez-Perez D, Schmidt T, Kulathunga SC and Seleem MN. Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor. Commun Biol 2023; 6: 360.
- [2] Collins R, Reith C, Emberson J, Armitage J, Baigent C and Blackwell L. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561.
- [3] Sarzani R, Allevi M, Giulietti F, Sarnari S, Scorcella S, and Di Agostini A. Patient-reported muscle symptoms and their characterization in a hypertensive population eligible for statin therapy: an exploratory study. Nutr Metab Cardiovasc Dis 2024; 34: 136-144.
- [4] Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, and Barnes EH. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: a meta-analysis of individual data from 27 randomized trials. Lancet 2012; 380: 581-590.
- [5] Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ and Ray KK. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-1022.
- [6] Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J and Genest J. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol 2016; 32: S35-S65.
- [7] Saxon DR and Eckel RH. Statin Intolerance: a Literature Review and Management Strategies. Prog Cardiovasc Dis 2016; 59: 153-164.
- [8] Doganer YC, Aydogan U, Kaplan U, Gormel S, Rohrer JE and Yuksel UC. Statin adherence in patients with high cardiovascular risk: a cross-sectional study. Postgrad Med 2023; 135: 361-369.
- [9] Onaisi R, Dumont R, Hasselgard-Rowe J, Safar D, Haller DM and Maisonneuve H. Multimorbidity and statin prescription for primary prevention of cardiovascular diseases: a cross-sectional study in general practice in France. Front Med (Lausanne) 2022; 9: 1089050.
- [10] Aivo J, Ruuskanen JO, Tornio A, Rautava P and Kyto V. Lack of Statin Therapy and Outcomes After Ischemic Stroke: a Population-Based Study. Stroke 2023; 54: 781-790.
- [11] Irwin JC, Khalesi S, Fenning AS and Vella RK. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: a systematic review and meta-analysis. Pharmacol Res 2018; 128: 264-273.
- [12] Iwere RB and Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol 2015; 80: 363-371.
- [13] Buettner C, Rippberger MJ, Smith JK, Leveille SG, Davis RB and Mittleman MA. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012; 125: 176-182.
- [14] Bruno RR, Rosa FC, Nahas PC, de Branco F and de Oliveira EP. Serum alpha-carotene, but Not Other Antioxidants, is Positively Associated with Muscle Strength in Older Adults: NHANES 2001-2002. Antioxidants (Basel) 2022; 11.
- [15] Masanes F, Rojano ILX, Salva A, Serra-Rexach JA, Artaza I and Formiga F. Cut-off Points for Muscle Mass Not Grip Strength or Gait Speed Determine Variations in Sarcopenia

All rights reserved. No reuse allowed without permission.


- Prevalence. J Nutr Health Aging 2017; 21: 825-829.
- [16] Wang YC, Bohannon RW, Li X, Sindhu B, and Kapellusch J. Hand-Grip Strength: Normative Reference Values and Equations for Individuals 18 to 85 Years of Age Residing in the United States. J Orthop Sports Phys Ther 2018; 48: 685-693.
- [17] Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C and Aihie SA. Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. Age Ageing 2010; 39: 185-191.
- [18] Veddeng S, Madland H, Molden E, Wyller TB and Romskaug R. Association between statin use and physical performance in home-dwelling older patients receiving polypharmacy: cross-sectional study. BMC Geriatr 2022; 22: 242.
- [19] Skrivankova VW, Richmond RC, Woolf B, Yarmolinsky J, Davies NM and Swanson SA. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: the STROBE-MR Statement. JAMA 2021; 326: 1614-1621.
- [20] Cai HX, Liang CC, Wang SJ, Guo JC, Wang Y, and Yu B. Renin-angiotensin system antagonists and mortality due to pneumonia, influenza, and chronic lower respiratory disease in patients with hypertension. J Geriatr Cardiol 2022; 19: 511-521.
- [21] Kramer H, Boucher RE, Leehey D, Fried L, Wei G and Greene T. Increasing Mortality in Adults with Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria. Diabetes Care 2018; 41: 775-781.
- [22] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
- [23] Zhu Y, Zhu F, Guo X, Huang S, Yang Y, and Zhang Q. Appendicular lean mass and the risk of stroke and Alzheimer's disease: a mendelian randomization study. BMC Geriatr 2024; 24: 438.
- [24] Studenski SA, Peters KW, Alley DE, Cawthon PM, Mclean RR and Harris TB. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 2014; 69: 547-558.
- [25] Peng P, Wu J, Fang W, Tian J, He M and Xiao F. Association between sarcopenia and osteoarthritis among the US adults: a cross-sectional study. Sci Rep 2024; 14: 296.
- [26] Van Ancum JM, Alcazar J, Meskers C, Nielsen BR, Suetta C and Maier AB. Impact of using the updated EWGSOP2 definition in diagnosing sarcopenia: a clinical perspective. Arch Gerontol Geriatr 2020; 90: 104125.
- [27] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, and Cederholm T. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31.
- [28] Liang Y, Wang J, Wang T, Li H, Yin C, and Liu J. Moderate selenium mitigates hand grip strength impairment associated with elevated blood cadmium and lead levels in middle-aged and elderly individuals: insights from NHANES 2011-2014. Front Pharmacol 2023; 14: 1324583.
- [29] Huang L, Lu Z, Zhou X, He L, You X and Chen C. U-Shaped Relationship Between Serum Lactate Dehydrogenase with All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2023; 18: 305-316.
- [30] Wang S, Tian W, Liu Y, Yan G, Fang S and Wang Y. Temporal trend of circulating transfatty acids and risk of long-term mortality in the general population. Clin Nutr 2021; 40:

All rights reserved. No reuse allowed without permission.

- 1095-1101.
- [31] Mera-Gaona M, Neumann U, Vargas-Canas R and Lopez DM. Evaluating the impact of multivariate imputation by MICE in feature selection. PLoS One 2021; 16: e0254720.
- [32] Suzuki T, Palus S and Springer J. Skeletal muscle wasting in chronic heart failure. ESC Heart Fail 2018; 5: 1099-1107.
- [33] Finegold JA, Manisty CH, Goldacre B, Barron AJ and Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21: 464-474.
- [34] Mansi I, Frei CR, Pugh MJ, Makris U and Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med 2013; 173: 1-10.
- [35] Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM and Cobbe SM. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-1630.
- [36] Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki L and Ahmed A. Statin therapy in the elderly: a review. Arch Gerontol Geriatr 2010; 50: 114-118.
- [37] Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS and Smith SJ. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther 2009; 14: 49-58.
- [38] Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM and Arnold AD. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol 2021; 78: 1210-1222.
- [39] Penson PE, Mancini G, Toth PP, Martin SS, Watts GF and Sahebkar A. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle 2018; 9: 1023-1033.
- [40] Cheng KY, Bao Z, Long Y, Liu C, Huang T and Cui C. Sarcopenia and Ageing. Subcell Biochem 2023; 103: 95-120.

Figure and tables

Figure 1 Flow of study



Abbreviations: NHANES, National Health and Nutrition Examination Survey; CVD, cardiovascular disease; HLP, hyperlipidemia; SNP, Single Nucleotide Polymorphism; LDH, Lactate Dehydrogenase.

A: Flow of study.

B: Two-sample Mendelian randomization study design.

Arrows represent associations.

Dashed lines with "x" in the middle represent genetic variants applied as instrumental variables

for Statins that should not be associated with potential confounding factors and do not exert an effect on sarcopenia-related traits and LDH via other pathways in assumptions 2 and 3, respectively.

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-PRESSO, MR-pleiotropy residual sum and outlier; LDH, Lactic dehydrogenase.

Table 1 Baseline characteristics of patients with cardiovascular disease, diabetes, or hyperlipidemia

| or hyperlipidemia | Statin drug use | | | | | | | | |
|------------------------|-----------------|----------------|---------------------------|---------|--|--|--|--|--|
| | Nonuse | Statin drugs | Lipid-lowering drugs | p | | | | | |
| | (13,474) | (8,481) | other than statins(n=594) | • | | | | | |
| Age, (year) | 55.4 ± 0.1 | 65.7 ± 0.1 | 63.3 ± 0.5 | < 0.001 | | | | | |
| Male, (%) | 48.2 | 53.5 | 52.2 | < 0.001 | | | | | |
| Race/ethnicity, (%) | | | | | | | | | |
| Hispanic-Mexican | 17.8 | 11.4 | 14.5 | < 0.001 | | | | | |
| Other Ethnicity | 18.2 | 16.2 | 18.0 | < 0.001 | | | | | |
| Non-Hispanic White | 42.2 | 52.3 | 54.0 | < 0.001 | | | | | |
| Non-Hispanic Black | 21.8 | 20.2 | 13.5 | < 0.001 | | | | | |
| Education status, (%) | | | | < 0.001 | | | | | |
| Less than high school | 29.9 | 28.2 | 30.6 | | | | | | |
| High school | 22.1 | 24.9 | 23.6 | | | | | | |
| More than high school | 48.1 | 46.9 | 45.8 | | | | | | |
| Marital status, (%) | | | | < 0.001 | | | | | |
| Married | 56.2 | 59.9 | 62.3 | | | | | | |
| Never married | 16.2 | 8.3 | 8.9 | | | | | | |
| other | 27.6 | 31.8 | 28.8 | | | | | | |
| PIR, (%) | | | | < 0.001 | | | | | |
| < 1.3 | 31.5 | 27.4 | 30.6 | | | | | | |
| 1.3-3.5 | 37.8 | 39.7 | 38.7 | | | | | | |
| > 3.5 | 30.7 | 32.9 | 30.8 | | | | | | |
| BMI, kg/m ² | | | | 0.003 | | | | | |
| 18.5-25 | 21.3 | 18.1 | 18.4 | | | | | | |
| 25-30 | 34.5 | 36.2 | 33.9 | | | | | | |
| ≥ 30 | 44.3 | 45.7 | 47.7 | | | | | | |
| Alcohols status, (%) | | | | < 0.001 | | | | | |
| =0, g/d | 38.5 | 44.2 | 45.3 | | | | | | |
| < 5, g/d | 42.5 | 39.1 | 40.4 | | | | | | |
| 5-30, g/d | 16.3 | 15.1 | 13.0 | | | | | | |
| > 30, g/d | 2.7 | 1.7 | 1.3 | | | | | | |
| Smoking status, (%) | | | | < 0.001 | | | | | |
| Never smoking | 52.0 | 46.8 | 46.6 | | | | | | |
| Former smoker | 28.2 | 39.4 | 37.0 | | | | | | |

| Current smoker | 19.8 | 13.8 | 16.3 | |
|------------------------|------|------|------|---------|
| Physical activity, (%) | 28.7 | 26.2 | 22.7 | 0.001 |
| HBP, (%) | 61.6 | 80.5 | 80.8 | < 0.001 |
| CKD, (%) | 11.8 | 23.6 | 25.2 | < 0.001 |
| COPD, (%) | 9.3 | 12.6 | 12.8 | < 0.001 |
| Cancer, (%) | 10.8 | 17.8 | 17.0 | < 0.001 |
| CVD, (%) | 20.0 | 35.3 | 26.9 | < 0.001 |
| Diabetes, (%) | 37.1 | 46.4 | 48.2 | < 0.001 |
| Hyperlipidemia, (%) | 71.0 | 85.8 | 88.0 | < 0.001 |

The data were adjusted for survey weights from the NHANES.

The data are presented as the means \pm SDs or percentages.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

Table 2 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers

| | Prevalence, % | nce, % Crude | | Adjusted | | After matching** | |
|---|---------------|------------------------|---------|------------------------|------|-----------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n=8,856) | | | | | | | |
| Nonusers | 21.42 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 33.60 | 1.35 (1.12 to 1.62) | < 0.001 | 1.31 (0.99 to 1.74) | 0.06 | 1.25 (1.00 to 1.55) | 0.05 |
| Lipid-lowering drugs other than statins | 35.11 | 1.36 (0.78 to 2.37) | 0.28 | 1.00 (0.49 to 2.02) | 1.00 | 1.23 (0.73 to 2.09) | 0.44 |
| ASM/Wt (n=8,839) | | | | | | | |
| Nonusers | 10.85 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 14.11 | 1.86 (1.62 to 2.13) | < 0.001 | 1.23 (0.99 to 1.54) | 0.06 | 1.14 (0.97 to 1.34) | 0.11 |
| Lipid-lowering drugs other than statins | 14.19 | 1.99 (1.33 to 2.97) | < 0.001 | 0.93 (0.53 to 1.62) | 0.79 | 0.92 (0.62 to 1.37) | 0.67 |
| ASM/Ht ² (n=8,803) | | | | | | | |
| Nonusers | 5.50 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.54 | 1.20 (0.95 to 1.52) | 0.12 | 1.11 (0.77 to 1.60) | 0.56 | 0.87 (0.64 to 1.18) | 0.38 |
| Lipid-lowering drugs other than statins | 4.17 | 0.75 (0.41 to 1.36) | 0.34 | 0.83 (0.31 to 2.25) | 0.71 | 0.99 (0.47 to 2.09) | 0.97 |
| | | β (95% CI) | P | B (95% CI) | P | B (95% CI) | P |
| Max HGS* (n=4,340) | _ | | | | | | 1 |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -3.01 (-3.97 to -2.06) | < 0.001 | -0.35 (-1.11 to 0.41) | 0.36 | -0.13 (-0.66 to 0.40) | 0.64 |
| Lipid-lowering drugs other than statins | | -3.79 (-5.95 to -1.63) | < 0.001 | -2.07 (-3.99 to -0.14) | 0.04 | -0.90 (-2.41 to 0.61) | 0.24 |

| Relative grip strength* (n=4,230) | _ | | | | | | |
|---|---------|-------------------------|---------|-----------------------|------|-----------------------|------|
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.23 (-0.30 to -0.17) | < 0.001 | -0.01 (-0.06 to 0.04) | 0.66 | -0.01 (-0.04 to 0.03) | 0.77 |
| Lipid-lowering drugs other than statins | | -0.34 (-0.49 to -0.19) | < 0.001 | -0.08 (-0.20 to 0.05) | 0.23 | -0.07 (-0.18 to 0.03) | 0.17 |
| Combined HGS* (n=4,275) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -5.9 (-7.86 to -3.93) | < 0.001 | -0.61 (-2.18 to 0.96) | 0.44 | -0.32 (-1.32 to 0.67) | 0.53 |
| Lipid-lowering drugs other than statins | | -6.82 (-10.88 to -2.76) | < 0.001 | -2.78 (-6.25 to 0.69) | 0.11 | -2.03 (-4.88 to 0.82) | 0.16 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= | =8,806) | | | | | | |
| Nonusers | 5.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.22 | 1.36 (1.13 to 1.63) | < 0.001 | 1.32 (1.00 to 1.75) | 0.05 | 1.26 (1.00 to 1.56) | 0.05 |
| Lipid-lowering drugs other than statins | 4.17 | 1.37 (0.79 to 2.39) | 0.26 | 1.01 (0.50 to 2.03) | 0.99 | 1.21 (0.72 to 2.05) | 0.47 |
| ASM and BMI definition (n=19,259) | | | | | | | |
| Nonusers | 10.80 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.20 | 0.76 (0.47 to 1.23) | 0.27 | 0.92 (0.51 to 1.66) | 0.78 | 0.98 (0.65 to 1.47) | 0.92 |
| Lipid-lowering drugs other than statins | 3.20 | 0.30 (0.08 to 1.16) | 0.08 | 0.38 (0.09 to 1.60) | 0.18 | 0.74 (0.23 to 2.44) | 0.62 |
| LDH* (n=21,908) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 2.55 (1.32 to 3.78) | < 0.001 | -0.55 (-1.81 to 0.71) | 0.39 | -0.57 (-1.72 to 0.58) | 0.33 |

| Lipid-lowering drugs other than statins | -0.42 (-3.71 to 2.88) | 0.80 | -2.77 (-6.35 to 0.81) | 0.13 | -0.28 (-3.31 to 2.75) | 0.86 |
|---|-----------------------|------|-----------------------|------|-----------------------|------|
| | | | | | 1 | |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

^{*}The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 3 Odds ratios of musculoskeletal pain for statin users compared to nonusers

| | Prevalence, % | Crude | | Adjusted | | After matchin | g* |
|---|---------------|---------------------|------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Any Region (n=5,136) | | | | | | | |
| Nonusers | 69.68 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 27.78 | 1.15 (0.96 to 1.38) | 0.12 | 1.15 (0.88 to 1.50) | 0.30 | 1.09 (0.91 to 1.31) | 0.36 |
| Lipid-lowering drugs other than statins | 2.24 | 1.08 (0.64 to 1.82) | 0.76 | 1.10 (0.59 to 2.04) | 0.75 | 1.04 (0.67 to 1.61) | 0.85 |
| Neck/Upper Back (n=5,136) | | | | | | | |
| Nonusers | 74.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 21.83 | 0.74 (0.56 to 0.97) | 0.03 | 0.96 (0.64 to 1.44) | 0.84 | 0.94 (0.67 to 1.32) | 0.73 |
| Lipid-lowering drugs other than statins | 4.15 | 1.52 (0.87 to 2.66) | 0.14 | 2.17 (1.07 to 4.39) | 0.03 | 2.19 (1.19 to 4.00) | 0.01 |
| Upper Extremities (n=5,136) | | | | | | | |
| Nonusers | 69.33 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 28.01 | 1.13 (0.92 to 1.38) | 0.23 | 1.11 (0.81 to 1.51) | 0.50 | 1.13 (0.93 to 1.39) | 0.22 |
| Lipid-lowering drugs other than statins | 2.66 | 1.16 (0.69 to 1.94) | 0.56 | 1.27 (0.68 to 2.38) | 0.44 | 1.25 (0.79 to 1.98) | 0.33 |
| Lower Back (n=5,136) | | | | | | | |
| Nonusers | 69.78 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 28.26 | 1.03 (0.82 to 1.29) | 0.82 | 1.05 (0.76 to 1.45) | 0.75 | 1.05 (0.79 to 1.39) | 0.74 |
| Lipid-lowering drugs other than statins | 1.96 | 0.66 (0.29 to 1.48) | 0.31 | 0.61 (0.24 to 1.54) | 0.28 | 0.74 (0.37 to 1.50) | 0.41 |
| Lower Extremities (n=5,136) | | | | | | | |
| Nonusers | 68.81 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 28.53 | 1.17 (0.95 to 1.45) | 0.14 | 1.12 (0.83 to 1.51) | 0.44 | 1.08 (0.84 to 1.41) | 0.54 |

| Lipid-lowering drugs other than statins | 2.66 | 1.22 (0.66 to 2.23) | 0.52 | 1.09 (0.54 to 2.22) | 0.80 | 1.01 (0.55 to 1.83) | 0.99 |
|---|------|---------------------|------|---------------------|------|---------------------|------|
|---|------|---------------------|------|---------------------|------|---------------------|------|

Abbreviations: OR, odds ratio; CI, confidence interval.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

^{*}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 4 The causal relationship between statins and sarcopenia-related traits based on two-sample Mendelian randomization analysis

| Outcome | SNPs | MR method | Beta/OR | 95% <i>CI</i> | <i>P</i> -value |
|----------------------------|------|-----------------|---------|---------------|-----------------|
| | 11 | IVW | -0.060 | -0.153, 0.033 | 0.208 |
| Appendicular lean mass | | MR Egger | -0.019 | -0.191, 0.153 | 0.834 |
| Appendicular lean mass | | Weighted median | -0.023 | -0.056, 0.010 | 0.173 |
| | 4 | MR PRESOO | -0.016 | -0.057, 0.025 | 0.488 |
| | 11 | IVW | -0.014 | -0.039, 0.012 | 0.289 |
| Hand grip strength (right) | | MR Egger | -0.003 | -0.050, 0.043 | 0.892 |
| manu grip strength (right) | | Weighted median | -0.010 | -0.031, 0.011 | 0.339 |
| | 8 | MR PRESOO | 0.003 | -0.017, 0.023 | 0.776 |
| | 11 | IVW | -0.216 | -0.044, 0.001 | 0.059 |
| Hand grip strength (left) | | MR Egger | -0.004 | -0.044, 0.036 | 0.847 |
| | | Weighted median | -0.013 | -0.031, 0.006 | 0.171 |
| | 10 | MR PRESOO | -0.021 | -0.041, 0.002 | 0.058 |
| | 11 | IVW | 1.042 | 0.889, 1.221 | 0.614 |
| Low hand grip strength | | MR Egger | 1.025 | 0.759, 1.384 | 0.875 |
| Low hand grip strength | | Weighted median | 1.028 | 0.839, 1,259 | 0.792 |
| | | MR PRESOO | 1.069 | 0.917, 1.247 | 0.411 |
| | 11 | IVW | 0.001 | -0.010, 0.011 | 0.939 |
| Walking pace | | MR Egger | 0.007 | -0.012, 0.026 | 0.497 |
| waining pace | | Weighted median | -0.002 | -0.016, 0.011 | 0.748 |
| | | MR PRESOO | 0.003 | -0.007, 0.012 | 0.649 |
| | 8 | IVW | -0.080 | -0.213, 0.053 | 0.238 |
| Lactate dehydrogenase | | MR Egger | 0.035 | -0.230, 0.230 | 0.804 |
| Luctate denyarogenase | | Weighted median | 0.003 | -0.082, 0.087 | 0.952 |
| | 6 | MR PRESOO | -0.030 | -0.100, 0.040 | 0.437 |

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MRpleiotropy residual sum and outlier.

significant. considered two-sided p-values less than 0.05 as statistically

Supplemental tables

Table S1 Details of studies and datasets used in the study

| Trait | Sample size (cases/controls) | Datatype | Unit | Ancestry | Consortium/ First Author | PMID or GWAS ID |
|----------------------------|------------------------------|------------|------|------------|--------------------------|-----------------|
| Statins | 290,385 (73,475/216,910) | Binary | / | European | UK Biobank | 31015401 |
| Appendicular lean mass | 450,243 | Continuous | kg | European | UK Biobank | 33097823 |
| Hand grip strength (right) | 461,089 | Continuous | SD | European | MRC-IEU | ukb-b-10215 |
| Hand grip strength (left) | 461,026 | Continuous | SD | European | MRC-IEU | ukb-b-7478 |
| Low hand grip strength | 121,055 (6,734/114,321) | Binary | / | European | Garan Jones | 33510174 |
| Walking pace | 459,915 | Continuous | km/s | European | MRC-IEU | ukb-b-4711 |
| Lactate dehydrogenase | 126,319 | Continuous | SD | East Asian | Ishigaki K | 29403010 |

Abbreviations: SD, Standard Deviation; PMID, PubMed Unique Identifier; GWAS ID, Genome-Wide Association Study Identifier; MRC-IEU, Medical Research Council Integrative Epidemiology Unit.

Table S2 SNPs are used as instrumental variables for Statins (P-value < 5×10⁻⁸)

| Traits | SNP | Chr | Position | Effect allele | another allele | Beta | SE | P-value | F-statistic |
|--------------------------|-------------|-----|-----------|---------------|----------------|--------------|-------------|-----------|-------------|
| Statins-ALM/HGS (right)/ | rs113911544 | 1 | 55706403 | G | A | 0.085085202 | 0.014373915 | 3.20E-09 | 35.0395019 |
| HGS (left)/LHGS/Walking | rs11591147 | 1 | 55505647 | T | G | -0.362323999 | 0.021494841 | 9.40E-64 | 284.1356506 |
| pace | rs1260326 | 2 | 27730940 | T | С | 0.059920058 | 0.005712328 | 9.70E-26 | 110.0317897 |
| | rs12725767 | 1 | 6676040 | G | A | 0.035128029 | 0.005856082 | 2.00E-09 | 35.98266012 |
| | rs12740374 | 1 | 109817590 | T | G | -0.156618273 | 0.006742468 | 2.30E-119 | 539.5691038 |
| | rs1367117 | 2 | 21263900 | A | G | 0.105726091 | 0.005900949 | 8.70E-72 | 321.0115277 |
| | rs4299376 | 2 | 44072576 | G | T | 0.086690463 | 0.005971001 | 9.20E-48 | 210.7892007 |
| | rs4541244 | 2 | 58917535 | T | C | -0.034275082 | 0.005711376 | 2.00E-09 | 36.01434333 |
| | rs570530 | 1 | 234866776 | A | G | -0.032541516 | 0.005613812 | 6.80E-09 | 33.60159042 |
| | rs693668 | 1 | 55521109 | G | A | -0.048941477 | 0.005866453 | 7.30E-17 | 69.5989924 |
| | rs79598313 | 1 | 27284913 | T | C | 0.146636976 | 0.018408443 | 1.60E-15 | 63.45310484 |
| Statins-LDH | rs113911544 | 1 | 55706403 | G | A | 0.085085202 | 0.014373915 | 3.20E-09 | 35.0395019 |
| | rs1260326 | 2 | 27730940 | T | C | 0.059920058 | 0.005712328 | 9.70E-26 | 110.0317897 |
| | rs12725767 | 1 | 6676040 | G | A | 0.035128029 | 0.005856082 | 2.00E-09 | 35.98266012 |
| | rs12740374 | 1 | 109817590 | T | G | -0.156618273 | 0.006742468 | 2.30E-119 | 539.5691038 |
| | rs1367117 | 2 | 21263900 | A | G | 0.105726091 | 0.005900949 | 8.70E-72 | 321.0115277 |
| | rs4541244 | 2 | 58917535 | T | C | -0.034275082 | 0.005711376 | 2.00E-09 | 36.01434333 |
| | rs570530 | 1 | 234866776 | A | G | -0.032541516 | 0.005613812 | 6.80E-09 | 33.60159042 |
| | rs693668 | 1 | 55521109 | G | A | -0.048941477 | 0.005866453 | 7.30E-17 | 69.5989924 |
| | rs7534572 | 1 | 62999675 | C | G | -0.074218207 | 0.005852643 | 7.50E-37 | 160.8114059 |

Abbreviations: SNP, Single nucleotide polymorphism, MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier. ALM, Appendicular Lean Muscle; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

Table S3 Definition of statins and linid-lowering drugs

| Table S3 Definition of statins and Generic drug code | Drug name |
|--|--|
| Statin drugs | |
| d00280 | lovastatin |
| d00348 | pravastatin |
| d00746 | simvastatin |
| d03183 | fluvastatin |
| d04105 | atorvastatin |
| d04140 | cerivastatin |
| d04787 | lovastatin; niacin |
| d04851 | rosuvastatin |
| d05048 | amlodipine; atorvastatin |
| d05348 | ezetimibe; simvastatin |
| d07110 | niacin; simvastatin |
| d07637 | pitavastatin |
| d07805 | simvastatin; sitagliptin |
| d08383 | evolocumab |
| Lipid-lowering drugs other than statins | |
| c00019 | antihyperlipidemic agents - unspecified |
| c00173 | hmg-coa reductase inhibitors - unspecified |
| d00193 | cholestyramine |
| d00196 | clofibrate |
| d00245 | gemfibrozil |
| d00353 | probucol |
| d00744 | colestipol |
| d04286 | fenofibrate |
| d04695 | colesevelam |
| d04824 | ezetimibe |
| d07371 | fenofibric acid |
| d07891 | icosapent |
| d08374 | alirocumab |
| h00036 | bezafibrate |
| | |

Table S4 Characteristics of cardiovascular disease, diabetes, or hyperlipidemia patients with Statin use or nonuse after matching

| Table 54 Characteristics | | After matching | 1 1 |
|--------------------------|-----------------|-------------------------|-------------------------|
| | Non-use (5,249) | Statin drug use (5,429) | Standardized difference |
| Age, (year) | 62.6 ± 0.2 | 64.7 ± 0.1 | < 0.001 |
| Male, (%) | 50.9 | 52.4 | < 0.001 |
| Race/ethnicity, (%) | | | |
| Hispanic-Mexican | 13.3 | 11.8 | < 0.001 |
| Other Ethnicity | 17.5 | 16.5 | < 0.001 |
| Non-Hispanic White | 47.0 | 51.3 | < 0.001 |
| Non-Hispanic Black | 22.2 | 20.4 | < 0.001 |
| Education status, (%) | | | < 0.001 |
| Less than high school | 29.6 | 28.5 | |
| High school | 23.6 | 24.3 | |
| More than high school | 46.8 | 47.2 | |
| Marital status, (%) | | | < 0.001 |
| Married | 57.2 | 59.1 | |
| Never married | 10.9 | 9.0 | |
| Other | 32.0 | 31.9 | |
| PIR, (%) | | | < 0.001 |
| < 1.3 | 30.0 | 27.8 | |
| 1.3-3.5 | 38.5 | 39.5 | |
| > 3.5 | 31.5 | 32.7 | |

| BMI, kg/m ² | | | < 0.001 |
|------------------------|------|------|---------|
| 18.5-25 | 20.4 | 18.2 | |
| 25-30 | 33.5 | 36.2 | |
| ≥ 30 | 46.1 | 45.7 | |
| Alcohols status, (%) | | | <0.001 |
| = 0, g/d | 42.5 | 43.7 | |
| < 5, g/d | 40.0 | 39.2 | |
| 5-30, g/d | 15.1 | 15.5 | |
| > 30, g/d | 2.3 | 1.6 | |
| Smoking status, (%) | | | < 0.001 |
| Never smoking | 49.0 | 47.4 | |
| Former smoker | 34.6 | 38.1 | |
| Current smoker | 16.4 | 14.5 | |
| Moderate exercise, (%) | 26.2 | 26.4 | < 0.001 |
| HBP, (%) | 76.6 | 79.2 | < 0.001 |
| CKD, (%) | 20.0 | 23.0 | < 0.001 |
| COPD, (%) | 12.1 | 12.6 | < 0.001 |
| Cancer, (%) | 15.6 | 17.1 | < 0.001 |
| CVD, (%) | 27.7 | 33.0 | < 0.001 |
| Diabetes, (%) | 43.9 | 45.1 | < 0.001 |
| Hyperlipidemia, (%) | 42.9 | 45.5 | < 0.001 |

Data were adjusted for survey weights of NHANES.

Data are presented as means \pm SD or percent.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular diseases; CKD, Chronic Kidney Disease; COPD,

Chronic Obstructive Pulmonary Disease.

Table S5 The association between statin users and skeletal muscle-related phenotypes compared with nonusers by stepwise regression analysis

| | ASM/BMI (n=8 | | ASM/Ht ² and bf Sa Obesity (n=8,8 | rcopenic | Max HGS (n=4,3 | • | Relative HGS (n=4 | | Combined HGS (n= | 4,275) | Neck/Upper (n=5,136) | Back |
|---------------------|---------------------|------------|---|------------|------------------------|------------|------------------------|------------|------------------------|------------|----------------------|------|
| | OR (95% CI) | P | OR (95% CI) | P | β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | OR (95% CI) | P |
| Unadjusted | 1.35 (1.12 to 1.62) | < 0.001 | 1.36 (1.13 to 1.63) | < 0.001 | -3.01 (-3.97 to -2.06) | < 0.001 | -0.23 (-0.30 to -0.17) | < 0.001 | -5.90 (-7.86 to -3.93) | < 0.001 | 0.74 (0.56 to 0.97) | 0.03 |
| Age adjustment | 1.01 (0.82 to 1.23) | 0.96 | 1.01 (0.83 to 1.23) | 0.91 | 0.67 (-0.22 to 1.56) | 0.14 | -0.02 (-0.10 to 0.05) | 0.5 | 1.31 (-0.50 to 3.11) | 0.15 | 0.83 (0.61 to 1.12) | 0.21 |
| + Sex | 1.24 (1.00 to 1.55) | 0.05 | 1.25 (1.01 to 1.56) | 0.05 | 0.10 (-0.64 to 0.84) | 0.78 | -0.06 (-0.12 to -0.01) | 0.03 | 0.24 (-1.26 to 1.74) | 0.75 | 0.85 (0.63 to 1.14) | 0.27 |
| + Race/ ethnicity | 1.29 (1.03 to 1.62) | 0.03 | 1.30 (1.04 to 1.63) | 0.02 | -0.09 (-0.81 to 0.63) | 0.80 | -0.07 (-0.13 to -0.02) | 0.01 | -0.14 (-1.61 to 1.33) | 0.84 | 0.83 (0.61 to 1.11) | 0.21 |
| +Education level | 1.29 (1.02 to 1.62) | 0.03 | 1.29 (1.03 to 1.63) | 0.03 | -0.09 (-0.83 to 0.66) | 0.82 | -0.07 (-0.13 to -0.02) | 0.01 | -0.14 (-1.64 to 1.35) | 0.85 | 0.83 (0.61 to 1.12) | 0.21 |
| +Marital status | 1.28 (1.02 to 1.62) | 0.03 | 1.29 (1.03 to 1.63) | 0.03 | -0.16 (-0.90 to 0.57) | 0.65 | -0.08 (-0.14 to -0.02) | 0.01 | -0.30 (-1.78 to 1.18) | 0.68 | 0.82 (0.61 to 1.12) | 0.2 |
| + PIR | 1.31 (1.02 to 1.69) | 0.03 | 1.32 (1.03 to 1.70) | 0.03 | -0.28 (-1.02 to 0.45) | 0.44 | -0.09 (-0.15 to -0.04) | < 0.001 | -0.48 (-1.98 to 1.01) | 0.51 | 0.86 (0.61 to 1.21) | 0.37 |
| + BMI | - | - | - | - | -0.55 (-1.24 to 0.13) | 0.11 | -0.04 (-0.08 to 0.01) | 0.08 | -1.05 (-2.42 to 0.31) | 0.13 | 0.88 (0.63 to 1.25) | 0.48 |
| + Alcohols statues | 1.33 (1.03 to 1.72) | 0.03 | 1.34 (1.04 to 1.73) | 0.03 | -0.49 (-1.22 to 0.23) | 0.18 | -0.04 (-0.08 to 0.01) | 0.10 | -0.90 (-2.30 to 0.51) | 0.2 | 0.82 (0.60 to 1.12) | 0.21 |
| + Smoking status | 1.34 (1.03 to 1.73) | 0.03 | 1.35 (1.04 to 1.74) | 0.02 | -0.49 (-1.23 to 0.24) | 0.18 | -0.04 (-0.08 to 0.01) | 0.10 | -0.90 (-2.31 to 0.52) | 0.21 | 0.82 (0.60 to 1.12) | 0.2 |
| + Physical activity | 1.35 (1.04 to 1.74) | 0.02 | 1.36 (1.05 to 1.75) | 0.02 | -0.50 (-1.27 to 0.28) | 0.2 | -0.04 (-0.09 to 0.01) | 0.13 | -0.91 (-2.40 to 0.58) | 0.22 | 0.81 (0.59 to 1.11) | 0.19 |

| + HBP | 1.31 (1.01 to 1.71) | 0.04 | 1.32 (1.02 to 1.72) | 0.04 | -0.54 (-1.32 to 0.24) | 0.17 | -0.04 (-0.08 to 0.01) | 0.15 | -0.97 (-2.48 to 0.54) | 0.20 | 0.82 (0.59 to 1.13) | 0.21 |
|------------------|---------------------|------|---------------------|------|-----------------------|------|-----------------------|------|-----------------------|------|---------------------|------|
| + CVD | 1.31 (0.99 to 1.72) | 0.06 | 1.32 (1.00 to 1.74) | 0.05 | -0.33 (-1.09 to 0.44) | 0.39 | -0.02 (-0.07 to 0.03) | 0.37 | -0.63 (-2.14 to 0.88) | 0.40 | 0.81 (0.56 to 1.18) | 0.27 |
| + Diabetes | 1.28 (0.97 to 1.69) | 0.08 | 1.29 (0.98 to 1.71) | 0.07 | -0.25 (-1.04 to 0.54) | 0.52 | -0.01 (-0.06 to 0.04) | 0.62 | -0.48 (-2.02 to 1.07) | 0.53 | 0.82 (0.56 to 1.19) | 0.28 |
| + Hyperlipidemia | 1.32 (0.99 to 1.75) | 0.06 | 1.33 (1.00 to 1.77) | 0.05 | -0.26 (-1.05 to 0.53) | 0.50 | -0.01 (-0.06 to 0.04) | 0.71 | -0.44 (-2.02 to 1.14) | 0.57 | 0.84 (0.56 to 1.24) | 0.36 |
| + CKD | 1.33 (0.99 to 1.78) | 0.06 | 1.34 (1.00 to 1.80) | 0.05 | -0.31 (-1.11 to 0.5) | 0.44 | -0.01 (-0.06 to 0.04) | 0.76 | -0.51 (-2.12 to 1.10) | 0.52 | 0.82 (0.58 to 1.17) | 0.26 |
| + COPD | 1.32 (0.98 to 1.76) | 0.07 | 1.33 (0.99 to 1.78) | 0.06 | -0.31 (-1.11 to 0.49) | 0.43 | -0.01 (-0.06 to 0.04) | 0.74 | -0.53 (-2.13 to 1.08) | 0.51 | 0.83 (0.58 to 1.19) | 0.29 |
| + Cancer | 1.32 (0.98 to 1.76) | 0.07 | 1.33 (0.99 to 1.78) | 0.06 | -0.32 (-1.12 to 0.48) | 0.42 | -0.01 (-0.06 to 0.04) | 0.72 | -0.55 (-2.14 to 1.05) | 0.49 | 0.85 (0.59 to 1.24) | 0.39 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; HGS, Hand grip strength; BMI, body mass index; Wt, weight; Ht, height; PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women.

Table S6 The results of sensitivity analysis for two-sample Mendelian randomization analysis of the causal relationships between Statins and sarcopenia-related traits

| Outcome | No. of IVs | Heterog | MR-Eg | ger pleioti | MR-PRESOO | | |
|----------------------------|------------|-------------|----------|-------------|-----------|-----------------|---------------------|
| | | Cochran's Q | P-value | intercept | SE | <i>P</i> -value | Global Test P-value |
| Appendicular lean mass | 11 | 346.6756844 | 2.02E-68 | -0.0042237 | 0.00746 | 0.585 | <0.001 |
| Hand grip strength (right) | 11 | 40.71459187 | 1.27E-05 | -0.0010619 | 0.00202 | 0.612 | <0.001 |
| Hand grip strength (left) | 11 | 32.39685682 | <0.001 | -0.0018087 | 0.00172 | 0.321 | <0.001 |
| Low hand grip strength | 11 | 10.56373443 | 0.393 | 0.00164006 | 0.01293 | 0.902 | 0.463 |
| Walking pace | 8 | 8.438255201 | 0.586 | -0.0006592 | 0.00082 | 0.443 | 0.622 |
| Lactate dehydrogenase | 11 | 38.72767287 | 2.20E-06 | -0.0082974 | 0.00844 | 0.363 | <0.001 |

Abbreviations: MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided p-values less than 0.05 as statistically significant.

Table S7 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among the population over 65 years old

| | Prevalence, % | Prevalence, % Crude | | Adjusted | - | After matching** | | |
|---|---------------|-----------------------|---------|-----------------------|------|----------------------|------|--|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
| Sarcopenic | | | | | | | | |
| ASM/BMI (n= 2,367) | | | | | | | | |
| Nonusers | 35.05 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | | |
| Statin users | 43.20 | 0.86 (0.65 to 1.13) | 0.27 | 1.04 (0.73 to 1.49) | 0.81 | 1.11 (0.80 to 1.55) | 0.52 | |
| Lipid-lowering drugs other than statins | 34.23 | 1.19 (0.53 to 2.67) | 0.68 | 1.02 (0.43 to 2.40) | 0.97 | 1.31 (0.58 to 2.97) | 0.51 | |
| ASM/Wt (n= 2,408) | | | | | | | | |
| Nonusers | 24.01 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | | |
| Statin users | 21.34 | 1.41 (1.12 to 1.77) | < 0.001 | 1.17 (0.83 to 1.63) | 0.36 | 1.16 (0.90 to 1.50) | 0.25 | |
| Lipid-lowering drugs other than statins | 27.26 | 0.96 (0.52 to 1.80) | 0.91 | 0.68 (0.29 to 1.59) | 0.36 | 0.87 (0.45 to 1.70) | 0.69 | |
| ASM/Ht^2 (n= 2,430) | | | | | | | | |
| Nonusers | 15.26 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | | |
| Statin users | 12.60 | 0.80(0.60 to 1.06) | 0.12 | 0.84 (0.55 to 1.27) | 0.39 | 0.74 (0.50 to 1.10) | 0.13 | |
| Lipid-lowering drugs other than statins | 7.08 | 0.42 (0.19 to 0.95) | 0.04 | 0.34 (0.15 to 0.78) | 0.01 | 0.57 (0.20 to 1.57) | 0.28 | |
| Max HGS* (n= 1,590) | _ | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | | |
| Statin users | | 0.54 (-0.81 to 1.88) | 0.42 | -0.22 (-0.94 to 0.51) | 0.55 | 0.14 (-0.63 to 0.91) | 0.72 | |
| Lipid-lowering drugs other than statins | | -0.30 (-3.42 to 2.83) | 0.85 | -0.32 (-2.20 to 1.56) | 0.73 | 0.10 (-2.21 to 2.40) | 0.94 | |
| Relative HGS* (n= 1,532) | | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | | |

| Statin users | | -0.01 (-0.1 to 0.08) | 0.81 | -0.02 (-0.07 to 0.03) | 0.41 | 0.02 (-0.04 to 0.07) | 0.52 |
|---|-------|------------------------|------|-----------------------|------|-----------------------|------|
| Lipid-lowering drugs other than statins | | -0.02 (-0.23 to 0.19) | 0.86 | 0.03 (-0.11 to 0.17) | 0.64 | -0.03 (-0.19 to 0.13) | 0.73 |
| Combined HGS* (n= 1,560) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 0.86 (-1.70 to 3.42) | 0.50 | -0.58 (-1.88 to 0.72) | 0.37 | -0.06 (-1.56 to 1.44) | 0.94 |
| Lipid-lowering drugs other than statins | | 0.15 (-6.25 to 6.55) | 0.96 | 0.09 (-3.28 to 3.46) | 0.96 | -1.24 (-5.70 to 3.22) | 0.59 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= | | | | | | | |
| 2,369) | | | | | | | |
| Nonusers | 14.68 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 12.60 | 0.87 (0.66 to 1.14) | 0.29 | 1.06 (0.74 to 1.52) | 0.74 | 1.15 (0.83 to 1.59) | 0.41 |
| Lipid-lowering drugs other than statins | 7.08 | 1.20 (0.53 to 2.69) | 0.66 | 1.03 (0.44 to 2.44) | 0.95 | 1.36 (0.6 to 3.07) | 0.46 |
| ASM and BMI definition (n= 7,839) | | | | | | | |
| Nonusers | 14.80 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.10 | 0.54 (0.29 to 1.00) | 0.05 | 0.74 (0.33 to 1.67) | 0.47 | 0.83 (0.48 to 1.46) | 0.53 |
| Lipid-lowering drugs other than statins | 4.60 | 0.31 (0.05 to 1.92) | 0.21 | 0.42 (0.06 to 2.81) | 0.37 | 0.91 (0.21 to 4.04) | 0.91 |
| LDH* (n= 8,954) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -2.34 (-4.15 to -0.54) | 0.01 | -0.73 (-2.65 to 1.19) | 0.45 | 0.04 (-1.58 to 1.66) | 0.96 |
| Lipid-lowering drugs other than statins | | -2.97 (-8.28 to 2.35) | 0.27 | -1.81 (-7.51 to 3.89) | 0.53 | -0.44 (-4.76 to 3.89) | 0.84 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 2,312) | | | | | | | |

| Nonusers | 33.74 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Statin users | 35.99 | 1.10 (0.86 to 1.42) | 0.43 | 1.13 (0.82 to 1.55) | 0.44 | 0.99 (0.77 to 1.27) | 0.91 |
| Lipid-lowering drugs other than statins | 32.47 | 0.94 (0.51 to 1.76) | 0.85 | 0.92 (0.44 to 1.91) | 0.82 | 1.19 (0.64 to 2.18) | 0.58 |
| Neck/Upper Back (n= 2,312) | | | | | | | |
| Nonusers | 7.01 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.02 | 0.85 (0.58 to 1.25) | 0.40 | 0.77 (0.48 to 1.24) | 0.27 | 0.74 (0.45 to 1.22) | 0.23 |
| Lipid-lowering drugs other than statins | 11.68 | 1.75 (0.84 to 3.66) | 0.13 | 1.83 (0.92 to 3.63) | 0.08 | 1.80 (0.69 to 4.68) | 0.23 |
| Upper Extremities (n= 2,312) | | | | | | | |
| Nonusers | 23.40 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 25.68 | 1.13 (0.84 to 1.52) | 0.41 | 1.23 (0.85 to 1.80) | 0.27 | 1.08 (0.82 to 1.42) | 0.58 |
| Lipid-lowering drugs other than statins | 25.76 | 1.14 (0.54 to 2.37) | 0.73 | 1.24 (0.59 to 2.63) | 0.56 | 1.58 (0.83 to 3.01) | 0.16 |
| Lower Back (n= 2,312) | | | | | | | |
| Nonusers | 7.46 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 9.74 | 1.34 (0.90 to 1.99) | 0.15 | 1.49 (0.92 to 2.42) | 0.10 | 1.07 (0.70 to 1.63) | 0.75 |
| Lipid-lowering drugs other than statins | 6.04 | 0.80 (0.28 to 2.29) | 0.67 | 1.11 (0.36 to 3.44) | 0.85 | 0.88 (0.30 to 2.62) | 0.82 |
| Lower Extremities (n= 2,312) | | | | | | | |
| Nonusers | 12.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.49 | 1.05 (0.74 to 1.50) | 0.78 | 0.91 (0.63 to 1.34) | 0.64 | 0.88 (0.61 to 1.29) | 0.52 |
| Lipid-lowering drugs other than statins | 10.23 | 0.77 (0.31 to 1.88) | 0.56 | 0.74 (0.24 to 2.33) | 0.60 | 0.96 (0.38 to 2.39) | 0.93 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school,

High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m2 in men or <5.5 kg/m2 in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S8 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with diabetes

| | Prevalence, % | Crude | | Adjusted | | After matchi | ng** |
|---|---------------|------------------------|---------|------------------------|------|-----------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 3,136) | | | | | | | |
| Nonusers | 31.76 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 45.27 | 1.02 (0.71 to 1.45) | 0.92 | 1.57 (0.94 to 2.61) | 0.09 | 1.29 (0.85 to 1.97) | 0.23 |
| Lipid-lowering drugs other than statins | 34.44 | 1.05 (0.51 to 2.18) | 0.90 | 1.11 (0.40 to 3.05) | 0.84 | 1.20 (0.43 to 3.38) | 0.73 |
| ASM/Wt (n= 3,153) | | | | | | | |
| Nonusers | 14.26 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 16.43 | 1.34 (1.04 to 1.73) | 0.03 | 0.88 (0.63 to 1.23) | 0.45 | 0.96 (0.72 to 1.28) | 0.76 |
| Lipid-lowering drugs other than statins | 13.05 | 1.67 (0.78 to 3.56) | 0.18 | 0.72 (0.32 to 1.62) | 0.43 | 0.81 (0.40 to 1.66) | 0.57 |
| ASM/Ht ² (n= 3,169) | | | | | | | |
| Nonusers | 4.79 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 4.75 | 0.76 (0.49 to 1.17) | 0.21 | 0.46 (0.27 to 0.80) | 0.01 | 0.55 (0.32 to 0.93) | 0.03 |
| Lipid-lowering drugs other than statins | 2.37 | 0.58 (0.24 to 1.41) | 0.22 | 0.50 (0.19 to 1.37) | 0.18 | 0.61 (0.16 to 2.31) | 0.47 |
| Max HGS* (n= 1,746) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.14 (-2.01 to 1.73) | 0.88 | -0.59 (-1.83 to 0.65) | 0.34 | -0.50 (-1.76 to 0.75) | 0.43 |
| Lipid-lowering drugs other than statins | | -6.13 (-9.45 to -2.82) | < 0.001 | -3.86 (-6.95 to -0.77) | 0.02 | -3.43 (-7.85 to 1.00) | 0.13 |
| Relative HGS* (n= 1,685) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.09 (-0.23 to 0.05) | 0.21 | -0.03 (-0.14 to 0.08) | 0.54 | -0.07 (-0.16 to 0.02) | 0.12 |

| Lipid-lowering drugs other than statins | | -0.60 (-0.86 to -0.34) | < 0.001 | -0.13 (-0.36 to 0.11) | 0.29 | -0.47 (-0.79 to -0.15) | < 0.001 |
|--|-------|-------------------------|---------|-----------------------|------|--------------------------|---------|
| Combined HGS* (n= 1,711) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.27 (-4.14 to 3.59) | 0.89 | -0.86 (-3.41 to 1.70) | 0.50 | -1.18 (-3.50 to 1.14) | 0.32 |
| Lipid-lowering drugs other than statins | | -9.71 (-16.59 to -2.82) | 0.01 | -4.87 (-9.87 to 0.13) | 0.06 | -11.85 (-20.39 to -3.32) | 0.01 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 3,139) | | | | | | | |
| Nonusers | 4.35 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 4.36 | 1.02 (0.72 to 1.46) | 0.90 | 1.58 (0.95 to 2.66) | 0.08 | 1.52 (1.00 to 2.30) | 0.05 |
| Lipid-lowering drugs other than statins | 2.37 | 1.06 (0.51 to 2.20) | 0.87 | 1.12 (0.40 to 3.09) | 0.83 | 1.47 (0.52 to 4.15) | 0.46 |
| ASM and BMI definition (n= 7,473) | | | | | | | |
| Nonusers | 10.71 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 7.73 | 0.59 (0.27 to 1.27) | 0.18 | 1.05 (0.47 to 2.34) | 0.91 | 1.41 (0.67 to 2.96) | 0.36 |
| Lipid-lowering drugs other than statins | 4.68 | 0.46 (0.06 to 3.50) | 0.45 | 0.47 (0.06 to 3.92) | 0.49 | 1.05 (0.13 to 8.72) | 0.96 |
| LDH* (n= 8,973) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 1.11 (-1.48 to 3.71) | 0.40 | 0.39 (-2.22 to 2.99) | 0.77 | -0.75 (-3.27 to 1.78) | 0.56 |
| Lipid-lowering drugs other than statins | | -0.06 (-5.38 to 5.25) | 0.98 | -1.58 (-7.05 to 3.89) | 0.57 | 1.90 (-5.21 to 9.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 1,843) | | | | | | | |
| Nonusers | 37.86 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 51.70 | 0.84 (0.63 to 1.11) | 0.21 | 0.88 (0.64 to 1.21) | 0.43 | 0.82 (0.60 to 1.11) | 0.20 |
| Lipid-lowering drugs other than statins | 46.79 | 0.60 (0.24 to 1.49) | 0.26 | 0.37 (0.13 to 1.05) | 0.06 | 0.53 (0.24 to 1.16) | 0.11 |

| Neck/Upper Back (n= 1,843) | | | | | | | |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Nonusers | 8.30 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 8.51 | 0.54 (0.36 to 0.82) | 0.01 | 0.77 (0.46 to 1.27) | 0.29 | 0.71 (0.42 to 1.20) | 0.20 |
| Lipid-lowering drugs other than statins | 19.42 | 0.85 (0.30 to 2.37) | 0.74 | 0.53 (0.12 to 2.33) | 0.39 | 1.05 (0.35 to 3.17) | 0.94 |
| Upper Extremities (n= 1,843) | | | | | | | |
| Nonusers | 25.81 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 36.91 | 0.84 (0.62 to 1.15) | 0.27 | 0.94 (0.64 to 1.36) | 0.72 | 0.86 (0.62 to 1.19) | 0.36 |
| Lipid-lowering drugs other than statins | 32.53 | 0.64 (0.22 to 1.85) | 0.40 | 0.52 (0.17 to 1.53) | 0.23 | 0.71 (0.31 to 1.61) | 0.42 |
| Lower Back (n= 1,843) | | | | | | | |
| Nonusers | 14.52 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 13.15 | 0.66 (0.46 to 0.94) | 0.02 | 0.75 (0.46 to 1.22) | 0.23 | 0.77 (0.51 to 1.18) | 0.23 |
| Lipid-lowering drugs other than statins | 12.89 | 0.54 (0.16 to 1.76) | 0.30 | 0.57 (0.16 to 2.05) | 0.38 | 0.71 (0.25 to 2.00) | 0.52 |
| Lower Extremities (n= 1,843) | | | | | | | |
| Nonusers | 15.33 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 23.06 | 0.89 (0.61 to 1.30) | 0.53 | 1.05 (0.66 to 1.67) | 0.83 | 0.90 (0.61 to 1.34) | 0.61 |
| Lipid-lowering drugs other than statins | 20.80 | 0.67 (0.22 to 2.01) | 0.46 | 0.61 (0.20 to 1.84) | 0.37 | 0.52 (0.18 to 1.48) | 0.22 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S9 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with cardiovascular disease

| | Prevalence, % | Crude | | Adjusted | | After matchin | g** |
|---|---------------|------------------------|---------|------------------------|------|-----------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 1,641) | | | | | | | |
| Nonusers | 33.76 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 40.61 | 1.02 (0.71 to 1.45) | 0.92 | 1.57 (0.94 to 2.61) | 0.09 | 1.29 (0.85 to 1.97) | 0.23 |
| Lipid-lowering drugs other than statins | 45.97 | 1.05 (0.51 to 2.18) | 0.90 | 1.11 (0.40 to 3.05) | 0.84 | 1.20 (0.43 to 3.38) | 0.73 |
| ASM/Wt (n= 1,671) | | | | | | | |
| Nonusers | 15.67 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 15.92 | 1.34 (1.04 to 1.73) | 0.03 | 0.88 (0.63 to 1.23) | 0.45 | 0.96 (0.72 to 1.28) | 0.76 |
| Lipid-lowering drugs other than statins | 16.32 | 1.67 (0.78 to 3.56) | 0.18 | 0.72 (0.32 to 1.62) | 0.43 | 0.81 (0.40 to 1.66) | 0.57 |
| ASM/Ht ² (n= 1,676) | | | | | | | |
| Nonusers | 10.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.51 | 0.76 (0.49 to 1.17) | 0.21 | 0.46 (0.27 to 0.8) | 0.01 | 0.55 (0.32 to 0.93) | 0.03 |
| Lipid-lowering drugs other than statins | 6.61 | 0.58 (0.24 to 1.41) | 0.22 | 0.50 (0.19 to 1.37) | 0.18 | 0.61 (0.16 to 2.31) | 0.47 |
| Max HGS* (n= 996) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.14 (-2.01 to 1.73) | 0.88 | -0.59 (-1.83 to 0.65) | 0.34 | -0.50 (-1.76 to 0.75) | 0.43 |
| Lipid-lowering drugs other than statins | | -6.13 (-9.45 to -2.82) | < 0.001 | -3.86 (-6.95 to -0.77) | 0.02 | -3.43 (-7.85 to 1.00) | 0.13 |
| Relative HGS* (n= 947) | _ | | | | | | |
| Nonusers | | Ref. | 1 | Ref. | | Ref. | |

| Statin users | | -0.09 (-0.23 to 0.05) | 0.21 | -0.03 (-0.14 to 0.08) | 0.54 | -0.07 (-0.16 to 0.02) | 0.12 |
|--|-------|-------------------------|---------|-----------------------|------|--------------------------|---------|
| Lipid-lowering drugs other than statins | | -0.60 (-0.86 to -0.34) | < 0.001 | -0.13 (-0.36 to 0.11) | 0.29 | -0.47 (-0.79 to -0.15) | < 0.001 |
| Combined HGS* (n= 968) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.27 (-4.14 to 3.59) | 0.89 | -0.86 (-3.41 to 1.7) | 0.50 | -1.18 (-3.50 to 1.14) | 0.32 |
| Lipid-lowering drugs other than statins | | -9.71 (-16.59 to -2.82) | 0.01 | -4.87 (-9.87 to 0.13) | 0.06 | -11.85 (-20.39 to -3.32) | 0.01 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht2 and Body Fat Percent Definition (n= 1,643) | | | | | | | |
| Nonusers | 10.14 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 7.14 | 1.02 (0.72 to 1.46) | 0.90 | 1.58 (0.95 to 2.66) | 0.08 | 1.52 (1.00 to 2.30) | 0.05 |
| Lipid-lowering drugs other than statins | 6.61 | 1.06 (0.51 to 2.20) | 0.87 | 1.12 (0.40 to 3.09) | 0.83 | 1.47 (0.52 to 4.15) | 0.46 |
| ASM and BMI definition (n= 4,725) | | | | | | | |
| Nonusers | 49.18 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.73 | 0.59 (0.27 to 1.27) | 0.18 | 1.05 (0.47 to 2.34) | 0.91 | 1.41 (0.67 to 2.96) | 0.36 |
| Lipid-lowering drugs other than statins | 36.72 | 0.46 (0.06 to 3.50) | 0.45 | 0.47 (0.06 to 3.92) | 0.49 | 1.05 (0.13 to 8.72) | 0.96 |
| LDH* (n= 5,340) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 1.11 (-1.48 to 3.71) | 0.40 | 0.39 (-2.22 to 2.99) | 0.77 | -0.75 (-3.27 to 1.78) | 0.56 |
| Lipid-lowering drugs other than statins | | -0.06 (-5.38 to 5.25) | 0.98 | -1.58 (-7.05 to 3.89) | 0.57 | 1.90 (-5.21 to 9.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 1,158) | | | | | | | |
| Nonusers | 49.18 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.73 | 0.84 (0.63 to 1.11) | 0.21 | 0.88 (0.64 to 1.21) | 0.43 | 0.82 (0.60 to 1.11) | 0.20 |

| Lipid-lowering drugs other than statins | 36.72 | 0.60 (0.24 to 1.49) | 0.26 | 0.37 (0.13 to 1.05) | 0.06 | 0.53 (0.24 to 1.16) | 0.11 |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Neck/Upper Back (n= 1,158) | | | | | | | |
| Nonusers | 16.46 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 9.68 | 0.54 (0.36 to 0.82) | 0.01 | 0.77 (0.46 to 1.27) | 0.29 | 0.71 (0.42 to 1.20) | 0.20 |
| Lipid-lowering drugs other than statins | 14.29 | 0.85 (0.30 to 2.37) | 0.74 | 0.53 (0.12 to 2.33) | 0.39 | 1.05 (0.35 to 3.17) | 0.94 |
| Upper Extremities (n= 1,158) | | | | | | | |
| Nonusers | 34.93 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 31.13 | 0.84 (0.62 to 1.15) | 0.27 | 0.94 (0.64 to 1.36) | 0.72 | 0.86 (0.62 to 1.19) | 0.36 |
| Lipid-lowering drugs other than statins | 25.48 | 0.64 (0.22 to 1.85) | 0.40 | 0.52 (0.17 to 1.53) | 0.23 | 0.71 (0.31 to 1.61) | 0.42 |
| Lower Back (n= 1,158) | | | | | | | |
| Nonusers | 20.31 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 14.39 | 0.66 (0.46 to 0.94) | 0.02 | 0.75 (0.46 to 1.22) | 0.23 | 0.77 (0.51 to 1.18) | 0.23 |
| Lipid-lowering drugs other than statins | 12.07 | 0.54 (0.16 to 1.76) | 0.30 | 0.57 (0.16 to 2.05) | 0.38 | 0.71 (0.25 to 2.00) | 0.52 |
| Lower Extremities (n= 1,158) | | | | | | | |
| Nonusers | 23.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 21 | 0.89 (0.61 to 1.30) | 0.53 | 1.05 (0.66 to 1.67) | 0.83 | 0.90 (0.61 to 1.34) | 0.61 |
| Lipid-lowering drugs other than statins | 16.71 | 0.67 (0.22 to 2.01) | 0.46 | 0.61 (0.20 to 1.84) | 0.37 | 0.52 (0.18 to 1.48) | 0.22 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase; We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m2 in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin

Table S10 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with hyperlipidemia

| | Prevalence, % | Crude | | Adjusted | | After matchin | g** |
|---|---------------|------------------------|---------|-----------------------|------|-----------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 6,627) | | | | | | | |
| Nonusers | 18.39 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 32.33 | 1.43 (1.19 to 1.72) | < 0.001 | 1.15 (0.85 to 1.56) | 0.37 | 1.13 (0.88 to 1.45) | 0.36 |
| Lipid-lowering drugs other than statins | 35.10 | 1.58 (0.90 to 2.79) | 0.11 | 1.08 (0.51 to 2.28) | 0.85 | 1.26 (0.72 to 2.20) | 0.42 |
| ASM/Wt (n= 6,638) | | | | | | | |
| Nonusers | 10.11 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.90 | 2.12 (1.83 to 2.46) | < 0.001 | 1.20 (0.94 to 1.54) | 0.15 | 1.08 (0.89 to 1.31) | 0.45 |
| Lipid-lowering drugs other than statins | 15.12 | 2.40 (1.57 to 3.68) | < 0.001 | 0.98 (0.54 to 1.79) | 0.95 | 0.88 (0.57 to 1.36) | 0.58 |
| ASM/Ht2 (n= 6,640) | | | | | | | |
| Nonusers | 5.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.26 | 1.24 (0.97 to 1.60) | 0.09 | 1.21 (0.83 to 1.77) | 0.31 | 0.96 (0.68 to 1.37) | 0.83 |
| Lipid-lowering drugs other than statins | 4.16 | 0.81 (0.42 to 1.55) | 0.51 | 1.19 (0.41 to 3.47) | 0.75 | 1.30 (0.59 to 2.88) | 0.52 |
| Max HGS* (n= 3,407) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -3.38 (-4.40 to -2.36) | < 0.001 | -0.10 (-1.02 to 0.83) | 0.83 | 0.10 (-0.50 to 0.70) | 0.75 |
| Lipid-lowering drugs other than statins | | -3.93 (-6.21 to -1.65) | < 0.001 | -2.04 (-4.21 to 0.12) | 0.06 | -0.81 (-2.37 to 0.75) | 0.31 |
| Relative HGS* (n= 3,329) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |

| Statin users | | -0.29 (-0.37 to -0.21) | < 0.001 | -0.01 (-0.08 to 0.06) | 0.76 | 0.01 (-0.03 to 0.05) | 0.56 |
|--|-------|-------------------------|---------|-----------------------|------|-----------------------|------|
| Lipid-lowering drugs other than statins | | -0.37 (-0.54 to -0.21) | < 0.001 | -0.11 (-0.25 to 0.04) | 0.13 | -0.07 (-0.18 to 0.03) | 0.17 |
| Combined HGS* (n= 3,362) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -6.46 (-8.59 to -4.34) | < 0.001 | 0.03 (-1.84 to 1.90) | 0.98 | 0.43 (-0.69 to 1.54) | 0.45 |
| Lipid-lowering drugs other than statins | | -6.93 (-11.24 to -2.63) | < 0.001 | -2.59 (-6.43 to 1.24) | 0.18 | -1.81 (-4.69 to 1.06) | 0.22 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 6,627) | | | | | | | |
| Nonusers | 4.75 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 5.97 | 1.44 (1.20 to 1.73) | < 0.001 | 1.17 (0.86 to 1.58) | 0.32 | 1.13 (0.88 to 1.45) | 0.35 |
| Lipid-lowering drugs other than statins | 4.16 | 1.60 (0.91 to 2.81) | 0.11 | 1.09 (0.51 to 2.31) | 0.82 | 1.24 (0.71 to 2.16) | 0.45 |
| ASM and BMI definition (n= 14,406) | | | | | | | |
| Nonusers | 9.50 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 9.30 | 0.98 (0.58 to 1.64) | 0.93 | 0.93 (0.48 to 1.78) | 0.82 | 1.02 (0.64 to 1.63) | 0.94 |
| Lipid-lowering drugs other than statins | 3.60 | 0.38 (0.09 to 1.51) | 0.17 | 0.43 (0.10 to 1.86) | 0.25 | 0.78 (0.23 to 2.64) | 0.69 |
| LDH* (n= 16,274) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 3.27 (2.00 to 4.54) | < 0.001 | -0.36 (-1.80 to 1.08) | 0.62 | -0.17 (-1.48 to 1.15) | 0.80 |
| Lipid-lowering drugs other than statins | | 1.37 (-2.32 to 5.06) | 0.47 | -1.04 (-5.00 to 2.92) | 0.6 | 0.85 (-2.31 to 4.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 3,741) | | | | | | | |
| Nonusers | 39.06 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 43.01 | 1.18 (0.98 to 1.42) | 0.09 | 1.15 (0.87 to 1.52) | 0.30 | 1.11 (0.89 to 1.38) | 0.35 |

| 39.83 | 1.03 (0.63 to 1.71) | 0.90 | 1.20 (0.64 to 2.25) | 0.57 | 1.13 (0.70 to 1.81) | 0.61 |
|-------|---|-------|---------------------|-------|---------------------|---------|
| | | | | | | |
| 10.95 | 1.00 (Ref.) | | | | 1.00 (Ref.) | |
| 8.39 | 0.74 (0.54 to 1.03) | 0.08 | 1.03 (0.65 to 1.62) | 0.89 | 1.05 (0.70 to 1.56) | 0.83 |
| 15.59 | 1.50 (0.80 to 2.84) | 0.20 | 2.57 (1.18 to 5.57) | 0.02 | 2.62 (1.36 to 5.08) | < 0.001 |
| | | | | | | |
| 26.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| 29.46 | 1.13 (0.92 to 1.39) | 0.23 | 1.10 (0.82 to 1.47) | 0.53 | 1.11 (0.88 to 1.41) | 0.39 |
| 28.95 | 1.11 (0.67 to 1.83) | 0.69 | 1.27 (0.71 to 2.27) | 0.41 | 1.26 (0.77 to 2.07) | 0.36 |
| | | | | | | |
| 11.73 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| 13.19 | 1.14 (0.88 to 1.48) | 0.30 | 1.15 (0.80 to 1.66) | 0.43 | 1.22 (0.87 to 1.71) | 0.24 |
| 5.19 | 0.41 (0.17 to 1.03) | 0.06 | 0.50 (0.18 to 1.44) | 0.19 | 0.76 (0.35 to 1.68) | 0.50 |
| | | | | | | |
| 15.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| 18.17 | 1.25 (0.99 to 1.57) | 0.06 | 1.14 (0.78 to 1.66) | 0.50 | 1.14 (0.84 to 1.55) | 0.41 |
| 15.29 | 1.01 (0.56 to 1.84) | 0.96 | 1.06 (0.51 to 2.19) | 0.88 | 1.03 (0.53 to 1.99) | 0.93 |
| | 10.95 8.39 15.59 26.92 29.46 28.95 11.73 13.19 5.19 15.10 18.17 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase; We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hypertension(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S11 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes

| | Prevalence, % | Crude | Crude | | Adjusted | | g** |
|---|---------------|---------------------|---------|---------------------|----------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | Р | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 10,412) | | | | | | | |
| Nonusers | 19.08 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 35.88 | 1.78 (1.44 to 2.19) | < 0.001 | 1.33 (0.97 to 1.82) | 0.08 | 1.25 (0.99 to 1.59) | 0.06 |
| Lipid-lowering drugs other than statins | 38.03 | 1.81 (1.01 to 3.23) | 0.05 | 1.11 (0.55 to 2.26) | 0.77 | 1.52 (0.85 to 2.71) | 0.16 |
| ASM/Wt (n= 10,459) | | | | | | | |
| Nonusers | 8.30 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.84 | 2.37 (2.04 to 2.76) | < 0.001 | 1.24 (0.97 to 1.58) | 0.09 | 1.22 (1.02 to 1.47) | 0.03 |
| Lipid-lowering drugs other than statins | 14.07 | 2.60 (1.67 to 4.06) | < 0.001 | 0.96 (0.54 to 1.71) | 0.89 | 1.06 (0.68 to 1.65) | 0.79 |
| ASM/Ht2 (n= 10,474) | | | | | | | |
| Nonusers | 5.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 7.20 | 1.23 (0.94 to 1.62) | 0.13 | 1.19 (0.80 to 1.75) | 0.38 | 0.94 (0.66 to 1.33) | 0.72 |
| Lipid-lowering drugs other than statins | 5.31 | 0.89 (0.50 to 1.58) | 0.69 | 0.78 (0.32 to 1.88) | 0.58 | 1.29 (0.56 to 2.99) | 0.55 |
| Max HGS* (n= 4,526) | | | | | | | |

| Nonusers | | Ref. | | Ref. | | Ref. | |
|---|------|-------------------------|---------|------------------------|------|-----------------------|------|
| Statin users | | -4.53 (-5.43 to -3.63) | < 0.001 | -0.61 (-1.19 to -0.04) | 0.04 | -0.45 (-1.04 to 0.14) | 0.14 |
| Lipid-lowering drugs other than statins | | -5.78 (-8.22 to -3.33) | < 0.001 | -2.20 (-4.08 to -0.31) | 0.02 | -1.17 (-2.88 to 0.54) | 0.18 |
| Relative HGS* (n= 4,410) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.39 (-0.46 to -0.32) | < 0.001 | -0.03 (-0.07 to 0.02) | 0.24 | -0.03 (-0.07 to 0.01) | 0.15 |
| Lipid-lowering drugs other than statins | | -0.64 (-0.8 to -0.48) | < 0.001 | -0.1 (-0.24 to 0.04) | 0.15 | -0.09 (-0.21 to 0.03) | 0.13 |
| Combined HGS* (n= 4,461) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -8.91 (-10.66 to -7.17) | < 0.001 | -1.29 (-2.44 to -0.14) | 0.03 | -1.06 (-2.17 to 0.05) | 0.06 |
| Lipid-lowering drugs other than statins | | -11.34 (-15.92 to - | < 0.001 | -4.02 (-7.06 to -0.99) | 0.01 | -2.33 (-5.47 to 0.81) | 0.15 |
| | | 6.76) | | | | | |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 10,415) | | | | | | | |
| Nonusers | 5.08 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 6.77 | 1.78 (1.44 to 2.20) | < 0.001 | 1.33 (0.97 to 1.83) | 0.07 | 1.23 (0.96 to 1.57) | 0.10 |
|---|-------|---------------------|---------|-----------------------|------|-----------------------|------|
| Lipid-lowering drugs other than statins | 4.28 | 1.82 (1.02 to 3.24) | 0.04 | 1.12 (0.55 to 2.27) | 0.76 | 1.51 (0.83 to 2.73) | 0.18 |
| ASM and BMI definition (n= 21,553) | | | | | | | |
| Nonusers | 7.90 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.50 | 1.09 (0.62 to 1.90) | 0.77 | 1.18 (0.58 to 2.41) | 0.64 | 0.85 (0.53 to 1.34) | 0.47 |
| Lipid-lowering drugs other than statins | 5.00 | 0.63 (0.17 to 2.33) | 0.49 | 0.56 (0.13 to 2.49) | 0.45 | 0.86 (0.26 to 2.90) | 0.81 |
| LDH * (n= 24,501) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 4.64 (3.36 to 5.93) | < 0.001 | -0.73 (-2.10 to 0.64) | 0.30 | -0.28 (-1.79 to 1.22) | 0.71 |
| Lipid-lowering drugs other than statins | | 4.01 (0.18 to 7.84) | 0.04 | -1.44 (-5.43 to 2.55) | 0.48 | -0.62 (-4.69 to 3.46) | 0.77 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 6,226) | | | | | | | |
| Nonusers | 33.04 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.40 | 1.62 (1.33 to 1.97) | < 0.001 | 1.22 (0.96 to 1.54) | 0.11 | 1.10 (0.89 to 1.35) | 0.38 |
| Lipid-lowering drugs other than statins | 37.35 | 1.21 (0.71 to 2.05) | 0.48 | 0.88 (0.44 to 1.77) | 0.72 | 0.93 (0.57 to 1.52) | 0.77 |
| Neck/Upper Back (n= 6,226) | | | | | | | |
| Nonusers | 9.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.40 | 0.93 (0.75 to 1.15) | 0.47 | 0.94 (0.66 to 1.34) | 0.73 | 0.89 (0.61 to 1.30) | 0.54 |

| Lipid-lowering drugs other than statins | 14.41 | 1.70 (0.90 to 3.19) | 0.10 | 1.57 (0.68 to 3.60) | 0.28 | 1.82 (0.90 to 3.65) | 0.09 |
|---|-------|---------------------|---------|---------------------|------|---------------------|------|
| Upper Extremities (n= 6,226) | | | | | | | |
| Nonusers | 21.49 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 30.08 | 1.57 (1.26 to 1.96) | < 0.001 | 1.14 (0.83 to 1.59) | 0.40 | 1.14 (0.91 to 1.43) | 0.25 |
| Lipid-lowering drugs other than statins | 27.77 | 1.40 (0.77 to 2.55) | 0.26 | 1.15 (0.57 to 2.30) | 0.69 | 1.25 (0.75 to 2.09) | 0.39 |
| Lower Back (n= 6,226) | | | | | | | |
| Nonusers | 11.22 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.20 | 1.20 (0.93 to 1.55) | 0.15 | 1.05 (0.75 to 1.47) | 0.76 | 1.10 (0.80 to 1.51) | 0.54 |
| Lipid-lowering drugs other than statins | 10.26 | 0.90 (0.41 to 2.00) | 0.80 | 0.66 (0.26 to 1.69) | 0.38 | 0.75 (0.34 to 1.65) | 0.48 |
| Lower Extremities (n= 6,226) | | | | | | | |
| Nonusers | 12.79 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 18.98 | 1.60 (1.25 to 2.04) | < 0.001 | 1.22 (0.89 to 1.68) | 0.20 | 1.07 (0.80 to 1.42) | 0.65 |
| Lipid-lowering drugs other than statins | 19.74 | 1.68 (0.87 to 3.22) | 0.12 | 1.14 (0.51 to 2.53) | 0.74 | 1.05 (0.55 to 2.03) | 0.88 |
| | | | | | | | |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3,

1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women


ASM/Wt cutoffs are <29.76% in men or <22.31% in women

^{*}The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Figure and tables

Figure 1 Flow of study



Abbreviations: NHANES, National Health and Nutrition Examination Survey; CVD, cardiovascular disease; HLP, hyperlipidemia; SNP, Single Nucleotide Polymorphism; LDH, Lactate Dehydrogenase.

A: Flow of study.

B: Two-sample Mendelian randomization study design.

Arrows represent associations.

Dashed lines with "x" in the middle represent genetic variants applied as instrumental variables

for Statins that should not be associated with potential confounding factors and do not exert an effect on sarcopenia-related traits and LDH via other pathways in assumptions 2 and 3, respectively.

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-PRESSO, MR-pleiotropy residual sum and outlier; LDH, Lactic dehydrogenase.

Table 1 Baseline characteristics of patients with cardiovascular disease, diabetes, or hyperlipidemia

| | | Sta | tin drug use | |
|------------------------|----------------|----------------|---------------------------|---------|
| | Nonuse | Statin drugs | Lipid-lowering drugs | p |
| | (13,474) | (8,481) | other than statins(n=594) | |
| Age, (year) | 55.4 ± 0.1 | 65.7 ± 0.1 | 63.3 ± 0.5 | < 0.001 |
| Male, (%) | 48.2 | 53.5 | 52.2 | < 0.001 |
| Race/ethnicity, (%) | | | | |
| Hispanic-Mexican | 17.8 | 11.4 | 14.5 | < 0.001 |
| Other Ethnicity | 18.2 | 16.2 | 18.0 | < 0.001 |
| Non-Hispanic White | 42.2 | 52.3 | 54.0 | < 0.001 |
| Non-Hispanic Black | 21.8 | 20.2 | 13.5 | < 0.001 |
| Education status, (%) | | | | < 0.001 |
| Less than high school | 29.9 | 28.2 | 30.6 | |
| High school | 22.1 | 24.9 | 23.6 | |
| More than high school | 48.1 | 46.9 | 45.8 | |
| Marital status, (%) | | | | < 0.001 |
| Married | 56.2 | 59.9 | 62.3 | |
| Never married | 16.2 | 8.3 | 8.9 | |
| other | 27.6 | 31.8 | 28.8 | |
| PIR, (%) | | | | < 0.001 |
| < 1.3 | 31.5 | 27.4 | 30.6 | |
| 1.3-3.5 | 37.8 | 39.7 | 38.7 | |
| > 3.5 | 30.7 | 32.9 | 30.8 | |
| BMI, kg/m ² | | | | 0.003 |
| 18.5-25 | 21.3 | 18.1 | 18.4 | |
| 25-30 | 34.5 | 36.2 | 33.9 | |
| ≥ 30 | 44.3 | 45.7 | 47.7 | |
| Alcohols status, (%) | | | | <0.001 |
| | | 1 | i | |

| =0, g/d | 38.5 | 44.2 | 45.3 | |
|------------------------|------|------|------|---------|
| < 5, g/d | 42.5 | 39.1 | 40.4 | |
| 5-30, g/d | 16.3 | 15.1 | 13.0 | |
| > 30, g/d | 2.7 | 1.7 | 1.3 | |
| Smoking status, (%) | | | | < 0.001 |
| Never smoking | 52.0 | 46.8 | 46.6 | |
| Former smoker | 28.2 | 39.4 | 37.0 | |
| Current smoker | 19.8 | 13.8 | 16.3 | |
| Physical activity, (%) | 28.7 | 26.2 | 22.7 | 0.001 |
| HBP, (%) | 61.6 | 80.5 | 80.8 | < 0.001 |
| CKD, (%) | 11.8 | 23.6 | 25.2 | < 0.001 |
| COPD, (%) | 9.3 | 12.6 | 12.8 | < 0.001 |
| Cancer, (%) | 10.8 | 17.8 | 17.0 | < 0.001 |
| CVD, (%) | 20.0 | 35.3 | 26.9 | < 0.001 |
| Diabetes, (%) | 37.1 | 46.4 | 48.2 | < 0.001 |
| Hyperlipidemia, (%) | 71.0 | 85.8 | 88.0 | < 0.001 |

The data were adjusted for survey weights from the NHANES.

The data are presented as the means \pm SDs or percentages.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

Table 2 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers

| | Prevalence, % | Crude | ude Adjusted | | | After matching** | |
|---|---------------|---------------------|--------------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n=8,856) | | | | | | | |
| Nonusers | 21.42 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 33.60 | 1.35 (1.12 to 1.62) | < 0.001 | 1.31 (0.99 to 1.74) | 0.06 | 1.25 (1.00 to 1.55) | 0.05 |
| Lipid-lowering drugs other than statins | 35.11 | 1.36 (0.78 to 2.37) | 0.28 | 1.00 (0.49 to 2.02) | 1.00 | 1.23 (0.73 to 2.09) | 0.44 |
| ASM/Wt (n=8,839) | | | | | | | |
| Nonusers | 10.85 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 14.11 | 1.86 (1.62 to 2.13) | < 0.001 | 1.23 (0.99 to 1.54) | 0.06 | 1.14 (0.97 to 1.34) | 0.11 |
| Lipid-lowering drugs other than statins | 14.19 | 1.99 (1.33 to 2.97) | < 0.001 | 0.93 (0.53 to 1.62) | 0.79 | 0.92 (0.62 to 1.37) | 0.67 |
| ASM/Ht ² (n=8,803) | | | | | | | |
| Nonusers | 5.50 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.54 | 1.20 (0.95 to 1.52) | 0.12 | 1.11 (0.77 to 1.60) | 0.56 | 0.87 (0.64 to 1.18) | 0.38 |
| Lipid-lowering drugs other than statins | 4.17 | 0.75 (0.41 to 1.36) | 0.34 | 0.83 (0.31 to 2.25) | 0.71 | 0.99 (0.47 to 2.09) | 0.97 |
| | | β (95% CI) | P | B (95% CI) | P | B (95% CI) | P |

| Max HGS* (n=4,340) | _ | | | | | | |
|--|------|-------------------------|---------|------------------------|------|-----------------------|------|
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -3.01 (-3.97 to -2.06) | <0.001 | -0.35 (-1.11 to 0.41) | 0.36 | -0.13 (-0.66 to 0.40) | 0.64 |
| Lipid-lowering drugs other than statins | | -3.79 (-5.95 to -1.63) | <0.001 | -2.07 (-3.99 to -0.14) | 0.04 | -0.90 (-2.41 to 0.61) | 0.24 |
| Relative grip strength* (n=4,230) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.23 (-0.30 to -0.17) | < 0.001 | -0.01 (-0.06 to 0.04) | 0.66 | -0.01 (-0.04 to 0.03) | 0.77 |
| Lipid-lowering drugs other than statins | | -0.34 (-0.49 to -0.19) | <0.001 | -0.08 (-0.20 to | 0.23 | -0.07 (-0.18 to 0.03) | 0.17 |
| | | | | 0.05) | | | |
| Combined HGS* (n=4,275) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -5.9 (-7.86 to -3.93) | <0.001 | -0.61 (-2.18 to 0.96) | 0.44 | -0.32 (-1.32 to 0.67) | 0.53 |
| Lipid-lowering drugs other than statins | | -6.82 (-10.88 to -2.76) | <0.001 | -2.78 (-6.25 to 0.69) | 0.11 | -2.03 (-4.88 to 0.82) | 0.16 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n=8,8 | 306) | | | | | | |
| Nonusers | 5.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 6.22 | 1.36 (1.13 to 1.63) | <0.001 | 1.32 (1.00 to 1.75) | 0.05 | 1.26 (1.00 to 1.56) | 0.05 |
|---|-------|-----------------------|--------|-----------------------|------|-----------------------|------|
| Lipid-lowering drugs other than statins | 4.17 | 1.37 (0.79 to 2.39) | 0.26 | 1.01 (0.50 to 2.03) | 0.99 | 1.21 (0.72 to 2.05) | 0.47 |
| ASM and BMI definition (n=19,259) | | | | | | | |
| Nonusers | 10.80 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.20 | 0.76 (0.47 to 1.23) | 0.27 | 0.92 (0.51 to 1.66) | 0.78 | 0.98 (0.65 to 1.47) | 0.92 |
| Lipid-lowering drugs other than statins | 3.20 | 0.30 (0.08 to 1.16) | 0.08 | 0.38 (0.09 to 1.60) | 0.18 | 0.74 (0.23 to 2.44) | 0.62 |
| LDH* (n=21,908) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 2.55 (1.32 to 3.78) | <0.001 | -0.55 (-1.81 to 0.71) | 0.39 | -0.57 (-1.72 to 0.58) | 0.33 |
| Lipid-lowering drugs other than statins | | -0.42 (-3.71 to 2.88) | 0.80 | -2.77 (-6.35 to 0.81) | 0.13 | -0.28 (-3.31 to 2.75) | 0.86 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No),

chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

 ASM/Ht^2 cutoffs are <7 kg/m2 in men or <5.5 kg/m 2 in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 3 Odds ratios of musculoskeletal pain for statin users compared to nonusers

| | Prevalence, % | Crude | Crude | | | After matchin | g* |
|---|---------------|---------------------|-------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Any Region (n=5,136) | | | | | | | |
| Nonusers | 69.68 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 27.78 | 1.15 (0.96 to 1.38) | 0.12 | 1.15 (0.88 to 1.50) | 0.30 | 1.09 (0.91 to 1.31) | 0.36 |
| Lipid-lowering drugs other than statins | 2.24 | 1.08 (0.64 to 1.82) | 0.76 | 1.10 (0.59 to 2.04) | 0.75 | 1.04 (0.67 to 1.61) | 0.85 |
| Neck/Upper Back (n=5,136) | | | | | | | |
| Nonusers | 74.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 21.83 | 0.74 (0.56 to 0.97) | 0.03 | 0.96 (0.64 to 1.44) | 0.84 | 0.94 (0.67 to 1.32) | 0.73 |
| Lipid-lowering drugs other than statins | 4.15 | 1.52 (0.87 to 2.66) | 0.14 | 2.17 (1.07 to 4.39) | 0.03 | 2.19 (1.19 to 4.00) | 0.01 |
| Upper Extremities (n=5,136) | | | | | | | |
| Nonusers | 69.33 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 28.01 | 1.13 (0.92 to 1.38) | 0.23 | 1.11 (0.81 to 1.51) | 0.50 | 1.13 (0.93 to 1.39) | 0.22 |
| Lipid-lowering drugs other than statins | 2.66 | 1.16 (0.69 to 1.94) | 0.56 | 1.27 (0.68 to 2.38) | 0.44 | 1.25 (0.79 to 1.98) | 0.33 |
| Lower Back (n=5,136) | | | | | | | |
| Nonusers | 69.78 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 28.26 | 1.03 (0.82 to 1.29) | 0.82 | 1.05 (0.76 to 1.45) | 0.75 | 1.05 (0.79 to 1.39) | 0.74 |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Lipid-lowering drugs other than statins | 1.96 | 0.66 (0.29 to 1.48) | 0.31 | 0.61 (0.24 to 1.54) | 0.28 | 0.74 (0.37 to 1.50) | 0.41 |
| Lower Extremities (n=5,136) | | | | | | | |
| Nonusers | 68.81 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 28.53 | 1.17 (0.95 to 1.45) | 0.14 | 1.12 (0.83 to 1.51) | 0.44 | 1.08 (0.84 to 1.41) | 0.54 |
| Lipid-lowering drugs other than statins | 2.66 | 1.22 (0.66 to 2.23) | 0.52 | 1.09 (0.54 to 2.22) | 0.80 | 1.01 (0.55 to 1.83) | 0.99 |

Abbreviations: OR, odds ratio; CI, confidence interval.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic bistructive pulmonary disease, cancer (Yes, No).

^{*}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 4 The causal relationship between statins and sarcopenia-related traits based on two-sample Mendelian randomization analysis

| Outcome | SNPs | MR method | Beta/OR | 95%CI | <i>P</i> -value |
|----------------------------------|------|-----------------|---------|---------------|-----------------|
| | 11 | IVW | -0.060 | -0.153, 0.033 | 0.208 |
| | | MR Egger | -0.019 | -0.191, 0.153 | 0.834 |
| Appendicular lean mass | | Weighted median | -0.023 | -0.056, 0.010 | 0.173 |
| | 4 | MR PRESOO | -0.016 | -0.057, 0.025 | 0.488 |
| | 11 | IVW | -0.014 | -0.039, 0.012 | 0.289 |
| Here I and a second of the least | | MR Egger | -0.003 | -0.050, 0.043 | 0.892 |
| Hand grip strength (right) | | Weighted median | -0.010 | -0.031, 0.011 | 0.339 |
| | 8 | MR PRESOO | 0.003 | -0.017, 0.023 | 0.776 |
| | 11 | IVW | -0.216 | -0.044, 0.001 | 0.059 |
| Hand onin atmosph (left) | | MR Egger | -0.004 | -0.044, 0.036 | 0.847 |
| Hand grip strength (left) | | Weighted median | -0.013 | -0.031, 0.006 | 0.171 |
| | 10 | MR PRESOO | -0.021 | -0.041, 0.002 | 0.058 |
| | 11 | IVW | 1.042 | 0.889, 1.221 | 0.614 |
| Low hand guin strongth | | MR Egger | 1.025 | 0.759, 1.384 | 0.875 |
| Low hand grip strength | | Weighted median | 1.028 | 0.839, 1,259 | 0.792 |
| | | MR PRESOO | 1.069 | 0.917, 1.247 | 0.411 |
| | 11 | IVW | 0.001 | -0.010, 0.011 | 0.939 |
| Walking pace | | MR Egger | 0.007 | -0.012, 0.026 | 0.497 |
| waiking pace | | Weighted median | -0.002 | -0.016, 0.011 | 0.748 |
| | | MR PRESOO | 0.003 | -0.007, 0.012 | 0.649 |
| | 8 | IVW | -0.080 | -0.213, 0.053 | 0.238 |
| Lactate dehydrogenase | | MR Egger | 0.035 | -0.230, 0.230 | 0.804 |
| Lactate denyurogenase | | Weighted median | 0.003 | -0.082, 0.087 | 0.952 |
| | 6 | MR PRESOO | -0.030 | -0.100, 0.040 | 0.437 |

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided p-values less than 0.05 as statistically significant.

Supplemental tables

Table S1 Details of studies and datasets used in the study

| Trait | Sample size (cases/controls) | Datatype | Unit | Ancestry | Consortium/ First Author | PMID or GWAS ID |
|----------------------------|------------------------------|------------|------|------------|--------------------------|-----------------|
| Statins | 290,385 (73,475/216,910) | Binary | / | European | UK Biobank | 31015401 |
| Appendicular lean mass | 450,243 | Continuous | kg | European | UK Biobank | 33097823 |
| Hand grip strength (right) | 461,089 | Continuous | SD | European | MRC-IEU | ukb-b-10215 |
| Hand grip strength (left) | 461,026 | Continuous | SD | European | MRC-IEU | ukb-b-7478 |
| Low hand grip strength | 121,055 (6,734/114,321) | Binary | / | European | Garan Jones | 33510174 |
| Walking pace | 459,915 | Continuous | km/s | European | MRC-IEU | ukb-b-4711 |
| Lactate dehydrogenase | 126,319 | Continuous | SD | East Asian | Ishigaki K | 29403010 |

Abbreviations: SD, Standard Deviation; PMID, PubMed Unique Identifier; GWAS ID, Genome-Wide Association Study Identifier; MRC-IEU, Medical Research Council Integrative Epidemiology Unit.

Table S2 SNPs are used as instrumental variables for Statins (P-value $< 5 \times 10^{-8}$)

| Traits | SNP | Chr | Position | Effect allele | another allele | Beta | SE | P-value | F-statistic |
|--------------------------|-------------|-----|-----------|---------------|----------------|--------------|-------------|-----------|-------------|
| Statins-ALM/HGS (right)/ | rs113911544 | 1 | 55706403 | G | A | 0.085085202 | 0.014373915 | 3.20E-09 | 35.0395019 |
| HGS (left)/LHGS/Walking | rs11591147 | 1 | 55505647 | Т | G | -0.362323999 | 0.021494841 | 9.40E-64 | 284.1356506 |
| pace | rs1260326 | 2 | 27730940 | Т | С | 0.059920058 | 0.005712328 | 9.70E-26 | 110.0317897 |
| | rs12725767 | 1 | 6676040 | G | A | 0.035128029 | 0.005856082 | 2.00E-09 | 35.98266012 |
| | rs12740374 | 1 | 109817590 | Т | G | -0.156618273 | 0.006742468 | 2.30E-119 | 539.5691038 |
| | rs1367117 | 2 | 21263900 | A | G | 0.105726091 | 0.005900949 | 8.70E-72 | 321.0115277 |
| | rs4299376 | 2 | 44072576 | G | Т | 0.086690463 | 0.005971001 | 9.20E-48 | 210.7892007 |
| | rs4541244 | 2 | 58917535 | Т | С | -0.034275082 | 0.005711376 | 2.00E-09 | 36.01434333 |
| | rs570530 | 1 | 234866776 | A | G | -0.032541516 | 0.005613812 | 6.80E-09 | 33.60159042 |
| | rs693668 | 1 | 55521109 | G | A | -0.048941477 | 0.005866453 | 7.30E-17 | 69.5989924 |
| | rs79598313 | 1 | 27284913 | Т | С | 0.146636976 | 0.018408443 | 1.60E-15 | 63.45310484 |
| Statins-LDH | rs113911544 | 1 | 55706403 | G | A | 0.085085202 | 0.014373915 | 3.20E-09 | 35.0395019 |
| | rs1260326 | 2 | 27730940 | Т | С | 0.059920058 | 0.005712328 | 9.70E-26 | 110.0317897 |
| | rs12725767 | 1 | 6676040 | G | A | 0.035128029 | 0.005856082 | 2.00E-09 | 35.98266012 |
| | rs12740374 | 1 | 109817590 | Т | G | -0.156618273 | 0.006742468 | 2.30E-119 | 539.5691038 |

| rs1367117 | 2 | 21263900 | A | G | 0.105726091 | 0.005900949 | 8.70E-72 | 321.0115277 |
|-----------|---|-----------|---|---|--------------|-------------|----------|-------------|
| rs4541244 | 2 | 58917535 | Т | С | -0.034275082 | 0.005711376 | 2.00E-09 | 36.01434333 |
| rs570530 | 1 | 234866776 | A | G | -0.032541516 | 0.005613812 | 6.80E-09 | 33.60159042 |
| rs693668 | 1 | 55521109 | G | A | -0.048941477 | 0.005866453 | 7.30E-17 | 69.5989924 |
| rs7534572 | 1 | 62999675 | С | G | -0.074218207 | 0.005852643 | 7.50E-37 | 160.8114059 |

Abbreviations: SNP, Single nucleotide polymorphism, MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier. ALM, Appendicular

Lean Muscle; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

Table S3 Definition of statins and lipid-lowering drugs

| d00280 lovastatin d00348 pravastatin d00746 simvastatin d03183 fluvastatin d04105 atorvastatin d04140 cerivastatin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05048 ezetimibe; simvastatin d07110 niacin; simvastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol | Generic drug code | Drug name |
|---|---|--|
| d00348 pravastatin d00746 simvastatin d03183 fluvastatin d04105 atorvastatin d04140 cerivastatin d04851 lovastatin; niacin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00193 cholestyramine d00196 clofibrate d000245 gemfibrozil d00744 colestipol d04286 fenofibrate | Statin drugs | |
| d00746 simvastatin d03183 fluvastatin d04105 atorvastatin d04140 cerivastatin d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05048 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00193 cholestyramine d00196 clofibrate d000245 gemfibrozil d00744 colestipol d004286 fenofibrate | d00280 | lovastatin |
| fluvastatin d04105 atorvastatin d04140 cerivastatin d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00193 cholestyramine d00196 d00196 d00196 d00245 gemfibrozil d00353 probucol d00744 d04286 fenofibrate | d00348 | pravastatin |
| d04105 d04140 cerivastatin d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified hmg-coa reductase inhibitors - unspecified d00193 d00196 clofibrate d000245 gemfibrozil d00353 probucol d00744 colestipol | d00746 | simvastatin |
| d04140 cerivastatin d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol | d03183 | fluvastatin |
| d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol colestipol d00744 colestipol d04286 fenofibrate | d04105 | atorvastatin |
| d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol colestipol d00744 colestipol | d04140 | cerivastatin |
| amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 d00196 clofibrate d000245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d04787 | lovastatin; niacin |
| d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d000245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d04851 | rosuvastatin |
| d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d05048 | amlodipine; atorvastatin |
| d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d05348 | ezetimibe; simvastatin |
| d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d07110 | niacin; simvastatin |
| d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol colestipol d00744 colestipol | d07637 | pitavastatin |
| Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol colestipol d04286 fenofibrate | d07805 | simvastatin; sitagliptin |
| antihyperlipidemic agents - unspecified hmg-coa reductase inhibitors - unspecified cholestyramine clofibrate d00196 d00245 gemfibrozil d00353 probucol colestipol d04286 fenofibrate | d08383 | evolocumab |
| hmg-coa reductase inhibitors - unspecified cholestyramine clofibrate d00196 d00245 gemfibrozil d00353 probucol colestipol d04286 fenofibrate | Lipid-lowering drugs other than statins | |
| d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | c00019 | antihyperlipidemic agents - unspecified |
| d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | c00173 | hmg-coa reductase inhibitors - unspecified |
| d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d00193 | cholestyramine |
| d00353 probucol d00744 colestipol d04286 fenofibrate | d00196 | clofibrate |
| d00744 colestipol d04286 fenofibrate | d00245 | gemfibrozil |
| d04286 fenofibrate | d00353 | probucol |
| | d00744 | colestipol |
| d04695 colesevelam | d04286 | fenofibrate |
| <u>l</u> | d04695 | colesevelam |
| d04824 ezetimibe | d04824 | ezetimibe |
| d07371 fenofibric acid | d07371 | fenofibric acid |

| d07891 | icosapent |
|--------|-------------|
| d08374 | alirocumab |
| h00036 | bezafibrate |

Table S4 Characteristics of cardiovascular disease, diabetes, or hyperlipidemia patients with Statin use or nonuse after matching

| | | After matching | |
|-----------------------|-----------------|-------------------------|-------------------------|
| | Non-use (5,249) | Statin drug use (5,429) | Standardized difference |
| Age, (year) | 62.6 ± 0.2 | 64.7 ± 0.1 | <0.001 |
| Male, (%) | 50.9 | 52.4 | < 0.001 |
| Race/ethnicity, (%) | | | |
| Hispanic-Mexican | 13.3 | 11.8 | < 0.001 |
| Other Ethnicity | 17.5 | 16.5 | < 0.001 |
| Non-Hispanic White | 47.0 | 51.3 | <0.001 |
| Non-Hispanic Black | 22.2 | 20.4 | < 0.001 |
| Education status, (%) | | | < 0.001 |
| Less than high school | 29.6 | 28.5 | |
| High school | 23.6 | 24.3 | |
| More than high school | 46.8 | 47.2 | |
| Marital status, (%) | | | <0.001 |
| Married | 57.2 | 59.1 | |
| Never married | 10.9 | 9.0 | |

| | | | ī |
|------------------------|------|------|--------|
| Other | 32.0 | 31.9 | |
| PIR, (%) | | | <0.001 |
| < 1.3 | 30.0 | 27.8 | |
| 1.3-3.5 | 38.5 | 39.5 | |
| > 3.5 | 31.5 | 32.7 | |
| BMI, kg/m ² | | | <0.001 |
| 18.5-25 | 20.4 | 18.2 | |
| 25-30 | 33.5 | 36.2 | |
| ≥ 30 | 46.1 | 45.7 | |
| Alcohols status, (%) | | | <0.001 |
| = 0, g/d | 42.5 | 43.7 | |
| < 5, g/d | 40.0 | 39.2 | |
| 5-30, g/d | 15.1 | 15.5 | |
| > 30, g/d | 2.3 | 1.6 | |
| Smoking status, (%) | | | <0.001 |
| Never smoking | 49.0 | 47.4 | |
| Former smoker | 34.6 | 38.1 | |

| Current smoker | 16.4 | 14.5 | |
|------------------------|------|------|---------|
| Moderate exercise, (%) | 26.2 | 26.4 | < 0.001 |
| HBP, (%) | 76.6 | 79.2 | <0.001 |
| CKD, (%) | 20.0 | 23.0 | <0.001 |
| COPD, (%) | 12.1 | 12.6 | <0.001 |
| Cancer, (%) | 15.6 | 17.1 | < 0.001 |
| CVD, (%) | 27.7 | 33.0 | < 0.001 |
| Diabetes, (%) | 43.9 | 45.1 | <0.001 |
| Hyperlipidemia, (%) | 42.9 | 45.5 | <0.001 |

Data were adjusted for survey weights of NHANES.

Data are presented as means \pm SD or percent.

We considered two-sided p-values less than 0.05 as statistically significant.

 $Abbreviations: PIR, Poverty\ income\ ratio;\ BMI,\ body\ mass\ index;\ HBP,\ hypertension;\ CVD,\ cardiovascular\ diseases;\ CKD,\ Chronic\ Kidney\ Disease;\ COPD,\ cordiovascular\ diseases;\ CKD,\ Chronic\ Kidney\ Disease;\ CKD,\ Chronic\ CKD,\ Chronic\ CKD,\ CKD,\ CKD,\ CKD,\ CKD,\$

Chronic Obstructive Pulmonary Disease.

Table S5 The association between statin users and skeletal muscle-related phenotypes compared with nonusers by stepwise regression analysis

| | ASM/BMI (n=8 | | ASM/Ht ² and bf Sar Obesity (n=8,8 | rcopenic | Max HGS (n=4,3 | • | Relative HGS (n=4, | | Combined HGS (n=4 | 4,275) | Neck/Upper (n=5,136) | Back |
|---------------------|---------------------|------------|--|------------|------------------------|------------|------------------------|------------|------------------------|------------|----------------------|------|
| | OR (95% CI) | P | OR (95% CI) | P | β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | OR (95% CI) | P |
| Unadjusted | 1.35 (1.12 to 1.62) | < 0.001 | 1.36 (1.13 to 1.63) | < 0.001 | -3.01 (-3.97 to -2.06) | < 0.001 | -0.23 (-0.30 to -0.17) | < 0.001 | -5.90 (-7.86 to -3.93) | < 0.001 | 0.74 (0.56 to 0.97) | 0.03 |
| Age adjustment | 1.01 (0.82 to 1.23) | 0.96 | 1.01 (0.83 to 1.23) | 0.91 | 0.67 (-0.22 to 1.56) | 0.14 | -0.02 (-0.10 to 0.05) | 0.5 | 1.31 (-0.50 to 3.11) | 0.15 | 0.83 (0.61 to 1.12) | 0.21 |
| + Sex | 1.24 (1.00 to 1.55) | 0.05 | 1.25 (1.01 to 1.56) | 0.05 | 0.10 (-0.64 to 0.84) | 0.78 | -0.06 (-0.12 to -0.01) | 0.03 | 0.24 (-1.26 to 1.74) | 0.75 | 0.85 (0.63 to 1.14) | 0.27 |
| + Race/ ethnicity | 1.29 (1.03 to 1.62) | 0.03 | 1.30 (1.04 to 1.63) | 0.02 | -0.09 (-0.81 to 0.63) | 0.80 | -0.07 (-0.13 to -0.02) | 0.01 | -0.14 (-1.61 to 1.33) | 0.84 | 0.83 (0.61 to 1.11) | 0.21 |
| +Education level | 1.29 (1.02 to 1.62) | 0.03 | 1.29 (1.03 to 1.63) | 0.03 | -0.09 (-0.83 to 0.66) | 0.82 | -0.07 (-0.13 to -0.02) | 0.01 | -0.14 (-1.64 to 1.35) | 0.85 | 0.83 (0.61 to 1.12) | 0.21 |
| +Marital status | 1.28 (1.02 to 1.62) | 0.03 | 1.29 (1.03 to 1.63) | 0.03 | -0.16 (-0.90 to 0.57) | 0.65 | -0.08 (-0.14 to -0.02) | 0.01 | -0.30 (-1.78 to 1.18) | 0.68 | 0.82 (0.61 to 1.12) | 0.2 |
| + PIR | 1.31 (1.02 to 1.69) | 0.03 | 1.32 (1.03 to 1.70) | 0.03 | -0.28 (-1.02 to 0.45) | 0.44 | -0.09 (-0.15 to -0.04) | < 0.001 | -0.48 (-1.98 to 1.01) | 0.51 | 0.86 (0.61 to 1.21) | 0.37 |
| + BMI | - | - | - | - | -0.55 (-1.24 to 0.13) | 0.11 | -0.04 (-0.08 to 0.01) | 0.08 | -1.05 (-2.42 to 0.31) | 0.13 | 0.88 (0.63 to 1.25) | 0.48 |
| + Alcohols statues | 1.33 (1.03 to 1.72) | 0.03 | 1.34 (1.04 to 1.73) | 0.03 | -0.49 (-1.22 to 0.23) | 0.18 | -0.04 (-0.08 to 0.01) | 0.10 | -0.90 (-2.30 to 0.51) | 0.2 | 0.82 (0.60 to 1.12) | 0.21 |
| + Smoking status | 1.34 (1.03 to 1.73) | 0.03 | 1.35 (1.04 to 1.74) | 0.02 | -0.49 (-1.23 to 0.24) | 0.18 | -0.04 (-0.08 to 0.01) | 0.10 | -0.90 (-2.31 to 0.52) | 0.21 | 0.82 (0.60 to 1.12) | 0.2 |
| + Physical activity | 1.35 (1.04 to 1.74) | 0.02 | 1.36 (1.05 to 1.75) | 0.02 | -0.50 (-1.27 to 0.28) | 0.2 | -0.04 (-0.09 to 0.01) | 0.13 | -0.91 (-2.40 to 0.58) | 0.22 | 0.81 (0.59 to 1.11) | 0.19 |

| + HBP | 1.31 (1.01 to 1.71) | 0.04 | 1.32 (1.02 to 1.72) | 0.04 | -0.54 (-1.32 to 0.24) | 0.17 | -0.04 (-0.08 to 0.01) | 0.15 | -0.97 (-2.48 to 0.54) | 0.20 | 0.82 (0.59 to 1.13) | 0.21 |
|------------------|---------------------|------|---------------------|------|-----------------------|------|-----------------------|------|-----------------------|------|---------------------|------|
| + CVD | 1.31 (0.99 to 1.72) | 0.06 | 1.32 (1.00 to 1.74) | 0.05 | -0.33 (-1.09 to 0.44) | 0.39 | -0.02 (-0.07 to 0.03) | 0.37 | -0.63 (-2.14 to 0.88) | 0.40 | 0.81 (0.56 to 1.18) | 0.27 |
| + Diabetes | 1.28 (0.97 to 1.69) | 0.08 | 1.29 (0.98 to 1.71) | 0.07 | -0.25 (-1.04 to 0.54) | 0.52 | -0.01 (-0.06 to 0.04) | 0.62 | -0.48 (-2.02 to 1.07) | 0.53 | 0.82 (0.56 to 1.19) | 0.28 |
| + Hyperlipidemia | 1.32 (0.99 to 1.75) | 0.06 | 1.33 (1.00 to 1.77) | 0.05 | -0.26 (-1.05 to 0.53) | 0.50 | -0.01 (-0.06 to 0.04) | 0.71 | -0.44 (-2.02 to 1.14) | 0.57 | 0.84 (0.56 to 1.24) | 0.36 |
| + CKD | 1.33 (0.99 to 1.78) | 0.06 | 1.34 (1.00 to 1.80) | 0.05 | -0.31 (-1.11 to 0.5) | 0.44 | -0.01 (-0.06 to 0.04) | 0.76 | -0.51 (-2.12 to 1.10) | 0.52 | 0.82 (0.58 to 1.17) | 0.26 |
| + COPD | 1.32 (0.98 to 1.76) | 0.07 | 1.33 (0.99 to 1.78) | 0.06 | -0.31 (-1.11 to 0.49) | 0.43 | -0.01 (-0.06 to 0.04) | 0.74 | -0.53 (-2.13 to 1.08) | 0.51 | 0.83 (0.58 to 1.19) | 0.29 |
| + Cancer | 1.32 (0.98 to 1.76) | 0.07 | 1.33 (0.99 to 1.78) | 0.06 | -0.32 (-1.12 to 0.48) | 0.42 | -0.01 (-0.06 to 0.04) | 0.72 | -0.55 (-2.14 to 1.05) | 0.49 | 0.85 (0.59 to 1.24) | 0.39 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; HGS, Hand grip strength; BMI, body mass index; Wt, weight; Ht, height; PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women.

Table S6 The results of sensitivity analysis for two-sample Mendelian randomization analysis of the causal relationships between Statins and sarcopenia-related traits

| Outcome | No. of IVs | Heterogeneity | | MR-Eg | ger pleiotr | opy test | MR-PRESOO |
|----------------------------|------------|---------------|----------|------------|-------------|----------|---------------------|
| | | Cochran's Q | P-value | intercept | SE | P-value | Global Test P-value |
| Appendicular lean mass | 11 | 346.6756844 | 2.02E-68 | -0.0042237 | 0.00746 | 0.585 | <0.001 |
| Hand grip strength (right) | 11 | 40.71459187 | 1.27E-05 | -0.0010619 | 0.00202 | 0.612 | <0.001 |
| Hand grip strength (left) | 11 | 32.39685682 | <0.001 | -0.0018087 | 0.00172 | 0.321 | <0.001 |
| Low hand grip strength | 11 | 10.56373443 | 0.393 | 0.00164006 | 0.01293 | 0.902 | 0.463 |
| Walking pace | 8 | 8.438255201 | 0.586 | -0.0006592 | 0.00082 | 0.443 | 0.622 |
| Lactate dehydrogenase | 11 | 38.72767287 | 2.20E-06 | -0.0082974 | 0.00844 | 0.363 | <0.001 |

Abbreviations: MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided p-values less than 0.05 as statistically significant.

Table S7 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among the population over 65 years old

| | Prevalence, % | Crude | | Adjusted | | After match | ing** |
|---|---------------|---------------------|---------|---------------------|------|---------------------|-------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 2,367) | | | | | | | |
| Nonusers | 35.05 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 43.20 | 0.86 (0.65 to 1.13) | 0.27 | 1.04 (0.73 to 1.49) | 0.81 | 1.11 (0.80 to 1.55) | 0.52 |
| Lipid-lowering drugs other than statins | 34.23 | 1.19 (0.53 to 2.67) | 0.68 | 1.02 (0.43 to 2.40) | 0.97 | 1.31 (0.58 to 2.97) | 0.51 |
| ASM/Wt (n= 2,408) | | | | | | | |
| Nonusers | 24.01 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 21.34 | 1.41 (1.12 to 1.77) | < 0.001 | 1.17 (0.83 to 1.63) | 0.36 | 1.16 (0.90 to 1.50) | 0.25 |
| Lipid-lowering drugs other than statins | 27.26 | 0.96 (0.52 to 1.80) | 0.91 | 0.68 (0.29 to 1.59) | 0.36 | 0.87 (0.45 to 1.70) | 0.69 |
| $ASM/Ht^2 (n=2,430)$ | | | | | | | |
| Nonusers | 15.26 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 12.60 | 0.80(0.60 to 1.06) | 0.12 | 0.84 (0.55 to 1.27) | 0.39 | 0.74 (0.50 to 1.10) | 0.13 |
| Lipid-lowering drugs other than statins | 7.08 | 0.42 (0.19 to 0.95) | 0.04 | 0.34 (0.15 to 0.78) | 0.01 | 0.57 (0.20 to 1.57) | 0.28 |
| Max HGS* (n= 1,590) | _ | | | | | | |

| Nonusers | | Ref. | | Ref. | | Ref. | |
|---|-------|-----------------------|------|-----------------------|------|-----------------------|------|
| Statin users | | 0.54 (-0.81 to 1.88) | 0.42 | -0.22 (-0.94 to 0.51) | 0.55 | 0.14 (-0.63 to 0.91) | 0.72 |
| Lipid-lowering drugs other than statins | | -0.30 (-3.42 to 2.83) | 0.85 | -0.32 (-2.20 to 1.56) | 0.73 | 0.10 (-2.21 to 2.40) | 0.94 |
| Relative HGS* (n= 1,532) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.01 (-0.1 to 0.08) | 0.81 | -0.02 (-0.07 to 0.03) | 0.41 | 0.02 (-0.04 to 0.07) | 0.52 |
| Lipid-lowering drugs other than statins | | -0.02 (-0.23 to 0.19) | 0.86 | 0.03 (-0.11 to 0.17) | 0.64 | -0.03 (-0.19 to 0.13) | 0.73 |
| Combined HGS* (n= 1,560) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 0.86 (-1.70 to 3.42) | 0.50 | -0.58 (-1.88 to 0.72) | 0.37 | -0.06 (-1.56 to 1.44) | 0.94 |
| Lipid-lowering drugs other than statins | | 0.15 (-6.25 to 6.55) | 0.96 | 0.09 (-3.28 to 3.46) | 0.96 | -1.24 (-5.70 to 3.22) | 0.59 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= | | | | | | | |
| 2,369) | | | | | | | |
| Nonusers | 14.68 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 12.60 | 0.87 (0.66 to 1.14) | 0.29 | 1.06 (0.74 to 1.52) | 0.74 | 1.15 (0.83 to 1.59) | 0.41 |
| Lipid-lowering drugs other than statins | 7.08 | 1.20 (0.53 to 2.69) | 0.66 | 1.03 (0.44 to 2.44) | 0.95 | 1.36 (0.6 to 3.07) | 0.46 |

| ASM and BMI definition (n= 7,839) | | | | | | | |
|---|-------|------------------------|------|-----------------------|------|-----------------------|------|
| Nonusers | 14.80 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.10 | 0.54 (0.29 to 1.00) | 0.05 | 0.74 (0.33 to 1.67) | 0.47 | 0.83 (0.48 to 1.46) | 0.53 |
| Lipid-lowering drugs other than statins | 4.60 | 0.31 (0.05 to 1.92) | 0.21 | 0.42 (0.06 to 2.81) | 0.37 | 0.91 (0.21 to 4.04) | 0.91 |
| LDH* (n= 8,954) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -2.34 (-4.15 to -0.54) | 0.01 | -0.73 (-2.65 to 1.19) | 0.45 | 0.04 (-1.58 to 1.66) | 0.96 |
| Lipid-lowering drugs other than statins | | -2.97 (-8.28 to 2.35) | 0.27 | -1.81 (-7.51 to 3.89) | 0.53 | -0.44 (-4.76 to 3.89) | 0.84 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 2,312) | | | | | | | |
| Nonusers | 33.74 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 35.99 | 1.10 (0.86 to 1.42) | 0.43 | 1.13 (0.82 to 1.55) | 0.44 | 0.99 (0.77 to 1.27) | 0.91 |
| Lipid-lowering drugs other than statins | 32.47 | 0.94 (0.51 to 1.76) | 0.85 | 0.92 (0.44 to 1.91) | 0.82 | 1.19 (0.64 to 2.18) | 0.58 |
| Neck/Upper Back (n= 2,312) | | | | | | | |
| Nonusers | 7.01 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.02 | 0.85 (0.58 to 1.25) | 0.40 | 0.77 (0.48 to 1.24) | 0.27 | 0.74 (0.45 to 1.22) | 0.23 |
| Lipid-lowering drugs other than statins | 11.68 | 1.75 (0.84 to 3.66) | 0.13 | 1.83 (0.92 to 3.63) | 0.08 | 1.80 (0.69 to 4.68) | 0.23 |

| Upper Extremities (n= 2,312) | | | | | | | |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Nonusers | 23.40 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 25.68 | 1.13 (0.84 to 1.52) | 0.41 | 1.23 (0.85 to 1.80) | 0.27 | 1.08 (0.82 to 1.42) | 0.58 |
| Lipid-lowering drugs other than statins | 25.76 | 1.14 (0.54 to 2.37) | 0.73 | 1.24 (0.59 to 2.63) | 0.56 | 1.58 (0.83 to 3.01) | 0.16 |
| Lower Back (n= 2,312) | | | | | | | |
| Nonusers | 7.46 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 9.74 | 1.34 (0.90 to 1.99) | 0.15 | 1.49 (0.92 to 2.42) | 0.10 | 1.07 (0.70 to 1.63) | 0.75 |
| Lipid-lowering drugs other than statins | 6.04 | 0.80 (0.28 to 2.29) | 0.67 | 1.11 (0.36 to 3.44) | 0.85 | 0.88 (0.30 to 2.62) | 0.82 |
| Lower Extremities (n= 2,312) | | | | | | | |
| Nonusers | 12.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.49 | 1.05 (0.74 to 1.50) | 0.78 | 0.91 (0.63 to 1.34) | 0.64 | 0.88 (0.61 to 1.29) | 0.52 |
| Lipid-lowering drugs other than statins | 10.23 | 0.77 (0.31 to 1.88) | 0.56 | 0.74 (0.24 to 2.33) | 0.60 | 0.96 (0.38 to 2.39) | 0.93 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase; We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m2 in men or <5.5 kg/m2 in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S8 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with diabetes

| | Prevalence, % | e, % Crude | | Adjusted | | After matching** | |
|---|---------------|---------------------|------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 3,136) | | | | | | | |
| Nonusers | 31.76 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 45.27 | 1.02 (0.71 to 1.45) | 0.92 | 1.57 (0.94 to 2.61) | 0.09 | 1.29 (0.85 to 1.97) | 0.23 |
| Lipid-lowering drugs other than statins | 34.44 | 1.05 (0.51 to 2.18) | 0.90 | 1.11 (0.40 to 3.05) | 0.84 | 1.20 (0.43 to 3.38) | 0.73 |
| ASM/Wt (n= 3,153) | | | | | | | |
| Nonusers | 14.26 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 16.43 | 1.34 (1.04 to 1.73) | 0.03 | 0.88 (0.63 to 1.23) | 0.45 | 0.96 (0.72 to 1.28) | 0.76 |
| Lipid-lowering drugs other than statins | 13.05 | 1.67 (0.78 to 3.56) | 0.18 | 0.72 (0.32 to 1.62) | 0.43 | 0.81 (0.40 to 1.66) | 0.57 |
| ASM/Ht^2 (n= 3,169) | | | | | | | |
| Nonusers | 4.79 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 4.75 | 0.76 (0.49 to 1.17) | 0.21 | 0.46 (0.27 to 0.80) | 0.01 | 0.55 (0.32 to 0.93) | 0.03 |
| Lipid-lowering drugs other than statins | 2.37 | 0.58 (0.24 to 1.41) | 0.22 | 0.50 (0.19 to 1.37) | 0.18 | 0.61 (0.16 to 2.31) | 0.47 |
| Max HGS* (n= 1,746) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |

| Statin users | | -0.14 (-2.01 to 1.73) | 0.88 | -0.59 (-1.83 to 0.65) | 0.34 | -0.50 (-1.76 to 0.75) | 0.43 |
|--|-------|-------------------------|---------|------------------------|------|--------------------------|---------|
| Lipid-lowering drugs other than statins | | -6.13 (-9.45 to -2.82) | < 0.001 | -3.86 (-6.95 to -0.77) | 0.02 | -3.43 (-7.85 to 1.00) | 0.13 |
| Relative HGS* (n= 1,685) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.09 (-0.23 to 0.05) | 0.21 | -0.03 (-0.14 to 0.08) | 0.54 | -0.07 (-0.16 to 0.02) | 0.12 |
| Lipid-lowering drugs other than statins | | -0.60 (-0.86 to -0.34) | < 0.001 | -0.13 (-0.36 to 0.11) | 0.29 | -0.47 (-0.79 to -0.15) | < 0.001 |
| Combined HGS* (n= 1,711) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.27 (-4.14 to 3.59) | 0.89 | -0.86 (-3.41 to 1.70) | 0.50 | -1.18 (-3.50 to 1.14) | 0.32 |
| Lipid-lowering drugs other than statins | | -9.71 (-16.59 to -2.82) | 0.01 | -4.87 (-9.87 to 0.13) | 0.06 | -11.85 (-20.39 to -3.32) | 0.01 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 3,139) | | | | | | | |
| Nonusers | 4.35 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 4.36 | 1.02 (0.72 to 1.46) | 0.90 | 1.58 (0.95 to 2.66) | 0.08 | 1.52 (1.00 to 2.30) | 0.05 |
| Lipid-lowering drugs other than statins | 2.37 | 1.06 (0.51 to 2.20) | 0.87 | 1.12 (0.40 to 3.09) | 0.83 | 1.47 (0.52 to 4.15) | 0.46 |
| ASM and BMI definition (n= 7,473) | | | | | | | |
| Nonusers | 10.71 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 7.73 | 0.59 (0.27 to 1.27) | 0.18 | 1.05 (0.47 to 2.34) | 0.91 | 1.41 (0.67 to 2.96) | 0.36 |

| Lipid-lowering drugs other than statins | 4.68 | 0.46 (0.06 to 3.50) | 0.45 | 0.47 (0.06 to 3.92) | 0.49 | 1.05 (0.13 to 8.72) | 0.96 |
|---|-------|-----------------------|------|-----------------------|------|-----------------------|------|
| LDH* (n= 8,973) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 1.11 (-1.48 to 3.71) | 0.40 | 0.39 (-2.22 to 2.99) | 0.77 | -0.75 (-3.27 to 1.78) | 0.56 |
| Lipid-lowering drugs other than statins | | -0.06 (-5.38 to 5.25) | 0.98 | -1.58 (-7.05 to 3.89) | 0.57 | 1.90 (-5.21 to 9.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 1,843) | | | | | | | |
| Nonusers | 37.86 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 51.70 | 0.84 (0.63 to 1.11) | 0.21 | 0.88 (0.64 to 1.21) | 0.43 | 0.82 (0.60 to 1.11) | 0.20 |
| Lipid-lowering drugs other than statins | 46.79 | 0.60 (0.24 to 1.49) | 0.26 | 0.37 (0.13 to 1.05) | 0.06 | 0.53 (0.24 to 1.16) | 0.11 |
| Neck/Upper Back (n= 1,843) | | | | | | | |
| Nonusers | 8.30 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 8.51 | 0.54 (0.36 to 0.82) | 0.01 | 0.77 (0.46 to 1.27) | 0.29 | 0.71 (0.42 to 1.20) | 0.20 |
| Lipid-lowering drugs other than statins | 19.42 | 0.85 (0.30 to 2.37) | 0.74 | 0.53 (0.12 to 2.33) | 0.39 | 1.05 (0.35 to 3.17) | 0.94 |
| Upper Extremities (n= 1,843) | | | | | | | |
| Nonusers | 25.81 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 36.91 | 0.84 (0.62 to 1.15) | 0.27 | 0.94 (0.64 to 1.36) | 0.72 | 0.86 (0.62 to 1.19) | 0.36 |
| Lipid-lowering drugs other than statins | 32.53 | 0.64 (0.22 to 1.85) | 0.40 | 0.52 (0.17 to 1.53) | 0.23 | 0.71 (0.31 to 1.61) | 0.42 |
| Lower Back (n= 1,843) | | | | | | | |

| Nonusers | 14.52 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Statin users | 13.15 | 0.66 (0.46 to 0.94) | 0.02 | 0.75 (0.46 to 1.22) | 0.23 | 0.77 (0.51 to 1.18) | 0.23 |
| Lipid-lowering drugs other than statins | 12.89 | 0.54 (0.16 to 1.76) | 0.30 | 0.57 (0.16 to 2.05) | 0.38 | 0.71 (0.25 to 2.00) | 0.52 |
| Lower Extremities (n= 1,843) | | | | | | | |
| Nonusers | 15.33 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 23.06 | 0.89 (0.61 to 1.30) | 0.53 | 1.05 (0.66 to 1.67) | 0.83 | 0.90 (0.61 to 1.34) | 0.61 |
| Lipid-lowering drugs other than statins | 20.80 | 0.67 (0.22 to 2.01) | 0.46 | 0.61 (0.20 to 1.84) | 0.37 | 0.52 (0.18 to 1.48) | 0.22 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S9 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with cardiovascular disease

| | Prevalence, % | Crude | | Adjusted | | After matching** | |
|---|---------------|---------------------|------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 1,641) | | | | | | | |
| Nonusers | 33.76 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 40.61 | 1.02 (0.71 to 1.45) | 0.92 | 1.57 (0.94 to 2.61) | 0.09 | 1.29 (0.85 to 1.97) | 0.23 |
| Lipid-lowering drugs other than statins | 45.97 | 1.05 (0.51 to 2.18) | 0.90 | 1.11 (0.40 to 3.05) | 0.84 | 1.20 (0.43 to 3.38) | 0.73 |
| ASM/Wt (n= 1,671) | | | | | | | |
| Nonusers | 15.67 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 15.92 | 1.34 (1.04 to 1.73) | 0.03 | 0.88 (0.63 to 1.23) | 0.45 | 0.96 (0.72 to 1.28) | 0.76 |
| Lipid-lowering drugs other than statins | 16.32 | 1.67 (0.78 to 3.56) | 0.18 | 0.72 (0.32 to 1.62) | 0.43 | 0.81 (0.40 to 1.66) | 0.57 |
| ASM/Ht ² (n= 1,676) | | | | | | | |
| Nonusers | 10.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.51 | 0.76 (0.49 to 1.17) | 0.21 | 0.46 (0.27 to 0.8) | 0.01 | 0.55 (0.32 to 0.93) | 0.03 |
| Lipid-lowering drugs other than statins | 6.61 | 0.58 (0.24 to 1.41) | 0.22 | 0.50 (0.19 to 1.37) | 0.18 | 0.61 (0.16 to 2.31) | 0.47 |
| Max HGS* (n= 996) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |

| Statin users | | -0.14 (-2.01 to 1.73) | 0.88 | -0.59 (-1.83 to 0.65) | 0.34 | -0.50 (-1.76 to 0.75) | 0.43 |
|--|-------|-------------------------|---------|------------------------|------|--------------------------|---------|
| Lipid-lowering drugs other than statins | | -6.13 (-9.45 to -2.82) | < 0.001 | -3.86 (-6.95 to -0.77) | 0.02 | -3.43 (-7.85 to 1.00) | 0.13 |
| Relative HGS* (n= 947) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.09 (-0.23 to 0.05) | 0.21 | -0.03 (-0.14 to 0.08) | 0.54 | -0.07 (-0.16 to 0.02) | 0.12 |
| Lipid-lowering drugs other than statins | | -0.60 (-0.86 to -0.34) | < 0.001 | -0.13 (-0.36 to 0.11) | 0.29 | -0.47 (-0.79 to -0.15) | < 0.001 |
| Combined HGS* (n= 968) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.27 (-4.14 to 3.59) | 0.89 | -0.86 (-3.41 to 1.7) | 0.50 | -1.18 (-3.50 to 1.14) | 0.32 |
| Lipid-lowering drugs other than statins | | -9.71 (-16.59 to -2.82) | 0.01 | -4.87 (-9.87 to 0.13) | 0.06 | -11.85 (-20.39 to -3.32) | 0.01 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht2 and Body Fat Percent Definition (n= 1,643) | | | | | | | |
| Nonusers | 10.14 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 7.14 | 1.02 (0.72 to 1.46) | 0.90 | 1.58 (0.95 to 2.66) | 0.08 | 1.52 (1.00 to 2.30) | 0.05 |
| Lipid-lowering drugs other than statins | 6.61 | 1.06 (0.51 to 2.20) | 0.87 | 1.12 (0.40 to 3.09) | 0.83 | 1.47 (0.52 to 4.15) | 0.46 |
| ASM and BMI definition (n= 4,725) | | | | | | | |
| Nonusers | 49.18 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.73 | 0.59 (0.27 to 1.27) | 0.18 | 1.05 (0.47 to 2.34) | 0.91 | 1.41 (0.67 to 2.96) | 0.36 |

| Lipid-lowering drugs other than statins | 36.72 | 0.46 (0.06 to 3.50) | 0.45 | 0.47 (0.06 to 3.92) | 0.49 | 1.05 (0.13 to 8.72) | 0.96 |
|---|-------|-----------------------|------|-----------------------|------|-----------------------|------|
| LDH* (n= 5,340) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 1.11 (-1.48 to 3.71) | 0.40 | 0.39 (-2.22 to 2.99) | 0.77 | -0.75 (-3.27 to 1.78) | 0.56 |
| Lipid-lowering drugs other than statins | | -0.06 (-5.38 to 5.25) | 0.98 | -1.58 (-7.05 to 3.89) | 0.57 | 1.90 (-5.21 to 9.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 1,158) | | | | | | | |
| Nonusers | 49.18 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.73 | 0.84 (0.63 to 1.11) | 0.21 | 0.88 (0.64 to 1.21) | 0.43 | 0.82 (0.60 to 1.11) | 0.20 |
| Lipid-lowering drugs other than statins | 36.72 | 0.60 (0.24 to 1.49) | 0.26 | 0.37 (0.13 to 1.05) | 0.06 | 0.53 (0.24 to 1.16) | 0.11 |
| Neck/Upper Back (n= 1,158) | | | | | | | |
| Nonusers | 16.46 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 9.68 | 0.54 (0.36 to 0.82) | 0.01 | 0.77 (0.46 to 1.27) | 0.29 | 0.71 (0.42 to 1.20) | 0.20 |
| Lipid-lowering drugs other than statins | 14.29 | 0.85 (0.30 to 2.37) | 0.74 | 0.53 (0.12 to 2.33) | 0.39 | 1.05 (0.35 to 3.17) | 0.94 |
| Upper Extremities (n= 1,158) | | | | | | | |
| Nonusers | 34.93 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 31.13 | 0.84 (0.62 to 1.15) | 0.27 | 0.94 (0.64 to 1.36) | 0.72 | 0.86 (0.62 to 1.19) | 0.36 |
| Lipid-lowering drugs other than statins | 25.48 | 0.64 (0.22 to 1.85) | 0.40 | 0.52 (0.17 to 1.53) | 0.23 | 0.71 (0.31 to 1.61) | 0.42 |
| Lower Back (n= 1,158) | | | | | | | |

| Nonusers | 20.31 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Statin users | 14.39 | 0.66 (0.46 to 0.94) | 0.02 | 0.75 (0.46 to 1.22) | 0.23 | 0.77 (0.51 to 1.18) | 0.23 |
| Lipid-lowering drugs other than statins | 12.07 | 0.54 (0.16 to 1.76) | 0.30 | 0.57 (0.16 to 2.05) | 0.38 | 0.71 (0.25 to 2.00) | 0.52 |
| Lower Extremities (n= 1,158) | | | | | | | |
| Nonusers | 23.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 21 | 0.89 (0.61 to 1.30) | 0.53 | 1.05 (0.66 to 1.67) | 0.83 | 0.90 (0.61 to 1.34) | 0.61 |
| Lipid-lowering drugs other than statins | 16.71 | 0.67 (0.22 to 2.01) | 0.46 | 0.61 (0.20 to 1.84) | 0.37 | 0.52 (0.18 to 1.48) | 0.22 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

^{*}The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin

Table S10 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with hyperlipidemia

| | Prevalence, % | Crude | | Adjusted | | After matching** | |
|---|---------------|---------------------|---------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 6,627) | | | | | | | |
| Nonusers | 18.39 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 32.33 | 1.43 (1.19 to 1.72) | < 0.001 | 1.15 (0.85 to 1.56) | 0.37 | 1.13 (0.88 to 1.45) | 0.36 |
| Lipid-lowering drugs other than statins | 35.10 | 1.58 (0.90 to 2.79) | 0.11 | 1.08 (0.51 to 2.28) | 0.85 | 1.26 (0.72 to 2.20) | 0.42 |
| ASM/Wt (n= 6,638) | | | | | | | |
| Nonusers | 10.11 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.90 | 2.12 (1.83 to 2.46) | < 0.001 | 1.20 (0.94 to 1.54) | 0.15 | 1.08 (0.89 to 1.31) | 0.45 |
| Lipid-lowering drugs other than statins | 15.12 | 2.40 (1.57 to 3.68) | < 0.001 | 0.98 (0.54 to 1.79) | 0.95 | 0.88 (0.57 to 1.36) | 0.58 |
| ASM/Ht2 (n= 6,640) | | | | | | | |
| Nonusers | 5.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.26 | 1.24 (0.97 to 1.60) | 0.09 | 1.21 (0.83 to 1.77) | 0.31 | 0.96 (0.68 to 1.37) | 0.83 |
| Lipid-lowering drugs other than statins | 4.16 | 0.81 (0.42 to 1.55) | 0.51 | 1.19 (0.41 to 3.47) | 0.75 | 1.30 (0.59 to 2.88) | 0.52 |
| Max HGS* (n= 3,407) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |

| Statin users | | -3.38 (-4.40 to -2.36) | < 0.001 | -0.10 (-1.02 to | 0.83 | 0.10 (-0.50 to 0.70) | 0.75 |
|--|------|-------------------------|---------|-----------------------|------|-----------------------|------|
| | | | | 0.83) | | | |
| Lipid-lowering drugs other than statins | | -3.93 (-6.21 to -1.65) | < 0.001 | -2.04 (-4.21 to 0.12) | 0.06 | -0.81 (-2.37 to 0.75) | 0.31 |
| Relative HGS* (n= 3,329) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.29 (-0.37 to -0.21) | < 0.001 | -0.01 (-0.08 to 0.06) | 0.76 | 0.01 (-0.03 to 0.05) | 0.56 |
| Lipid-lowering drugs other than statins | | -0.37 (-0.54 to -0.21) | < 0.001 | -0.11 (-0.25 to 0.04) | 0.13 | -0.07 (-0.18 to 0.03) | 0.17 |
| Combined HGS* (n= 3,362) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -6.46 (-8.59 to -4.34) | < 0.001 | 0.03 (-1.84 to 1.90) | 0.98 | 0.43 (-0.69 to 1.54) | 0.45 |
| Lipid-lowering drugs other than statins | | -6.93 (-11.24 to -2.63) | < 0.001 | -2.59 (-6.43 to 1.24) | 0.18 | -1.81 (-4.69 to 1.06) | 0.22 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 6,627) | | | | | | | |
| Nonusers | 4.75 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 5.97 | 1.44 (1.20 to 1.73) | < 0.001 | 1.17 (0.86 to 1.58) | 0.32 | 1.13 (0.88 to 1.45) | 0.35 |
| Lipid-lowering drugs other than statins | 4.16 | 1.60 (0.91 to 2.81) | 0.11 | 1.09 (0.51 to 2.31) | 0.82 | 1.24 (0.71 to 2.16) | 0.45 |
| ASM and BMI definition (n= 14,406) | | | | | | | |
| Nonusers | 9.50 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 9.30 | 0.98 (0.58 to 1.64) | 0.93 | 0.93 (0.48 to 1.78) | 0.82 | 1.02 (0.64 to 1.63) | 0.94 |
|---|-------|----------------------|---------|-----------------------|------|-----------------------|---------|
| Lipid-lowering drugs other than statins | 3.60 | 0.38 (0.09 to 1.51) | 0.17 | 0.43 (0.10 to 1.86) | 0.25 | 0.78 (0.23 to 2.64) | 0.69 |
| LDH* (n= 16,274) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 3.27 (2.00 to 4.54) | < 0.001 | -0.36 (-1.80 to | 0.62 | -0.17 (-1.48 to 1.15) | 0.80 |
| Lipid-lowering drugs other than statins | | 1.37 (-2.32 to 5.06) | 0.47 | -1.04 (-5.00 to 2.92) | 0.6 | 0.85 (-2.31 to 4.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 3,741) | | | | | | | |
| Nonusers | 39.06 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 43.01 | 1.18 (0.98 to 1.42) | 0.09 | 1.15 (0.87 to 1.52) | 0.30 | 1.11 (0.89 to 1.38) | 0.35 |
| Lipid-lowering drugs other than statins | 39.83 | 1.03 (0.63 to 1.71) | 0.90 | 1.20 (0.64 to 2.25) | 0.57 | 1.13 (0.70 to 1.81) | 0.61 |
| Neck/Upper Back (n= 3,741) | | | | | | | |
| Nonusers | 10.95 | 1.00 (Ref.) | | | | 1.00 (Ref.) | |
| Statin users | 8.39 | 0.74 (0.54 to 1.03) | 0.08 | 1.03 (0.65 to 1.62) | 0.89 | 1.05 (0.70 to 1.56) | 0.83 |
| Lipid-lowering drugs other than statins | 15.59 | 1.50 (0.80 to 2.84) | 0.20 | 2.57 (1.18 to 5.57) | 0.02 | 2.62 (1.36 to 5.08) | < 0.001 |
| Upper Extremities (n= 3,741) | | | | | | | |
| Nonusers | 26.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 29.46 | 1.13 (0.92 to 1.39) | 0.23 | 1.10 (0.82 to 1.47) | 0.53 | 1.11 (0.88 to 1.41) | 0.39 |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Lipid-lowering drugs other than statins | 28.95 | 1.11 (0.67 to 1.83) | 0.69 | 1.27 (0.71 to 2.27) | 0.41 | 1.26 (0.77 to 2.07) | 0.36 |
| Lower Back (n= 3,741) | | | | | | | |
| Nonusers | 11.73 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.19 | 1.14 (0.88 to 1.48) | 0.30 | 1.15 (0.80 to 1.66) | 0.43 | 1.22 (0.87 to 1.71) | 0.24 |
| Lipid-lowering drugs other than statins | 5.19 | 0.41 (0.17 to 1.03) | 0.06 | 0.50 (0.18 to 1.44) | 0.19 | 0.76 (0.35 to 1.68) | 0.50 |
| Lower Extremities (n= 3,741) | | | | | | | |
| Nonusers | 15.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 18.17 | 1.25 (0.99 to 1.57) | 0.06 | 1.14 (0.78 to 1.66) | 0.50 | 1.14 (0.84 to 1.55) | 0.41 |
| Lipid-lowering drugs other than statins | 15.29 | 1.01 (0.56 to 1.84) | 0.96 | 1.06 (0.51 to 2.19) | 0.88 | 1.03 (0.53 to 1.99) | 0.93 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

^{*}The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.



Table S11 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes

| | Prevalence, % | Crude | | Adjusted | | After matching** | |
|---|---------------|---------------------|---------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 10,412) | | | | | | | |
| Nonusers | 19.08 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 35.88 | 1.78 (1.44 to 2.19) | < 0.001 | 1.33 (0.97 to 1.82) | 0.08 | 1.25 (0.99 to 1.59) | 0.06 |
| Lipid-lowering drugs other than statins | 38.03 | 1.81 (1.01 to 3.23) | 0.05 | 1.11 (0.55 to 2.26) | 0.77 | 1.52 (0.85 to 2.71) | 0.16 |
| ASM/Wt (n= 10,459) | | | | | | | † |
| Nonusers | 8.30 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.84 | 2.37 (2.04 to 2.76) | < 0.001 | 1.24 (0.97 to 1.58) | 0.09 | 1.22 (1.02 to 1.47) | 0.03 |
| Lipid-lowering drugs other than statins | 14.07 | 2.60 (1.67 to 4.06) | < 0.001 | 0.96 (0.54 to 1.71) | 0.89 | 1.06 (0.68 to 1.65) | 0.79 |
| ASM/Ht2 (n= 10,474) | | | | | | | |
| Nonusers | 5.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 7.20 | 1.23 (0.94 to 1.62) | 0.13 | 1.19 (0.80 to 1.75) | 0.38 | 0.94 (0.66 to 1.33) | 0.72 |
|---|------|-------------------------|---------|------------------------|------|-----------------------|------|
| Lipid-lowering drugs other than statins | 5.31 | 0.89 (0.50 to 1.58) | 0.69 | 0.78 (0.32 to 1.88) | 0.58 | 1.29 (0.56 to 2.99) | 0.55 |
| Max HGS* (n= 4,526) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -4.53 (-5.43 to -3.63) | < 0.001 | -0.61 (-1.19 to -0.04) | 0.04 | -0.45 (-1.04 to 0.14) | 0.14 |
| Lipid-lowering drugs other than statins | | -5.78 (-8.22 to -3.33) | < 0.001 | -2.20 (-4.08 to -0.31) | 0.02 | -1.17 (-2.88 to 0.54) | 0.18 |
| Relative HGS* (n= 4,410) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.39 (-0.46 to -0.32) | < 0.001 | -0.03 (-0.07 to 0.02) | 0.24 | -0.03 (-0.07 to 0.01) | 0.15 |
| Lipid-lowering drugs other than statins | | -0.64 (-0.8 to -0.48) | < 0.001 | -0.1 (-0.24 to 0.04) | 0.15 | -0.09 (-0.21 to 0.03) | 0.13 |
| Combined HGS* (n= 4,461) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -8.91 (-10.66 to -7.17) | < 0.001 | -1.29 (-2.44 to -0.14) | 0.03 | -1.06 (-2.17 to 0.05) | 0.06 |

| Lipid-lowering drugs other than statins | | -11.34 (-15.92 to | < 0.001 | -4.02 (-7.06 to -0.99) | 0.01 | -2.33 (-5.47 to 0.81) | 0.15 |
|---|------|---------------------|---------|------------------------|------|-----------------------|------|
| | | -6.76) | | | | | |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 10,415) | | | | | | | |
| Nonusers | 5.08 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.77 | 1.78 (1.44 to 2.20) | < 0.001 | 1.33 (0.97 to 1.83) | 0.07 | 1.23 (0.96 to 1.57) | 0.10 |
| Lipid-lowering drugs other than statins | 4.28 | 1.82 (1.02 to 3.24) | 0.04 | 1.12 (0.55 to 2.27) | 0.76 | 1.51 (0.83 to 2.73) | 0.18 |
| ASM and BMI definition (n= 21,553) | | | | | | | |
| Nonusers | 7.90 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.50 | 1.09 (0.62 to 1.90) | 0.77 | 1.18 (0.58 to 2.41) | 0.64 | 0.85 (0.53 to 1.34) | 0.47 |
| Lipid-lowering drugs other than statins | 5.00 | 0.63 (0.17 to 2.33) | 0.49 | 0.56 (0.13 to 2.49) | 0.45 | 0.86 (0.26 to 2.90) | 0.81 |
| LDH* (n= 24,501) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 4.64 (3.36 to 5.93) | < 0.001 | -0.73 (-2.10 to 0.64) | 0.30 | -0.28 (-1.79 to 1.22) | 0.71 |

| | | | 1 | | | | |
|---|-------|---------------------|---------|-----------------------|------|-----------------------|------|
| Lipid-lowering drugs other than statins | | 4.01 (0.18 to 7.84) | 0.04 | -1.44 (-5.43 to 2.55) | 0.48 | -0.62 (-4.69 to 3.46) | 0.77 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 6,226) | | | | | | | |
| Nonusers | 33.04 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.40 | 1.62 (1.33 to 1.97) | < 0.001 | 1.22 (0.96 to 1.54) | 0.11 | 1.10 (0.89 to 1.35) | 0.38 |
| Lipid-lowering drugs other than statins | 37.35 | 1.21 (0.71 to 2.05) | 0.48 | 0.88 (0.44 to 1.77) | 0.72 | 0.93 (0.57 to 1.52) | 0.77 |
| Neck/Upper Back (n= 6,226) | | | | | | | |
| Nonusers | 9.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.40 | 0.93 (0.75 to 1.15) | 0.47 | 0.94 (0.66 to 1.34) | 0.73 | 0.89 (0.61 to 1.30) | 0.54 |
| Lipid-lowering drugs other than statins | 14.41 | 1.70 (0.90 to 3.19) | 0.10 | 1.57 (0.68 to 3.60) | 0.28 | 1.82 (0.90 to 3.65) | 0.09 |
| Upper Extremities (n= 6,226) | | | | | | | |
| Nonusers | 21.49 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 30.08 | 1.57 (1.26 to 1.96) | < 0.001 | 1.14 (0.83 to 1.59) | 0.40 | 1.14 (0.91 to 1.43) | 0.25 |
| Lipid-lowering drugs other than statins | 27.77 | 1.40 (0.77 to 2.55) | 0.26 | 1.15 (0.57 to 2.30) | 0.69 | 1.25 (0.75 to 2.09) | 0.39 |
| Lower Back (n= 6,226) | | | | | | | |

| Nonusers | 11.22 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
|---|-------|---------------------|---------|---------------------|------|---------------------|------|
| Statin users | 13.20 | 1.20 (0.93 to 1.55) | 0.15 | 1.05 (0.75 to 1.47) | 0.76 | 1.10 (0.80 to 1.51) | 0.54 |
| Lipid-lowering drugs other than statins | 10.26 | 0.90 (0.41 to 2.00) | 0.80 | 0.66 (0.26 to 1.69) | 0.38 | 0.75 (0.34 to 1.65) | 0.48 |
| Lower Extremities (n= 6,226) | | | | | | | |
| Nonusers | 12.79 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 18.98 | 1.60 (1.25 to 2.04) | < 0.001 | 1.22 (0.89 to 1.68) | 0.20 | 1.07 (0.80 to 1.42) | 0.65 |
| Lipid-lowering drugs other than statins | 19.74 | 1.68 (0.87 to 3.22) | 0.12 | 1.14 (0.51 to 2.53) | 0.74 | 1.05 (0.55 to 2.03) | 0.88 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women


ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Figure and tables

Figure 1 Flow of study



Abbreviations: NHANES, National Health and Nutrition Examination Survey; CVD, cardiovascular disease; HLP, hyperlipidemia; SNP, Single Nucleotide Polymorphism; LDH, Lactate Dehydrogenase.

A: Flow of study.

B: Two-sample Mendelian randomization study design.

Arrows represent associations.

Dashed lines with "x" in the middle represent genetic variants applied as instrumental variables

for Statins that should not be associated with potential confounding factors and do not exert an effect on sarcopenia-related traits and LDH via other pathways in assumptions 2 and 3, respectively.

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-PRESSO, MR-pleiotropy residual sum and outlier; LDH, Lactic dehydrogenase.

Table 1 Baseline characteristics of patients with cardiovascular disease, diabetes, or hyperlipidemia

| | | Sta | tin drug use | |
|------------------------|----------------|----------------|---------------------------|---------|
| | Nonuse | Statin drugs | Lipid-lowering drugs | p |
| | (13,474) | (8,481) | other than statins(n=594) | |
| Age, (year) | 55.4 ± 0.1 | 65.7 ± 0.1 | 63.3 ± 0.5 | < 0.001 |
| Male, (%) | 48.2 | 53.5 | 52.2 | < 0.001 |
| Race/ethnicity, (%) | | | | |
| Hispanic-Mexican | 17.8 | 11.4 | 14.5 | < 0.001 |
| Other Ethnicity | 18.2 | 16.2 | 18.0 | < 0.001 |
| Non-Hispanic White | 42.2 | 52.3 | 54.0 | < 0.001 |
| Non-Hispanic Black | 21.8 | 20.2 | 13.5 | <0.001 |
| Education status, (%) | | | | < 0.001 |
| Less than high school | 29.9 | 28.2 | 30.6 | |
| High school | 22.1 | 24.9 | 23.6 | |
| More than high school | 48.1 | 46.9 | 45.8 | |
| Marital status, (%) | | | | < 0.001 |
| Married | 56.2 | 59.9 | 62.3 | |
| Never married | 16.2 | 8.3 | 8.9 | |
| other | 27.6 | 31.8 | 28.8 | |
| PIR, (%) | | | | < 0.001 |
| < 1.3 | 31.5 | 27.4 | 30.6 | |
| 1.3-3.5 | 37.8 | 39.7 | 38.7 | |
| > 3.5 | 30.7 | 32.9 | 30.8 | |
| BMI, kg/m ² | | | | 0.003 |
| 18.5-25 | 21.3 | 18.1 | 18.4 | |
| 25-30 | 34.5 | 36.2 | 33.9 | |
| ≥ 30 | 44.3 | 45.7 | 47.7 | |
| Alcohols status, (%) | | | | <0.001 |
| | | 1 | i | |

| =0, g/d | 38.5 | 44.2 | 45.3 | |
|------------------------|------|------|------|---------|
| < 5, g/d | 42.5 | 39.1 | 40.4 | |
| 5-30, g/d | 16.3 | 15.1 | 13.0 | |
| > 30, g/d | 2.7 | 1.7 | 1.3 | |
| Smoking status, (%) | | | | < 0.001 |
| Never smoking | 52.0 | 46.8 | 46.6 | |
| Former smoker | 28.2 | 39.4 | 37.0 | |
| Current smoker | 19.8 | 13.8 | 16.3 | |
| Physical activity, (%) | 28.7 | 26.2 | 22.7 | 0.001 |
| HBP, (%) | 61.6 | 80.5 | 80.8 | < 0.001 |
| CKD, (%) | 11.8 | 23.6 | 25.2 | < 0.001 |
| COPD, (%) | 9.3 | 12.6 | 12.8 | < 0.001 |
| Cancer, (%) | 10.8 | 17.8 | 17.0 | < 0.001 |
| CVD, (%) | 20.0 | 35.3 | 26.9 | < 0.001 |
| Diabetes, (%) | 37.1 | 46.4 | 48.2 | < 0.001 |
| Hyperlipidemia, (%) | 71.0 | 85.8 | 88.0 | < 0.001 |

The data were adjusted for survey weights from the NHANES.

The data are presented as the means \pm SDs or percentages.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

Table 2 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers

| | Prevalence, % | Crude | | Adjusted | Adjusted | | ** |
|---|---------------|---------------------|---------|---------------------|----------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n=8,856) | | | | | | | |
| Nonusers | 21.42 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 33.60 | 1.35 (1.12 to 1.62) | < 0.001 | 1.31 (0.99 to 1.74) | 0.06 | 1.25 (1.00 to 1.55) | 0.05 |
| Lipid-lowering drugs other than statins | 35.11 | 1.36 (0.78 to 2.37) | 0.28 | 1.00 (0.49 to 2.02) | 1.00 | 1.23 (0.73 to 2.09) | 0.44 |
| ASM/Wt (n=8,839) | | | | | | | |
| Nonusers | 10.85 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 14.11 | 1.86 (1.62 to 2.13) | < 0.001 | 1.23 (0.99 to 1.54) | 0.06 | 1.14 (0.97 to 1.34) | 0.11 |
| Lipid-lowering drugs other than statins | 14.19 | 1.99 (1.33 to 2.97) | < 0.001 | 0.93 (0.53 to 1.62) | 0.79 | 0.92 (0.62 to 1.37) | 0.67 |
| ASM/Ht ² (n=8,803) | | | | | | | |
| Nonusers | 5.50 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.54 | 1.20 (0.95 to 1.52) | 0.12 | 1.11 (0.77 to 1.60) | 0.56 | 0.87 (0.64 to 1.18) | 0.38 |
| Lipid-lowering drugs other than statins | 4.17 | 0.75 (0.41 to 1.36) | 0.34 | 0.83 (0.31 to 2.25) | 0.71 | 0.99 (0.47 to 2.09) | 0.97 |
| | | β (95% CI) | P | B (95% CI) | P | B (95% CI) | P |

| Max HGS* (n=4,340) | _ | | | | | | |
|--|------|-------------------------|---------|------------------------|------|-----------------------|------|
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -3.01 (-3.97 to -2.06) | <0.001 | -0.35 (-1.11 to 0.41) | 0.36 | -0.13 (-0.66 to 0.40) | 0.64 |
| Lipid-lowering drugs other than statins | | -3.79 (-5.95 to -1.63) | <0.001 | -2.07 (-3.99 to -0.14) | 0.04 | -0.90 (-2.41 to 0.61) | 0.24 |
| Relative grip strength* (n=4,230) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.23 (-0.30 to -0.17) | < 0.001 | -0.01 (-0.06 to 0.04) | 0.66 | -0.01 (-0.04 to 0.03) | 0.77 |
| Lipid-lowering drugs other than statins | | -0.34 (-0.49 to -0.19) | <0.001 | -0.08 (-0.20 to | 0.23 | -0.07 (-0.18 to 0.03) | 0.17 |
| | | | | 0.05) | | | |
| Combined HGS* (n=4,275) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -5.9 (-7.86 to -3.93) | <0.001 | -0.61 (-2.18 to 0.96) | 0.44 | -0.32 (-1.32 to 0.67) | 0.53 |
| Lipid-lowering drugs other than statins | | -6.82 (-10.88 to -2.76) | <0.001 | -2.78 (-6.25 to 0.69) | 0.11 | -2.03 (-4.88 to 0.82) | 0.16 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n=8,8 | 306) | | | | | | |
| Nonusers | 5.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 6.22 | 1.36 (1.13 to 1.63) | <0.001 | 1.32 (1.00 to 1.75) | 0.05 | 1.26 (1.00 to 1.56) | 0.05 |
|---|-------|-----------------------|--------|-----------------------|------|-----------------------|------|
| Lipid-lowering drugs other than statins | 4.17 | 1.37 (0.79 to 2.39) | 0.26 | 1.01 (0.50 to 2.03) | 0.99 | 1.21 (0.72 to 2.05) | 0.47 |
| ASM and BMI definition (n=19,259) | | | | | | | |
| Nonusers | 10.80 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.20 | 0.76 (0.47 to 1.23) | 0.27 | 0.92 (0.51 to 1.66) | 0.78 | 0.98 (0.65 to 1.47) | 0.92 |
| Lipid-lowering drugs other than statins | 3.20 | 0.30 (0.08 to 1.16) | 0.08 | 0.38 (0.09 to 1.60) | 0.18 | 0.74 (0.23 to 2.44) | 0.62 |
| LDH* (n=21,908) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 2.55 (1.32 to 3.78) | <0.001 | -0.55 (-1.81 to 0.71) | 0.39 | -0.57 (-1.72 to 0.58) | 0.33 |
| Lipid-lowering drugs other than statins | | -0.42 (-3.71 to 2.88) | 0.80 | -2.77 (-6.35 to 0.81) | 0.13 | -0.28 (-3.31 to 2.75) | 0.86 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No),

chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

 ASM/Ht^2 cutoffs are <7 kg/m2 in men or <5.5 kg/m 2 in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 3 Odds ratios of musculoskeletal pain for statin users compared to nonusers

| | Prevalence, % | Crude | | Adjusted | | After matching* | |
|---|---------------|---------------------|------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Any Region (n=5,136) | | | | | | | |
| Nonusers | 69.68 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 27.78 | 1.15 (0.96 to 1.38) | 0.12 | 1.15 (0.88 to 1.50) | 0.30 | 1.09 (0.91 to 1.31) | 0.36 |
| Lipid-lowering drugs other than statins | 2.24 | 1.08 (0.64 to 1.82) | 0.76 | 1.10 (0.59 to 2.04) | 0.75 | 1.04 (0.67 to 1.61) | 0.85 |
| Neck/Upper Back (n=5,136) | | | | | | | |
| Nonusers | 74.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 21.83 | 0.74 (0.56 to 0.97) | 0.03 | 0.96 (0.64 to 1.44) | 0.84 | 0.94 (0.67 to 1.32) | 0.73 |
| Lipid-lowering drugs other than statins | 4.15 | 1.52 (0.87 to 2.66) | 0.14 | 2.17 (1.07 to 4.39) | 0.03 | 2.19 (1.19 to 4.00) | 0.01 |
| Upper Extremities (n=5,136) | | | | | | | |
| Nonusers | 69.33 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 28.01 | 1.13 (0.92 to 1.38) | 0.23 | 1.11 (0.81 to 1.51) | 0.50 | 1.13 (0.93 to 1.39) | 0.22 |
| Lipid-lowering drugs other than statins | 2.66 | 1.16 (0.69 to 1.94) | 0.56 | 1.27 (0.68 to 2.38) | 0.44 | 1.25 (0.79 to 1.98) | 0.33 |
| Lower Back (n=5,136) | | | | | | | |
| Nonusers | 69.78 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 28.26 | 1.03 (0.82 to 1.29) | 0.82 | 1.05 (0.76 to 1.45) | 0.75 | 1.05 (0.79 to 1.39) | 0.74 |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Lipid-lowering drugs other than statins | 1.96 | 0.66 (0.29 to 1.48) | 0.31 | 0.61 (0.24 to 1.54) | 0.28 | 0.74 (0.37 to 1.50) | 0.41 |
| Lower Extremities (n=5,136) | | | | | | | |
| Nonusers | 68.81 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 28.53 | 1.17 (0.95 to 1.45) | 0.14 | 1.12 (0.83 to 1.51) | 0.44 | 1.08 (0.84 to 1.41) | 0.54 |
| Lipid-lowering drugs other than statins | 2.66 | 1.22 (0.66 to 2.23) | 0.52 | 1.09 (0.54 to 2.22) | 0.80 | 1.01 (0.55 to 1.83) | 0.99 |

Abbreviations: OR, odds ratio; CI, confidence interval.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic bistructive pulmonary disease, cancer (Yes, No).

^{*}Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 4 The causal relationship between statins and sarcopenia-related traits based on two-sample Mendelian randomization analysis

| Outcome | SNPs | MR method | Beta/OR | 95%CI | <i>P</i> -value |
|----------------------------------|------|-----------------|---------|---------------|-----------------|
| | 11 | IVW | -0.060 | -0.153, 0.033 | 0.208 |
| | | MR Egger | -0.019 | -0.191, 0.153 | 0.834 |
| Appendicular lean mass | | Weighted median | -0.023 | -0.056, 0.010 | 0.173 |
| | 4 | MR PRESOO | -0.016 | -0.057, 0.025 | 0.488 |
| | 11 | IVW | -0.014 | -0.039, 0.012 | 0.289 |
| Here I and a second of the least | | MR Egger | -0.003 | -0.050, 0.043 | 0.892 |
| Hand grip strength (right) | | Weighted median | -0.010 | -0.031, 0.011 | 0.339 |
| | 8 | MR PRESOO | 0.003 | -0.017, 0.023 | 0.776 |
| | 11 | IVW | -0.216 | -0.044, 0.001 | 0.059 |
| Hand onin atmosph (left) | | MR Egger | -0.004 | -0.044, 0.036 | 0.847 |
| Hand grip strength (left) | | Weighted median | -0.013 | -0.031, 0.006 | 0.171 |
| | 10 | MR PRESOO | -0.021 | -0.041, 0.002 | 0.058 |
| | 11 | IVW | 1.042 | 0.889, 1.221 | 0.614 |
| Low hand guin strongth | | MR Egger | 1.025 | 0.759, 1.384 | 0.875 |
| Low hand grip strength | | Weighted median | 1.028 | 0.839, 1,259 | 0.792 |
| | | MR PRESOO | 1.069 | 0.917, 1.247 | 0.411 |
| | 11 | IVW | 0.001 | -0.010, 0.011 | 0.939 |
| Walking pace | | MR Egger | 0.007 | -0.012, 0.026 | 0.497 |
| waiking pace | | Weighted median | -0.002 | -0.016, 0.011 | 0.748 |
| | | MR PRESOO | 0.003 | -0.007, 0.012 | 0.649 |
| | 8 | IVW | -0.080 | -0.213, 0.053 | 0.238 |
| T. 44 11 3 | | MR Egger | 0.035 | -0.230, 0.230 | 0.804 |
| Lactate dehydrogenase | | Weighted median | 0.003 | -0.082, 0.087 | 0.952 |
| | 6 | MR PRESOO | -0.030 | -0.100, 0.040 | 0.437 |

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided p-values less than 0.05 as statistically significant.

Supplemental tables

Table S1 Details of studies and datasets used in the study

| Trait | Sample size (cases/controls) | Datatype | Unit | Ancestry | Consortium/ First Author | PMID or GWAS ID |
|----------------------------|------------------------------|------------|------|------------|--------------------------|-----------------|
| Statins | 290,385 (73,475/216,910) | Binary | / | European | UK Biobank | 31015401 |
| Appendicular lean mass | 450,243 | Continuous | kg | European | UK Biobank | 33097823 |
| Hand grip strength (right) | 461,089 | Continuous | SD | European | MRC-IEU | ukb-b-10215 |
| Hand grip strength (left) | 461,026 | Continuous | SD | European | MRC-IEU | ukb-b-7478 |
| Low hand grip strength | 121,055 (6,734/114,321) | Binary | / | European | Garan Jones | 33510174 |
| Walking pace | 459,915 | Continuous | km/s | European | MRC-IEU | ukb-b-4711 |
| Lactate dehydrogenase | 126,319 | Continuous | SD | East Asian | Ishigaki K | 29403010 |

Abbreviations: SD, Standard Deviation; PMID, PubMed Unique Identifier; GWAS ID, Genome-Wide Association Study Identifier; MRC-IEU, Medical Research Council Integrative Epidemiology Unit.

Table S2 SNPs are used as instrumental variables for Statins (P-value $< 5 \times 10^{-8}$)

| Traits | SNP | Chr | Position | Effect allele | another allele | Beta | SE | P-value | F-statistic |
|--------------------------|-------------|-----|-----------|---------------|----------------|--------------|-------------|-----------|-------------|
| Statins-ALM/HGS (right)/ | rs113911544 | 1 | 55706403 | G | A | 0.085085202 | 0.014373915 | 3.20E-09 | 35.0395019 |
| HGS (left)/LHGS/Walking | rs11591147 | 1 | 55505647 | Т | G | -0.362323999 | 0.021494841 | 9.40E-64 | 284.1356506 |
| pace | rs1260326 | 2 | 27730940 | Т | С | 0.059920058 | 0.005712328 | 9.70E-26 | 110.0317897 |
| | rs12725767 | 1 | 6676040 | G | A | 0.035128029 | 0.005856082 | 2.00E-09 | 35.98266012 |
| | rs12740374 | 1 | 109817590 | Т | G | -0.156618273 | 0.006742468 | 2.30E-119 | 539.5691038 |
| | rs1367117 | 2 | 21263900 | A | G | 0.105726091 | 0.005900949 | 8.70E-72 | 321.0115277 |
| | rs4299376 | 2 | 44072576 | G | Т | 0.086690463 | 0.005971001 | 9.20E-48 | 210.7892007 |
| | rs4541244 | 2 | 58917535 | Т | С | -0.034275082 | 0.005711376 | 2.00E-09 | 36.01434333 |
| | rs570530 | 1 | 234866776 | A | G | -0.032541516 | 0.005613812 | 6.80E-09 | 33.60159042 |
| | rs693668 | 1 | 55521109 | G | A | -0.048941477 | 0.005866453 | 7.30E-17 | 69.5989924 |
| | rs79598313 | 1 | 27284913 | Т | С | 0.146636976 | 0.018408443 | 1.60E-15 | 63.45310484 |
| Statins-LDH | rs113911544 | 1 | 55706403 | G | A | 0.085085202 | 0.014373915 | 3.20E-09 | 35.0395019 |
| | rs1260326 | 2 | 27730940 | Т | С | 0.059920058 | 0.005712328 | 9.70E-26 | 110.0317897 |
| | rs12725767 | 1 | 6676040 | G | A | 0.035128029 | 0.005856082 | 2.00E-09 | 35.98266012 |
| | rs12740374 | 1 | 109817590 | Т | G | -0.156618273 | 0.006742468 | 2.30E-119 | 539.5691038 |

| rs1367117 | 2 | 21263900 | A | G | 0.105726091 | 0.005900949 | 8.70E-72 | 321.0115277 |
|-----------|---|-----------|---|---|--------------|-------------|----------|-------------|
| rs4541244 | 2 | 58917535 | Т | С | -0.034275082 | 0.005711376 | 2.00E-09 | 36.01434333 |
| rs570530 | 1 | 234866776 | A | G | -0.032541516 | 0.005613812 | 6.80E-09 | 33.60159042 |
| rs693668 | 1 | 55521109 | G | A | -0.048941477 | 0.005866453 | 7.30E-17 | 69.5989924 |
| rs7534572 | 1 | 62999675 | С | G | -0.074218207 | 0.005852643 | 7.50E-37 | 160.8114059 |

Abbreviations: SNP, Single nucleotide polymorphism, MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier. ALM, Appendicular

Lean Muscle; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

Table S3 Definition of statins and lipid-lowering drugs

| d00280 lovastatin d00348 pravastatin d00746 simvastatin d03183 fluvastatin d04105 atorvastatin d04140 cerivastatin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05048 ezetimibe; simvastatin d07110 niacin; simvastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol | Generic drug code | Drug name |
|---|---|--|
| d00348 pravastatin d00746 simvastatin d03183 fluvastatin d04105 atorvastatin d04140 cerivastatin d04851 lovastatin; niacin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00193 cholestyramine d00196 clofibrate d000245 gemfibrozil d00744 colestipol d04286 fenofibrate | Statin drugs | |
| d00746 simvastatin d03183 fluvastatin d04105 atorvastatin d04140 cerivastatin d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05048 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00193 cholestyramine d00196 clofibrate d000245 gemfibrozil d00744 colestipol d004286 fenofibrate | d00280 | lovastatin |
| fluvastatin d04105 atorvastatin d04140 cerivastatin d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00193 cholestyramine d00196 d00196 d00196 d00245 gemfibrozil d00353 probucol d00744 d04286 fenofibrate | d00348 | pravastatin |
| d04105 d04140 cerivastatin d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified hmg-coa reductase inhibitors - unspecified d00193 d00196 clofibrate d000245 gemfibrozil d00353 probucol d00744 colestipol | d00746 | simvastatin |
| d04140 cerivastatin d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified d00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol | d03183 | fluvastatin |
| d04787 lovastatin; niacin d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol colestipol d00744 colestipol d04286 fenofibrate | d04105 | atorvastatin |
| d04851 rosuvastatin d05048 amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol colestipol d00744 colestipol | d04140 | cerivastatin |
| amlodipine; atorvastatin d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 d00196 clofibrate d000245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d04787 | lovastatin; niacin |
| d05348 ezetimibe; simvastatin d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d000245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d04851 | rosuvastatin |
| d07110 niacin; simvastatin d07637 pitavastatin d07805 simvastatin; sitagliptin evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d05048 | amlodipine; atorvastatin |
| d07637 pitavastatin d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d05348 | ezetimibe; simvastatin |
| d07805 simvastatin; sitagliptin d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d07110 | niacin; simvastatin |
| d08383 evolocumab Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified c00173 hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol colestipol d00744 colestipol | d07637 | pitavastatin |
| Lipid-lowering drugs other than statins c00019 antihyperlipidemic agents - unspecified hmg-coa reductase inhibitors - unspecified d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol colestipol d04286 fenofibrate | d07805 | simvastatin; sitagliptin |
| antihyperlipidemic agents - unspecified hmg-coa reductase inhibitors - unspecified cholestyramine clofibrate d00196 d00245 gemfibrozil d00353 probucol colestipol d04286 fenofibrate | d08383 | evolocumab |
| hmg-coa reductase inhibitors - unspecified cholestyramine clofibrate d00196 d00245 gemfibrozil d00353 probucol colestipol d04286 fenofibrate | Lipid-lowering drugs other than statins | |
| d00193 cholestyramine d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | c00019 | antihyperlipidemic agents - unspecified |
| d00196 clofibrate d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | c00173 | hmg-coa reductase inhibitors - unspecified |
| d00245 gemfibrozil d00353 probucol d00744 colestipol d04286 fenofibrate | d00193 | cholestyramine |
| d00353 probucol d00744 colestipol d04286 fenofibrate | d00196 | clofibrate |
| d00744 colestipol d04286 fenofibrate | d00245 | gemfibrozil |
| d04286 fenofibrate | d00353 | probucol |
| | d00744 | colestipol |
| d04695 colesevelam | d04286 | fenofibrate |
| <u>l</u> | d04695 | colesevelam |
| d04824 ezetimibe | d04824 | ezetimibe |
| d07371 fenofibric acid | d07371 | fenofibric acid |

| d07891 | icosapent |
|--------|-------------|
| d08374 | alirocumab |
| h00036 | bezafibrate |

Table S4 Characteristics of cardiovascular disease, diabetes, or hyperlipidemia patients with Statin use or nonuse after matching

| | | After matching | | | | | |
|-----------------------|-----------------|-------------------------|-------------------------|--|--|--|--|
| | Non-use (5,249) | Statin drug use (5,429) | Standardized difference | | | | |
| Age, (year) | 62.6 ± 0.2 | 64.7 ± 0.1 | <0.001 | | | | |
| Male, (%) | 50.9 | 52.4 | < 0.001 | | | | |
| Race/ethnicity, (%) | | | | | | | |
| Hispanic-Mexican | 13.3 | 11.8 | < 0.001 | | | | |
| Other Ethnicity | 17.5 | 16.5 | < 0.001 | | | | |
| Non-Hispanic White | 47.0 | 51.3 | <0.001 | | | | |
| Non-Hispanic Black | 22.2 | 20.4 | < 0.001 | | | | |
| Education status, (%) | | | < 0.001 | | | | |
| Less than high school | 29.6 | 28.5 | | | | | |
| High school | 23.6 | 24.3 | | | | | |
| More than high school | 46.8 | 47.2 | | | | | |
| Marital status, (%) | | | <0.001 | | | | |
| Married | 57.2 | 59.1 | | | | | |
| Never married | 10.9 | 9.0 | | | | | |

| | | | ī |
|------------------------|------|------|--------|
| Other | 32.0 | 31.9 | |
| PIR, (%) | | | <0.001 |
| < 1.3 | 30.0 | 27.8 | |
| 1.3-3.5 | 38.5 | 39.5 | |
| > 3.5 | 31.5 | 32.7 | |
| BMI, kg/m ² | | | <0.001 |
| 18.5-25 | 20.4 | 18.2 | |
| 25-30 | 33.5 | 36.2 | |
| ≥ 30 | 46.1 | 45.7 | |
| Alcohols status, (%) | | | <0.001 |
| = 0, g/d | 42.5 | 43.7 | |
| < 5, g/d | 40.0 | 39.2 | |
| 5-30, g/d | 15.1 | 15.5 | |
| > 30, g/d | 2.3 | 1.6 | |
| Smoking status, (%) | | | <0.001 |
| Never smoking | 49.0 | 47.4 | |
| Former smoker | 34.6 | 38.1 | |

| Current smoker | 16.4 | 14.5 | |
|------------------------|------|------|---------|
| Moderate exercise, (%) | 26.2 | 26.4 | < 0.001 |
| HBP, (%) | 76.6 | 79.2 | <0.001 |
| CKD, (%) | 20.0 | 23.0 | <0.001 |
| COPD, (%) | 12.1 | 12.6 | <0.001 |
| Cancer, (%) | 15.6 | 17.1 | < 0.001 |
| CVD, (%) | 27.7 | 33.0 | < 0.001 |
| Diabetes, (%) | 43.9 | 45.1 | <0.001 |
| Hyperlipidemia, (%) | 42.9 | 45.5 | <0.001 |

Data were adjusted for survey weights of NHANES.

Data are presented as means \pm SD or percent.

We considered two-sided p-values less than 0.05 as statistically significant.

 $Abbreviations: PIR, Poverty\ income\ ratio;\ BMI,\ body\ mass\ index;\ HBP,\ hypertension;\ CVD,\ cardiovascular\ diseases;\ CKD,\ Chronic\ Kidney\ Disease;\ COPD,\ cordiovascular\ diseases;\ CKD,\ Chronic\ Kidney\ Disease;\ CKD,\ Chronic\ CKD,\ Chronic\ CKD,\ CKD,\ CKD,\ CKD,\ CKD,\$

Chronic Obstructive Pulmonary Disease.

Table S5 The association between statin users and skeletal muscle-related phenotypes compared with nonusers by stepwise regression analysis

| | ASM/BMI (n=8 | | ASM/Ht ² and bf Sarcopenic Obesity (n=8,806) | | Max HGS (n=4,340) | | Relative HGS (n=4,230) | | Combined HGS (n=4,275) | | Neck/Upper (n=5,136) | Back |
|---------------------|---------------------|------------|--|------------|------------------------|------------|------------------------|------------|------------------------|------------|----------------------|------|
| | OR (95% CI) | P | OR (95% CI) | P | β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | OR (95% CI) | P |
| Unadjusted | 1.35 (1.12 to 1.62) | < 0.001 | 1.36 (1.13 to 1.63) | < 0.001 | -3.01 (-3.97 to -2.06) | < 0.001 | -0.23 (-0.30 to -0.17) | < 0.001 | -5.90 (-7.86 to -3.93) | < 0.001 | 0.74 (0.56 to 0.97) | 0.03 |
| Age adjustment | 1.01 (0.82 to 1.23) | 0.96 | 1.01 (0.83 to 1.23) | 0.91 | 0.67 (-0.22 to 1.56) | 0.14 | -0.02 (-0.10 to 0.05) | 0.5 | 1.31 (-0.50 to 3.11) | 0.15 | 0.83 (0.61 to 1.12) | 0.21 |
| + Sex | 1.24 (1.00 to 1.55) | 0.05 | 1.25 (1.01 to 1.56) | 0.05 | 0.10 (-0.64 to 0.84) | 0.78 | -0.06 (-0.12 to -0.01) | 0.03 | 0.24 (-1.26 to 1.74) | 0.75 | 0.85 (0.63 to 1.14) | 0.27 |
| + Race/ ethnicity | 1.29 (1.03 to 1.62) | 0.03 | 1.30 (1.04 to 1.63) | 0.02 | -0.09 (-0.81 to 0.63) | 0.80 | -0.07 (-0.13 to -0.02) | 0.01 | -0.14 (-1.61 to 1.33) | 0.84 | 0.83 (0.61 to 1.11) | 0.21 |
| +Education level | 1.29 (1.02 to 1.62) | 0.03 | 1.29 (1.03 to 1.63) | 0.03 | -0.09 (-0.83 to 0.66) | 0.82 | -0.07 (-0.13 to -0.02) | 0.01 | -0.14 (-1.64 to 1.35) | 0.85 | 0.83 (0.61 to 1.12) | 0.21 |
| +Marital status | 1.28 (1.02 to 1.62) | 0.03 | 1.29 (1.03 to 1.63) | 0.03 | -0.16 (-0.90 to 0.57) | 0.65 | -0.08 (-0.14 to -0.02) | 0.01 | -0.30 (-1.78 to 1.18) | 0.68 | 0.82 (0.61 to 1.12) | 0.2 |
| + PIR | 1.31 (1.02 to 1.69) | 0.03 | 1.32 (1.03 to 1.70) | 0.03 | -0.28 (-1.02 to 0.45) | 0.44 | -0.09 (-0.15 to -0.04) | < 0.001 | -0.48 (-1.98 to 1.01) | 0.51 | 0.86 (0.61 to 1.21) | 0.37 |
| + BMI | - | - | - | - | -0.55 (-1.24 to 0.13) | 0.11 | -0.04 (-0.08 to 0.01) | 0.08 | -1.05 (-2.42 to 0.31) | 0.13 | 0.88 (0.63 to 1.25) | 0.48 |
| + Alcohols statues | 1.33 (1.03 to 1.72) | 0.03 | 1.34 (1.04 to 1.73) | 0.03 | -0.49 (-1.22 to 0.23) | 0.18 | -0.04 (-0.08 to 0.01) | 0.10 | -0.90 (-2.30 to 0.51) | 0.2 | 0.82 (0.60 to 1.12) | 0.21 |
| + Smoking status | 1.34 (1.03 to 1.73) | 0.03 | 1.35 (1.04 to 1.74) | 0.02 | -0.49 (-1.23 to 0.24) | 0.18 | -0.04 (-0.08 to 0.01) | 0.10 | -0.90 (-2.31 to 0.52) | 0.21 | 0.82 (0.60 to 1.12) | 0.2 |
| + Physical activity | 1.35 (1.04 to 1.74) | 0.02 | 1.36 (1.05 to 1.75) | 0.02 | -0.50 (-1.27 to 0.28) | 0.2 | -0.04 (-0.09 to 0.01) | 0.13 | -0.91 (-2.40 to 0.58) | 0.22 | 0.81 (0.59 to 1.11) | 0.19 |

| + HBP | 1.31 (1.01 to 1.71) | 0.04 | 1.32 (1.02 to 1.72) | 0.04 | -0.54 (-1.32 to 0.24) | 0.17 | -0.04 (-0.08 to 0.01) | 0.15 | -0.97 (-2.48 to 0.54) | 0.20 | 0.82 (0.59 to 1.13) | 0.21 |
|------------------|---------------------|------|---------------------|------|-----------------------|------|-----------------------|------|-----------------------|------|---------------------|------|
| + CVD | 1.31 (0.99 to 1.72) | 0.06 | 1.32 (1.00 to 1.74) | 0.05 | -0.33 (-1.09 to 0.44) | 0.39 | -0.02 (-0.07 to 0.03) | 0.37 | -0.63 (-2.14 to 0.88) | 0.40 | 0.81 (0.56 to 1.18) | 0.27 |
| + Diabetes | 1.28 (0.97 to 1.69) | 0.08 | 1.29 (0.98 to 1.71) | 0.07 | -0.25 (-1.04 to 0.54) | 0.52 | -0.01 (-0.06 to 0.04) | 0.62 | -0.48 (-2.02 to 1.07) | 0.53 | 0.82 (0.56 to 1.19) | 0.28 |
| + Hyperlipidemia | 1.32 (0.99 to 1.75) | 0.06 | 1.33 (1.00 to 1.77) | 0.05 | -0.26 (-1.05 to 0.53) | 0.50 | -0.01 (-0.06 to 0.04) | 0.71 | -0.44 (-2.02 to 1.14) | 0.57 | 0.84 (0.56 to 1.24) | 0.36 |
| + CKD | 1.33 (0.99 to 1.78) | 0.06 | 1.34 (1.00 to 1.80) | 0.05 | -0.31 (-1.11 to 0.5) | 0.44 | -0.01 (-0.06 to 0.04) | 0.76 | -0.51 (-2.12 to 1.10) | 0.52 | 0.82 (0.58 to 1.17) | 0.26 |
| + COPD | 1.32 (0.98 to 1.76) | 0.07 | 1.33 (0.99 to 1.78) | 0.06 | -0.31 (-1.11 to 0.49) | 0.43 | -0.01 (-0.06 to 0.04) | 0.74 | -0.53 (-2.13 to 1.08) | 0.51 | 0.83 (0.58 to 1.19) | 0.29 |
| + Cancer | 1.32 (0.98 to 1.76) | 0.07 | 1.33 (0.99 to 1.78) | 0.06 | -0.32 (-1.12 to 0.48) | 0.42 | -0.01 (-0.06 to 0.04) | 0.72 | -0.55 (-2.14 to 1.05) | 0.49 | 0.85 (0.59 to 1.24) | 0.39 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; HGS, Hand grip strength; BMI, body mass index; Wt, weight; Ht, height; PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women.

Table S6 The results of sensitivity analysis for two-sample Mendelian randomization analysis of the causal relationships between Statins and sarcopenia-related traits

| Outcome | No. of IVs | Heteroger | eity MR-Egger pleiot | | | opy test | MR-PRESOO | |
|----------------------------|------------|-------------|----------------------|------------|---------|----------|---------------------|--|
| | | Cochran's Q | P-value | intercept | SE | P-value | Global Test P-value | |
| Appendicular lean mass | 11 | 346.6756844 | 2.02E-68 | -0.0042237 | 0.00746 | 0.585 | <0.001 | |
| Hand grip strength (right) | 11 | 40.71459187 | 1.27E-05 | -0.0010619 | 0.00202 | 0.612 | <0.001 | |
| Hand grip strength (left) | 11 | 32.39685682 | <0.001 | -0.0018087 | 0.00172 | 0.321 | <0.001 | |
| Low hand grip strength | 11 | 10.56373443 | 0.393 | 0.00164006 | 0.01293 | 0.902 | 0.463 | |
| Walking pace | 8 | 8.438255201 | 0.586 | -0.0006592 | 0.00082 | 0.443 | 0.622 | |
| Lactate dehydrogenase | 11 | 38.72767287 | 2.20E-06 | -0.0082974 | 0.00844 | 0.363 | <0.001 | |

Abbreviations: MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided p-values less than 0.05 as statistically significant.

Table S7 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among the population over 65 years old

| | Prevalence, % | Crude | | Adjusted | | After matching** | |
|---|---------------|---------------------|---------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 2,367) | | | | | | | |
| Nonusers | 35.05 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 43.20 | 0.86 (0.65 to 1.13) | 0.27 | 1.04 (0.73 to 1.49) | 0.81 | 1.11 (0.80 to 1.55) | 0.52 |
| Lipid-lowering drugs other than statins | 34.23 | 1.19 (0.53 to 2.67) | 0.68 | 1.02 (0.43 to 2.40) | 0.97 | 1.31 (0.58 to 2.97) | 0.51 |
| ASM/Wt (n= 2,408) | | | | | | | |
| Nonusers | 24.01 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 21.34 | 1.41 (1.12 to 1.77) | < 0.001 | 1.17 (0.83 to 1.63) | 0.36 | 1.16 (0.90 to 1.50) | 0.25 |
| Lipid-lowering drugs other than statins | 27.26 | 0.96 (0.52 to 1.80) | 0.91 | 0.68 (0.29 to 1.59) | 0.36 | 0.87 (0.45 to 1.70) | 0.69 |
| $ASM/Ht^2 (n=2,430)$ | | | | | | | |
| Nonusers | 15.26 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 12.60 | 0.80(0.60 to 1.06) | 0.12 | 0.84 (0.55 to 1.27) | 0.39 | 0.74 (0.50 to 1.10) | 0.13 |
| Lipid-lowering drugs other than statins | 7.08 | 0.42 (0.19 to 0.95) | 0.04 | 0.34 (0.15 to 0.78) | 0.01 | 0.57 (0.20 to 1.57) | 0.28 |
| Max HGS* (n= 1,590) | _ | | | | | | |

| Nonusers | | Ref. | | Ref. | | Ref. | |
|---|-------|-----------------------|------|-----------------------|------|-----------------------|------|
| Statin users | | 0.54 (-0.81 to 1.88) | 0.42 | -0.22 (-0.94 to 0.51) | 0.55 | 0.14 (-0.63 to 0.91) | 0.72 |
| Lipid-lowering drugs other than statins | | -0.30 (-3.42 to 2.83) | 0.85 | -0.32 (-2.20 to 1.56) | 0.73 | 0.10 (-2.21 to 2.40) | 0.94 |
| Relative HGS* (n= 1,532) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.01 (-0.1 to 0.08) | 0.81 | -0.02 (-0.07 to 0.03) | 0.41 | 0.02 (-0.04 to 0.07) | 0.52 |
| Lipid-lowering drugs other than statins | | -0.02 (-0.23 to 0.19) | 0.86 | 0.03 (-0.11 to 0.17) | 0.64 | -0.03 (-0.19 to 0.13) | 0.73 |
| Combined HGS* (n= 1,560) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 0.86 (-1.70 to 3.42) | 0.50 | -0.58 (-1.88 to 0.72) | 0.37 | -0.06 (-1.56 to 1.44) | 0.94 |
| Lipid-lowering drugs other than statins | | 0.15 (-6.25 to 6.55) | 0.96 | 0.09 (-3.28 to 3.46) | 0.96 | -1.24 (-5.70 to 3.22) | 0.59 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= | | | | | | | |
| 2,369) | | | | | | | |
| Nonusers | 14.68 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 12.60 | 0.87 (0.66 to 1.14) | 0.29 | 1.06 (0.74 to 1.52) | 0.74 | 1.15 (0.83 to 1.59) | 0.41 |
| Lipid-lowering drugs other than statins | 7.08 | 1.20 (0.53 to 2.69) | 0.66 | 1.03 (0.44 to 2.44) | 0.95 | 1.36 (0.6 to 3.07) | 0.46 |

| ASM and BMI definition (n= 7,839) | | | | | | | |
|---|-------|------------------------|------|-----------------------|------|-----------------------|------|
| Nonusers | 14.80 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.10 | 0.54 (0.29 to 1.00) | 0.05 | 0.74 (0.33 to 1.67) | 0.47 | 0.83 (0.48 to 1.46) | 0.53 |
| Lipid-lowering drugs other than statins | 4.60 | 0.31 (0.05 to 1.92) | 0.21 | 0.42 (0.06 to 2.81) | 0.37 | 0.91 (0.21 to 4.04) | 0.91 |
| LDH* (n= 8,954) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -2.34 (-4.15 to -0.54) | 0.01 | -0.73 (-2.65 to 1.19) | 0.45 | 0.04 (-1.58 to 1.66) | 0.96 |
| Lipid-lowering drugs other than statins | | -2.97 (-8.28 to 2.35) | 0.27 | -1.81 (-7.51 to 3.89) | 0.53 | -0.44 (-4.76 to 3.89) | 0.84 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 2,312) | | | | | | | |
| Nonusers | 33.74 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 35.99 | 1.10 (0.86 to 1.42) | 0.43 | 1.13 (0.82 to 1.55) | 0.44 | 0.99 (0.77 to 1.27) | 0.91 |
| Lipid-lowering drugs other than statins | 32.47 | 0.94 (0.51 to 1.76) | 0.85 | 0.92 (0.44 to 1.91) | 0.82 | 1.19 (0.64 to 2.18) | 0.58 |
| Neck/Upper Back (n= 2,312) | | | | | | | |
| Nonusers | 7.01 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.02 | 0.85 (0.58 to 1.25) | 0.40 | 0.77 (0.48 to 1.24) | 0.27 | 0.74 (0.45 to 1.22) | 0.23 |
| Lipid-lowering drugs other than statins | 11.68 | 1.75 (0.84 to 3.66) | 0.13 | 1.83 (0.92 to 3.63) | 0.08 | 1.80 (0.69 to 4.68) | 0.23 |

| Upper Extremities (n= 2,312) | | | | | | | |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Nonusers | 23.40 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 25.68 | 1.13 (0.84 to 1.52) | 0.41 | 1.23 (0.85 to 1.80) | 0.27 | 1.08 (0.82 to 1.42) | 0.58 |
| Lipid-lowering drugs other than statins | 25.76 | 1.14 (0.54 to 2.37) | 0.73 | 1.24 (0.59 to 2.63) | 0.56 | 1.58 (0.83 to 3.01) | 0.16 |
| Lower Back (n= 2,312) | | | | | | | |
| Nonusers | 7.46 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 9.74 | 1.34 (0.90 to 1.99) | 0.15 | 1.49 (0.92 to 2.42) | 0.10 | 1.07 (0.70 to 1.63) | 0.75 |
| Lipid-lowering drugs other than statins | 6.04 | 0.80 (0.28 to 2.29) | 0.67 | 1.11 (0.36 to 3.44) | 0.85 | 0.88 (0.30 to 2.62) | 0.82 |
| Lower Extremities (n= 2,312) | | | | | | | |
| Nonusers | 12.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.49 | 1.05 (0.74 to 1.50) | 0.78 | 0.91 (0.63 to 1.34) | 0.64 | 0.88 (0.61 to 1.29) | 0.52 |
| Lipid-lowering drugs other than statins | 10.23 | 0.77 (0.31 to 1.88) | 0.56 | 0.74 (0.24 to 2.33) | 0.60 | 0.96 (0.38 to 2.39) | 0.93 |

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase; We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m2, 25-30 kg/m2, ≥30 kg/m2), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m2 in men or <5.5 kg/m2 in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S8 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with diabetes

| | Prevalence, % | Crude | | Adjusted | | After matching | ** |
|---|---------------|---------------------|------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 3,136) | | | | | | | |
| Nonusers | 31.76 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 45.27 | 1.02 (0.71 to 1.45) | 0.92 | 1.57 (0.94 to 2.61) | 0.09 | 1.29 (0.85 to 1.97) | 0.23 |
| Lipid-lowering drugs other than statins | 34.44 | 1.05 (0.51 to 2.18) | 0.90 | 1.11 (0.40 to 3.05) | 0.84 | 1.20 (0.43 to 3.38) | 0.73 |
| ASM/Wt (n= 3,153) | | | | | | | |
| Nonusers | 14.26 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 16.43 | 1.34 (1.04 to 1.73) | 0.03 | 0.88 (0.63 to 1.23) | 0.45 | 0.96 (0.72 to 1.28) | 0.76 |
| Lipid-lowering drugs other than statins | 13.05 | 1.67 (0.78 to 3.56) | 0.18 | 0.72 (0.32 to 1.62) | 0.43 | 0.81 (0.40 to 1.66) | 0.57 |
| ASM/Ht^2 (n= 3,169) | | | | | | | |
| Nonusers | 4.79 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 4.75 | 0.76 (0.49 to 1.17) | 0.21 | 0.46 (0.27 to 0.80) | 0.01 | 0.55 (0.32 to 0.93) | 0.03 |
| Lipid-lowering drugs other than statins | 2.37 | 0.58 (0.24 to 1.41) | 0.22 | 0.50 (0.19 to 1.37) | 0.18 | 0.61 (0.16 to 2.31) | 0.47 |
| Max HGS* (n= 1,746) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |

| Statin users | | -0.14 (-2.01 to 1.73) | 0.88 | -0.59 (-1.83 to 0.65) | 0.34 | -0.50 (-1.76 to 0.75) | 0.43 |
|--|-------|-------------------------|---------|------------------------|------|--------------------------|---------|
| Lipid-lowering drugs other than statins | | -6.13 (-9.45 to -2.82) | < 0.001 | -3.86 (-6.95 to -0.77) | 0.02 | -3.43 (-7.85 to 1.00) | 0.13 |
| Relative HGS* (n= 1,685) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.09 (-0.23 to 0.05) | 0.21 | -0.03 (-0.14 to 0.08) | 0.54 | -0.07 (-0.16 to 0.02) | 0.12 |
| Lipid-lowering drugs other than statins | | -0.60 (-0.86 to -0.34) | < 0.001 | -0.13 (-0.36 to 0.11) | 0.29 | -0.47 (-0.79 to -0.15) | < 0.001 |
| Combined HGS* (n= 1,711) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.27 (-4.14 to 3.59) | 0.89 | -0.86 (-3.41 to 1.70) | 0.50 | -1.18 (-3.50 to 1.14) | 0.32 |
| Lipid-lowering drugs other than statins | | -9.71 (-16.59 to -2.82) | 0.01 | -4.87 (-9.87 to 0.13) | 0.06 | -11.85 (-20.39 to -3.32) | 0.01 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 3,139) | | | | | | | |
| Nonusers | 4.35 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 4.36 | 1.02 (0.72 to 1.46) | 0.90 | 1.58 (0.95 to 2.66) | 0.08 | 1.52 (1.00 to 2.30) | 0.05 |
| Lipid-lowering drugs other than statins | 2.37 | 1.06 (0.51 to 2.20) | 0.87 | 1.12 (0.40 to 3.09) | 0.83 | 1.47 (0.52 to 4.15) | 0.46 |
| ASM and BMI definition (n= 7,473) | | | | | | | |
| Nonusers | 10.71 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 7.73 | 0.59 (0.27 to 1.27) | 0.18 | 1.05 (0.47 to 2.34) | 0.91 | 1.41 (0.67 to 2.96) | 0.36 |

| Lipid-lowering drugs other than statins | 4.68 | 0.46 (0.06 to 3.50) | 0.45 | 0.47 (0.06 to 3.92) | 0.49 | 1.05 (0.13 to 8.72) | 0.96 |
|---|-------|-----------------------|------|-----------------------|------|-----------------------|------|
| LDH* (n= 8,973) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 1.11 (-1.48 to 3.71) | 0.40 | 0.39 (-2.22 to 2.99) | 0.77 | -0.75 (-3.27 to 1.78) | 0.56 |
| Lipid-lowering drugs other than statins | | -0.06 (-5.38 to 5.25) | 0.98 | -1.58 (-7.05 to 3.89) | 0.57 | 1.90 (-5.21 to 9.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 1,843) | | | | | | | |
| Nonusers | 37.86 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 51.70 | 0.84 (0.63 to 1.11) | 0.21 | 0.88 (0.64 to 1.21) | 0.43 | 0.82 (0.60 to 1.11) | 0.20 |
| Lipid-lowering drugs other than statins | 46.79 | 0.60 (0.24 to 1.49) | 0.26 | 0.37 (0.13 to 1.05) | 0.06 | 0.53 (0.24 to 1.16) | 0.11 |
| Neck/Upper Back (n= 1,843) | | | | | | | |
| Nonusers | 8.30 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 8.51 | 0.54 (0.36 to 0.82) | 0.01 | 0.77 (0.46 to 1.27) | 0.29 | 0.71 (0.42 to 1.20) | 0.20 |
| Lipid-lowering drugs other than statins | 19.42 | 0.85 (0.30 to 2.37) | 0.74 | 0.53 (0.12 to 2.33) | 0.39 | 1.05 (0.35 to 3.17) | 0.94 |
| Upper Extremities (n= 1,843) | | | | | | | |
| Nonusers | 25.81 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 36.91 | 0.84 (0.62 to 1.15) | 0.27 | 0.94 (0.64 to 1.36) | 0.72 | 0.86 (0.62 to 1.19) | 0.36 |
| Lipid-lowering drugs other than statins | 32.53 | 0.64 (0.22 to 1.85) | 0.40 | 0.52 (0.17 to 1.53) | 0.23 | 0.71 (0.31 to 1.61) | 0.42 |
| Lower Back (n= 1,843) | | | | | | | |

| Nonusers | 14.52 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Statin users | 13.15 | 0.66 (0.46 to 0.94) | 0.02 | 0.75 (0.46 to 1.22) | 0.23 | 0.77 (0.51 to 1.18) | 0.23 |
| Lipid-lowering drugs other than statins | 12.89 | 0.54 (0.16 to 1.76) | 0.30 | 0.57 (0.16 to 2.05) | 0.38 | 0.71 (0.25 to 2.00) | 0.52 |
| Lower Extremities (n= 1,843) | | | | | | | |
| Nonusers | 15.33 | 1.00(Ref.) | | 1.00(Ref.) | | 1.00(Ref.) | |
| Statin users | 23.06 | 0.89 (0.61 to 1.30) | 0.53 | 1.05 (0.66 to 1.67) | 0.83 | 0.90 (0.61 to 1.34) | 0.61 |
| Lipid-lowering drugs other than statins | 20.80 | 0.67 (0.22 to 2.01) | 0.46 | 0.61 (0.20 to 1.84) | 0.37 | 0.52 (0.18 to 1.48) | 0.22 |

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S9 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with cardiovascular disease

| | Prevalence, % | Crude | | Adjusted | | After matching | ** |
|---|---------------|---------------------|------|---------------------|------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 1,641) | | | | | | | |
| Nonusers | 33.76 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 40.61 | 1.02 (0.71 to 1.45) | 0.92 | 1.57 (0.94 to 2.61) | 0.09 | 1.29 (0.85 to 1.97) | 0.23 |
| Lipid-lowering drugs other than statins | 45.97 | 1.05 (0.51 to 2.18) | 0.90 | 1.11 (0.40 to 3.05) | 0.84 | 1.20 (0.43 to 3.38) | 0.73 |
| ASM/Wt (n= 1,671) | | | | | | | |
| Nonusers | 15.67 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 15.92 | 1.34 (1.04 to 1.73) | 0.03 | 0.88 (0.63 to 1.23) | 0.45 | 0.96 (0.72 to 1.28) | 0.76 |
| Lipid-lowering drugs other than statins | 16.32 | 1.67 (0.78 to 3.56) | 0.18 | 0.72 (0.32 to 1.62) | 0.43 | 0.81 (0.40 to 1.66) | 0.57 |
| ASM/Ht ² (n= 1,676) | | | | | | | |
| Nonusers | 10.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.51 | 0.76 (0.49 to 1.17) | 0.21 | 0.46 (0.27 to 0.8) | 0.01 | 0.55 (0.32 to 0.93) | 0.03 |
| Lipid-lowering drugs other than statins | 6.61 | 0.58 (0.24 to 1.41) | 0.22 | 0.50 (0.19 to 1.37) | 0.18 | 0.61 (0.16 to 2.31) | 0.47 |
| Max HGS* (n= 996) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |

| Statin users | | -0.14 (-2.01 to 1.73) | 0.88 | -0.59 (-1.83 to 0.65) | 0.34 | -0.50 (-1.76 to 0.75) | 0.43 |
|--|-------|-------------------------|---------|------------------------|------|--------------------------|---------|
| Lipid-lowering drugs other than statins | | -6.13 (-9.45 to -2.82) | < 0.001 | -3.86 (-6.95 to -0.77) | 0.02 | -3.43 (-7.85 to 1.00) | 0.13 |
| Relative HGS* (n= 947) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.09 (-0.23 to 0.05) | 0.21 | -0.03 (-0.14 to 0.08) | 0.54 | -0.07 (-0.16 to 0.02) | 0.12 |
| Lipid-lowering drugs other than statins | | -0.60 (-0.86 to -0.34) | < 0.001 | -0.13 (-0.36 to 0.11) | 0.29 | -0.47 (-0.79 to -0.15) | < 0.001 |
| Combined HGS* (n= 968) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.27 (-4.14 to 3.59) | 0.89 | -0.86 (-3.41 to 1.7) | 0.50 | -1.18 (-3.50 to 1.14) | 0.32 |
| Lipid-lowering drugs other than statins | | -9.71 (-16.59 to -2.82) | 0.01 | -4.87 (-9.87 to 0.13) | 0.06 | -11.85 (-20.39 to -3.32) | 0.01 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht2 and Body Fat Percent Definition (n= 1,643) | | | | | | | |
| Nonusers | 10.14 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 7.14 | 1.02 (0.72 to 1.46) | 0.90 | 1.58 (0.95 to 2.66) | 0.08 | 1.52 (1.00 to 2.30) | 0.05 |
| Lipid-lowering drugs other than statins | 6.61 | 1.06 (0.51 to 2.20) | 0.87 | 1.12 (0.40 to 3.09) | 0.83 | 1.47 (0.52 to 4.15) | 0.46 |
| ASM and BMI definition (n= 4,725) | | | | | | | |
| Nonusers | 49.18 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.73 | 0.59 (0.27 to 1.27) | 0.18 | 1.05 (0.47 to 2.34) | 0.91 | 1.41 (0.67 to 2.96) | 0.36 |

| Lipid-lowering drugs other than statins | 36.72 | 0.46 (0.06 to 3.50) | 0.45 | 0.47 (0.06 to 3.92) | 0.49 | 1.05 (0.13 to 8.72) | 0.96 |
|---|-------|-----------------------|------|-----------------------|------|-----------------------|------|
| LDH* (n= 5,340) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 1.11 (-1.48 to 3.71) | 0.40 | 0.39 (-2.22 to 2.99) | 0.77 | -0.75 (-3.27 to 1.78) | 0.56 |
| Lipid-lowering drugs other than statins | | -0.06 (-5.38 to 5.25) | 0.98 | -1.58 (-7.05 to 3.89) | 0.57 | 1.90 (-5.21 to 9.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 1,158) | | | | | | | |
| Nonusers | 49.18 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.73 | 0.84 (0.63 to 1.11) | 0.21 | 0.88 (0.64 to 1.21) | 0.43 | 0.82 (0.60 to 1.11) | 0.20 |
| Lipid-lowering drugs other than statins | 36.72 | 0.60 (0.24 to 1.49) | 0.26 | 0.37 (0.13 to 1.05) | 0.06 | 0.53 (0.24 to 1.16) | 0.11 |
| Neck/Upper Back (n= 1,158) | | | | | | | |
| Nonusers | 16.46 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 9.68 | 0.54 (0.36 to 0.82) | 0.01 | 0.77 (0.46 to 1.27) | 0.29 | 0.71 (0.42 to 1.20) | 0.20 |
| Lipid-lowering drugs other than statins | 14.29 | 0.85 (0.30 to 2.37) | 0.74 | 0.53 (0.12 to 2.33) | 0.39 | 1.05 (0.35 to 3.17) | 0.94 |
| Upper Extremities (n= 1,158) | | | | | | | |
| Nonusers | 34.93 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 31.13 | 0.84 (0.62 to 1.15) | 0.27 | 0.94 (0.64 to 1.36) | 0.72 | 0.86 (0.62 to 1.19) | 0.36 |
| Lipid-lowering drugs other than statins | 25.48 | 0.64 (0.22 to 1.85) | 0.40 | 0.52 (0.17 to 1.53) | 0.23 | 0.71 (0.31 to 1.61) | 0.42 |
| Lower Back (n= 1,158) | | | | | | | |

| Nonusers | 20.31 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Statin users | 14.39 | 0.66 (0.46 to 0.94) | 0.02 | 0.75 (0.46 to 1.22) | 0.23 | 0.77 (0.51 to 1.18) | 0.23 |
| Lipid-lowering drugs other than statins | 12.07 | 0.54 (0.16 to 1.76) | 0.30 | 0.57 (0.16 to 2.05) | 0.38 | 0.71 (0.25 to 2.00) | 0.52 |
| Lower Extremities (n= 1,158) | | | | | | | |
| Nonusers | 23.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 21 | 0.89 (0.61 to 1.30) | 0.53 | 1.05 (0.66 to 1.67) | 0.83 | 0.90 (0.61 to 1.34) | 0.61 |
| Lipid-lowering drugs other than statins | 16.71 | 0.67 (0.22 to 2.01) | 0.46 | 0.61 (0.20 to 1.84) | 0.37 | 0.52 (0.18 to 1.48) | 0.22 |

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

^{*}The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

^{**}Propensity score matching with 1: 1 ratio for use or nonuse of statin

Table S10 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with hyperlipidemia

| | Prevalence, % | Crude | Crude | | Adjusted | | ng** |
|---|---------------|---------------------|---------|---------------------|----------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 6,627) | | | | | | | |
| Nonusers | 18.39 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 32.33 | 1.43 (1.19 to 1.72) | < 0.001 | 1.15 (0.85 to 1.56) | 0.37 | 1.13 (0.88 to 1.45) | 0.36 |
| Lipid-lowering drugs other than statins | 35.10 | 1.58 (0.90 to 2.79) | 0.11 | 1.08 (0.51 to 2.28) | 0.85 | 1.26 (0.72 to 2.20) | 0.42 |
| ASM/Wt (n= 6,638) | | | | | | | |
| Nonusers | 10.11 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.90 | 2.12 (1.83 to 2.46) | < 0.001 | 1.20 (0.94 to 1.54) | 0.15 | 1.08 (0.89 to 1.31) | 0.45 |
| Lipid-lowering drugs other than statins | 15.12 | 2.40 (1.57 to 3.68) | < 0.001 | 0.98 (0.54 to 1.79) | 0.95 | 0.88 (0.57 to 1.36) | 0.58 |
| ASM/Ht2 (n= 6,640) | | | | | | | |
| Nonusers | 5.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.26 | 1.24 (0.97 to 1.60) | 0.09 | 1.21 (0.83 to 1.77) | 0.31 | 0.96 (0.68 to 1.37) | 0.83 |
| Lipid-lowering drugs other than statins | 4.16 | 0.81 (0.42 to 1.55) | 0.51 | 1.19 (0.41 to 3.47) | 0.75 | 1.30 (0.59 to 2.88) | 0.52 |
| Max HGS* (n= 3,407) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |

| Statin users | | -3.38 (-4.40 to -2.36) | < 0.001 | -0.10 (-1.02 to | 0.83 | 0.10 (-0.50 to 0.70) | 0.75 |
|--|------|-------------------------|---------|-----------------------|------|-----------------------|------|
| | | | | 0.83) | | | |
| Lipid-lowering drugs other than statins | | -3.93 (-6.21 to -1.65) | < 0.001 | -2.04 (-4.21 to 0.12) | 0.06 | -0.81 (-2.37 to 0.75) | 0.31 |
| Relative HGS* (n= 3,329) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.29 (-0.37 to -0.21) | < 0.001 | -0.01 (-0.08 to 0.06) | 0.76 | 0.01 (-0.03 to 0.05) | 0.56 |
| Lipid-lowering drugs other than statins | | -0.37 (-0.54 to -0.21) | < 0.001 | -0.11 (-0.25 to 0.04) | 0.13 | -0.07 (-0.18 to 0.03) | 0.17 |
| Combined HGS* (n= 3,362) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -6.46 (-8.59 to -4.34) | < 0.001 | 0.03 (-1.84 to 1.90) | 0.98 | 0.43 (-0.69 to 1.54) | 0.45 |
| Lipid-lowering drugs other than statins | | -6.93 (-11.24 to -2.63) | < 0.001 | -2.59 (-6.43 to 1.24) | 0.18 | -1.81 (-4.69 to 1.06) | 0.22 |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 6,627) | | | | | | | |
| Nonusers | 4.75 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 5.97 | 1.44 (1.20 to 1.73) | < 0.001 | 1.17 (0.86 to 1.58) | 0.32 | 1.13 (0.88 to 1.45) | 0.35 |
| Lipid-lowering drugs other than statins | 4.16 | 1.60 (0.91 to 2.81) | 0.11 | 1.09 (0.51 to 2.31) | 0.82 | 1.24 (0.71 to 2.16) | 0.45 |
| ASM and BMI definition (n= 14,406) | | | | | | | |
| Nonusers | 9.50 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 9.30 | 0.98 (0.58 to 1.64) | 0.93 | 0.93 (0.48 to 1.78) | 0.82 | 1.02 (0.64 to 1.63) | 0.94 |
|---|-------|----------------------|---------|-----------------------|------|-----------------------|---------|
| Lipid-lowering drugs other than statins | 3.60 | 0.38 (0.09 to 1.51) | 0.17 | 0.43 (0.10 to 1.86) | 0.25 | 0.78 (0.23 to 2.64) | 0.69 |
| LDH* (n= 16,274) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 3.27 (2.00 to 4.54) | < 0.001 | -0.36 (-1.80 to | 0.62 | -0.17 (-1.48 to 1.15) | 0.80 |
| Lipid-lowering drugs other than statins | | 1.37 (-2.32 to 5.06) | 0.47 | -1.04 (-5.00 to 2.92) | 0.6 | 0.85 (-2.31 to 4.01) | 0.60 |
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 3,741) | | | | | | | |
| Nonusers | 39.06 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 43.01 | 1.18 (0.98 to 1.42) | 0.09 | 1.15 (0.87 to 1.52) | 0.30 | 1.11 (0.89 to 1.38) | 0.35 |
| Lipid-lowering drugs other than statins | 39.83 | 1.03 (0.63 to 1.71) | 0.90 | 1.20 (0.64 to 2.25) | 0.57 | 1.13 (0.70 to 1.81) | 0.61 |
| Neck/Upper Back (n= 3,741) | | | | | | | |
| Nonusers | 10.95 | 1.00 (Ref.) | | | | 1.00 (Ref.) | |
| Statin users | 8.39 | 0.74 (0.54 to 1.03) | 0.08 | 1.03 (0.65 to 1.62) | 0.89 | 1.05 (0.70 to 1.56) | 0.83 |
| Lipid-lowering drugs other than statins | 15.59 | 1.50 (0.80 to 2.84) | 0.20 | 2.57 (1.18 to 5.57) | 0.02 | 2.62 (1.36 to 5.08) | < 0.001 |
| Upper Extremities (n= 3,741) | | | | | | | |
| Nonusers | 26.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 29.46 | 1.13 (0.92 to 1.39) | 0.23 | 1.10 (0.82 to 1.47) | 0.53 | 1.11 (0.88 to 1.41) | 0.39 |
|---|-------|---------------------|------|---------------------|------|---------------------|------|
| Lipid-lowering drugs other than statins | 28.95 | 1.11 (0.67 to 1.83) | 0.69 | 1.27 (0.71 to 2.27) | 0.41 | 1.26 (0.77 to 2.07) | 0.36 |
| Lower Back (n= 3,741) | | | | | | | |
| Nonusers | 11.73 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.19 | 1.14 (0.88 to 1.48) | 0.30 | 1.15 (0.80 to 1.66) | 0.43 | 1.22 (0.87 to 1.71) | 0.24 |
| Lipid-lowering drugs other than statins | 5.19 | 0.41 (0.17 to 1.03) | 0.06 | 0.50 (0.18 to 1.44) | 0.19 | 0.76 (0.35 to 1.68) | 0.50 |
| Lower Extremities (n= 3,741) | | | | | | | |
| Nonusers | 15.10 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 18.17 | 1.25 (0.99 to 1.57) | 0.06 | 1.14 (0.78 to 1.66) | 0.50 | 1.14 (0.84 to 1.55) | 0.41 |
| Lipid-lowering drugs other than statins | 15.29 | 1.01 (0.56 to 1.84) | 0.96 | 1.06 (0.51 to 2.19) | 0.88 | 1.03 (0.53 to 1.99) | 0.93 |

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

^{*}The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.



Table S11 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes

| | Prevalence, % | Crude | | Adjusted | After matching** | | |
|---|---------------|---------------------|---------|---------------------|------------------|---------------------|------|
| | | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Sarcopenic | | | | | | | |
| ASM/BMI (n= 10,412) | | | | | | | |
| Nonusers | 19.08 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 35.88 | 1.78 (1.44 to 2.19) | < 0.001 | 1.33 (0.97 to 1.82) | 0.08 | 1.25 (0.99 to 1.59) | 0.06 |
| Lipid-lowering drugs other than statins | 38.03 | 1.81 (1.01 to 3.23) | 0.05 | 1.11 (0.55 to 2.26) | 0.77 | 1.52 (0.85 to 2.71) | 0.16 |
| ASM/Wt (n= 10,459) | | | | | | | † |
| Nonusers | 8.30 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 13.84 | 2.37 (2.04 to 2.76) | < 0.001 | 1.24 (0.97 to 1.58) | 0.09 | 1.22 (1.02 to 1.47) | 0.03 |
| Lipid-lowering drugs other than statins | 14.07 | 2.60 (1.67 to 4.06) | < 0.001 | 0.96 (0.54 to 1.71) | 0.89 | 1.06 (0.68 to 1.65) | 0.79 |
| ASM/Ht2 (n= 10,474) | | | | | | | |
| Nonusers | 5.92 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |

| Statin users | 7.20 | 1.23 (0.94 to 1.62) | 0.13 | 1.19 (0.80 to 1.75) | 0.38 | 0.94 (0.66 to 1.33) | 0.72 |
|---|------|-------------------------|---------|------------------------|------|-----------------------|------|
| Lipid-lowering drugs other than statins | 5.31 | 0.89 (0.50 to 1.58) | 0.69 | 0.78 (0.32 to 1.88) | 0.58 | 1.29 (0.56 to 2.99) | 0.55 |
| Max HGS* (n= 4,526) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -4.53 (-5.43 to -3.63) | < 0.001 | -0.61 (-1.19 to -0.04) | 0.04 | -0.45 (-1.04 to 0.14) | 0.14 |
| Lipid-lowering drugs other than statins | | -5.78 (-8.22 to -3.33) | < 0.001 | -2.20 (-4.08 to -0.31) | 0.02 | -1.17 (-2.88 to 0.54) | 0.18 |
| Relative HGS* (n= 4,410) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -0.39 (-0.46 to -0.32) | < 0.001 | -0.03 (-0.07 to 0.02) | 0.24 | -0.03 (-0.07 to 0.01) | 0.15 |
| Lipid-lowering drugs other than statins | | -0.64 (-0.8 to -0.48) | < 0.001 | -0.1 (-0.24 to 0.04) | 0.15 | -0.09 (-0.21 to 0.03) | 0.13 |
| Combined HGS* (n= 4,461) | _ | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | -8.91 (-10.66 to -7.17) | < 0.001 | -1.29 (-2.44 to -0.14) | 0.03 | -1.06 (-2.17 to 0.05) | 0.06 |

| Lipid-lowering drugs other than statins | | -11.34 (-15.92 to | < 0.001 | -4.02 (-7.06 to -0.99) | 0.01 | -2.33 (-5.47 to 0.81) | 0.15 |
|---|------|---------------------|---------|------------------------|------|-----------------------|------|
| | | -6.76) | | | | | |
| Sarcopenic Obesity | | | | | | | |
| ASM/Ht ² and Body Fat Percent Definition (n= 10,415) | | | | | | | |
| Nonusers | 5.08 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 6.77 | 1.78 (1.44 to 2.20) | < 0.001 | 1.33 (0.97 to 1.83) | 0.07 | 1.23 (0.96 to 1.57) | 0.10 |
| Lipid-lowering drugs other than statins | 4.28 | 1.82 (1.02 to 3.24) | 0.04 | 1.12 (0.55 to 2.27) | 0.76 | 1.51 (0.83 to 2.73) | 0.18 |
| ASM and BMI definition (n= 21,553) | | | | | | | |
| Nonusers | 7.90 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.50 | 1.09 (0.62 to 1.90) | 0.77 | 1.18 (0.58 to 2.41) | 0.64 | 0.85 (0.53 to 1.34) | 0.47 |
| Lipid-lowering drugs other than statins | 5.00 | 0.63 (0.17 to 2.33) | 0.49 | 0.56 (0.13 to 2.49) | 0.45 | 0.86 (0.26 to 2.90) | 0.81 |
| LDH* (n= 24,501) | | | | | | | |
| Nonusers | | Ref. | | Ref. | | Ref. | |
| Statin users | | 4.64 (3.36 to 5.93) | < 0.001 | -0.73 (-2.10 to 0.64) | 0.30 | -0.28 (-1.79 to 1.22) | 0.71 |

| Lipid-lowering drugs other than statins | | 4.01 (0.18 to 7.84) | 0.04 | -1.44 (-5.43 to 2.55) | 0.48 | -0.62 (-4.69 to 3.46) | 0.77 |
|---|-------|---------------------|---------|-----------------------|------|-----------------------|------|
| Musculoskeletal Pain Symptoms | | | | | | | |
| Any Region (n= 6,226) | | | | | | | |
| Nonusers | 33.04 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 44.40 | 1.62 (1.33 to 1.97) | < 0.001 | 1.22 (0.96 to 1.54) | 0.11 | 1.10 (0.89 to 1.35) | 0.38 |
| Lipid-lowering drugs other than statins | 37.35 | 1.21 (0.71 to 2.05) | 0.48 | 0.88 (0.44 to 1.77) | 0.72 | 0.93 (0.57 to 1.52) | 0.77 |
| Neck/Upper Back (n= 6,226) | | | | | | | |
| Nonusers | 9.02 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 8.40 | 0.93 (0.75 to 1.15) | 0.47 | 0.94 (0.66 to 1.34) | 0.73 | 0.89 (0.61 to 1.30) | 0.54 |
| Lipid-lowering drugs other than statins | 14.41 | 1.70 (0.90 to 3.19) | 0.10 | 1.57 (0.68 to 3.60) | 0.28 | 1.82 (0.90 to 3.65) | 0.09 |
| Upper Extremities (n= 6,226) | | | | | | | |
| Nonusers | 21.49 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 30.08 | 1.57 (1.26 to 1.96) | < 0.001 | 1.14 (0.83 to 1.59) | 0.40 | 1.14 (0.91 to 1.43) | 0.25 |
| Lipid-lowering drugs other than statins | 27.77 | 1.40 (0.77 to 2.55) | 0.26 | 1.15 (0.57 to 2.30) | 0.69 | 1.25 (0.75 to 2.09) | 0.39 |
| Lower Back (n= 6,226) | | | | | | | |

| Nonusers | 11.22 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
|---|-------|---------------------|---------|---------------------|------|---------------------|------|
| Statin users | 13.20 | 1.20 (0.93 to 1.55) | 0.15 | 1.05 (0.75 to 1.47) | 0.76 | 1.10 (0.80 to 1.51) | 0.54 |
| Lipid-lowering drugs other than statins | 10.26 | 0.90 (0.41 to 2.00) | 0.80 | 0.66 (0.26 to 1.69) | 0.38 | 0.75 (0.34 to 1.65) | 0.48 |
| Lower Extremities (n= 6,226) | | | | | | | |
| Nonusers | 12.79 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Statin users | 18.98 | 1.60 (1.25 to 2.04) | < 0.001 | 1.22 (0.89 to 1.68) | 0.20 | 1.07 (0.80 to 1.42) | 0.65 |
| Lipid-lowering drugs other than statins | 19.74 | 1.68 (0.87 to 3.22) | 0.12 | 1.14 (0.51 to 2.53) | 0.74 | 1.05 (0.55 to 2.03) | 0.88 |

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.